universidade estadual do cearÁ prÓ-reitoria de … · À laritza ferreira lima e simone vieira...
TRANSCRIPT
UNIVERSIDADE ESTADUAL DO CEARÁ
PRÓ-REITORIA DE PÓS-GRADUAÇÃO E PESQUISA
FACULDADE DE VETERINÁRIA
PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS VETERINÁRIAS
JOHANNA LEIVA REVILLA
Teste de toxicidade da fração da Auxemma oncocalyx e onconcalyxona A sobre o
desenvolvimento folicular e embrionário in vitro
FORTALEZA – CEARÁ
2016
JOHANNA LEIVA REVILLA
TESTE DE TOXICIDADE DA FRAÇÃO DA AUXEMMA ONCOCALYX E
ONCONCALYXONA A SOBRE O DESENVOLVIMENTO FOLICULAR E
EMBRIONÁRIO IN VITRO
Tese apresentada ao Curso de Doutorado em
Ciências Veterinárias do programa de Pós-
graduação em Ciências Veterinárias da Faculdade
de Veterinária da Universidade Estadual do
Ceará, como requisito parcial à obtenção do título
de doutor em Ciências Veterinárias. Área de
Concentração: Reprodução e Sanidade Animal.
Orientador: Prof. Dr. José Ricardo de Figueiredo
FORTALEZA – CEARÁ
2016
Dedico,
A minha família, Jorge e Patricia, porque
eles me deram o seu amor e apoio
incondicional e constante durante toda a
minha vida.
Aos meus amigos, por seu inabalável
apoio, amizade e amor.
AGRADECIMENTOS
À Universidade Estadual do Ceará (UECE), ao Programa de Pós-Graduação em Ciências
Veterinárias (PPGCV), aos professores e aos funcionários por esses anos colaborando
com minha formação profissional.
Ao Laboratório de Manipulação de Oócitos inclusos em Folículos Pré-Antrais
(LAMOFOPA) da UECE, por dar-me todo o suporte para a realização dessa tese.
À Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) pelo
incentivo financeiro, através da bolsa de doutorado concedida.
Ao meu orientador, professor Dr. José Ricardo de Figueiredo, pela oportunidade de
ingressar em sua equipe, pela confiança depositada, por todos os ensinamentos, por me
orientar na execução desta tese e por me incentivar cada vez mais no exercício das minhas
capacidades, e por acreditar no meu trabalho.
À Profa. Dra. Ana Paula Ribeiro Rodrigues, pela confiança concedida e orientação
durante meu doutorado, que através do seu exemplo profissional foi de grande
importância no meu crescimento professional.
Aos membros da banca, Profa. Dra. Juliana Jales de Hollanda Celestino, Prof. Dr. Dárcio
Ítalo Alves Teixeira, Dr. Luis Alberto Vieira, Prof. Dr. José Roberto Viana da Silva e a
Dra. Ticiana Franco Pereira da Silva pelas correções desta tese, contribuindo para torna-
la ainda melhor.
À Carolina Maside Mielgo e Luis Alberto Vieira, por me co-orientar e pelo exemplo como
profissionais e amigos, sempre com a maior e melhor vontade de me ajudar em tudo.
Obrigada por ser parte da minha família, vocês são pessoas incríveis!
À Profa. Dra. Juliana Jales de Hollanda Celestino, pela constante assessoria, ajuda e
correções de todos meus artigos.
À minhas bruxas queridas, Anna Clara Accioly Ferreira (Chats) e Denise Damasceno
Guerreiro (Denaise), obrigada por tanta amizade, força, motivação e tantos momentos
cheios de alegrias, eu vou levar vocês sempre no meu coração.
A Jesús de los Reyes Cadenas Moreno, por ter sido meu irmão e braço direito durante
meus experimentos, por ter tido tanta paciência comigo, por todas as receitas de cozinha,
muito obrigada. Você sempre vai ser uma parte da minha família.
À Giovanna e à minha Família brasileira, os Quintino, Camila, Michelle, Lourdes e
Antonio Airton. Obrigada por ter me recebido de braços abertos e como se fosse uma
filha. Serei eternamente grata por ter ganho uma família cheia de tanto amor.
À Laritza Ferreira Lima e Simone Vieira Castro, pela ajuda e orientação durante meu
início no LAMOFOPA.
A Renato Felix da Silva, pelos milhões de capilares e pela amizade. Obrigada filho.
À Francisco Leo Nascimento de Aguiar (Pequeño Leo), pelas palavras de motivação,
incentivo, ajuda, amizade e pela grata companhia durante as viagens a Mossoró.
A Victor Macêdo Paes (Estrela) e Hudson Henrique Vieira Correia (Huds), pelos debates
no horário de almoço, o companheirismo, a ajuda e amizade.
Prof. Claudio Cabral e Benner Geraldo Alves, pelas mil e uma análises de estatística.
Obrigada pela paciência.
A toda equipe do LAMOFOPA que me auxiliou de alguma forma e as pessoas que
fizeram meus dias mais felizes: Rita Kelly, Lidiane Sales, Seu João, César Camelo, Gildas
Mbemya Tetaping, Juliana Zani, Naiza Arcângela Ribeiro de Sá, Nathalie Jiatsa, Yago
Pinto, Andreza de Sá Nunes, Gerlane Modesto, Gabriel da Silva, Leticia Ferreira, Deysi
Dipaz Berrocal, Diego Montano, Kayse Najara, Luana Gaudencio, Luciana Mascena
Silva, Marcela Pinheiro Paz, Geovania Canafístula, Rebeca Rocha, Kele Amaral Alves,
Jamily Bruno, Valdevane Araujo e Carlos Lobo.
E, por fim um agradecimento especial à minha família, Jorge e Patricia, vocês são minha
razão de viver, sem vocês eu não teria conseguido. Muito obrigada por todo o amor e
apoio que sempre me deram. Amo muito vocês!
RESUMO
O objetivo foi avaliar o efeito da Auxemma oncocalyx (A. oncocalyx) e seu composto
ativo oncocalyxona A (onco A) sobre os folículos pré-antrais, a maturação oocitária e a
qualidade embrionária in vitro. Para a Fase I, fragmentos ovarianos caprinos foram
cultivados por 1-7 dias nos tratamentos: controle cultivado sozinho ou suplementado com
DMSO, BMP-15, doxorubicina (DXR), A. oncocalyx (1.2, 12 ou 34 µg/mL) ou onco A
(1, 10 ou 30 µg/mL). Foram avaliados: sobrevivência, crescimento, apoptose e
proliferação. Na fase II, folículos secundários isolados caprinos foram cultivados nos
grupos; controle não-cultivado, controle cultivado, DMSO, DXR, A. oncocalyx ou onco
A. Além disso, complexo culmulus oócito (CCOs) caprinos foram maturados in vitro
(MIV) nos grupos: controle-cultivados sozinho; ou suplementado com DMSO; DXR; A.
oncocalyx ou onco A, e foram avaliados a morfologia, sobrevivência, apoptose e
configuração da cromatina. Finalmente, para a fase III, CCOs porcinos foram MIV na
presença de DXR; A. oncocalyx ou onco A e a competência oocitária foi avaliada
(experimento 1). Também, embriões porcinos foram cultivados in vitro nos mesmos
tratamentos e o desenvolvimento embrionário foi avaliado (experimento 2). Na fase I, a
DXR reduziu o percentual de viabilidade folicular sendo que para a A. oncocalyx e onco
A esta redução ocorreu de forma concentração-dependente (P <0,05). DXR, A. oncocalyx
1.2 e onco A 1 aumentaram (P <0,05) a apoptose. A DXR diminuiu (P<0,05) a
proliferação celular. Porém, na fase II, houve uma redução no percentual de folículos
intactos, formação antro, taxa de crescimento e proliferação celular (P <0,05) comparado
ao controle. A DXR apresentou indicadores de apoptose maiores (P <0,05). Após a MIV
de CCOs caprinos, DXR, A. oncocalyx e onco A aumentaram (P <0,05) os oócitos
anormais e diminuíram a viabilidade em comparação com o controle (P <0,05).
Finalmente, na fase III, no experimento 1, a DXR, A. oncocalyx e onco A reduziram (P
<0,05) a viabilidade oocitária e a eficiência da MIV (P <0,05). Após a FIV, todas as
drogas reduziram (P <0,05) a eficiência da FIV e o percentual de embriões clivados, no
entanto, apenas a DXR diminuiu o percentual de blastocistos. No experimento 2, a DXR
e A. oncocalyx diminuíram (P <0,05) o percentual de embriões clivados, mas não teve
nenhum efeito sobre a formação de blastocisto. Em conclusão, A. oncocalyx e onco A
afetam a foliculogênese in vitro em caprinos de forma concentração-dependente. A Onco
A tem um efeito menos prejudicial do que a DXR na sobrevivência de folículos pré-
antrais. Também, A. oncocalyx e onco A não apresentam um efeito tóxico sobre folículos
secundários isolados caprinos nas taxas de maturação de CCOs. Porém, estas substâncias
afetam negativamente a viabilidade oocitária. Além disso, em suínos, a adição de DXR
durante MIV ou cultivo embrionário in vitro afeta negativamente a eficiência da FIV e a
taxa de clivagem. Além disso, a exposição de CCOs suínos à DXR, apenas durante a
MIV, foi mais prejudicial à manutenção da viabilidade oocitária e à formação de
blastocistos, quando comparado à A. oncocalyx e onco A.
Palavras-chave: Auxemma oncocalyx. Oncocalyxona A. Cultivo in vitro. Maturação in
vitro. Embriões.
ABSTRACT
The goal was to evaluate the effect of Auxemma oncocalyx (A. oncocalyx) and its active
compound oncocalyxone A (onco A) on the in vitro culture of preantral follicles, oocyte
maturation and embryo quality. For phase I, caprine ovarian fragments were cultured for
1 and 7 days in different conditions: cultured control alone or supplemented with DMSO,
BMP-15, doxorubicin (DXR), A. oncocalyx (1.2, 12 or 34 µg/ml) or onco A (1, 10 or 30
µg/ml). The following endpoints were evaluated: survival, growth, apoptosis and
proliferation. For phase II, isolated secondary caprine follicles were cultured in groups;
non-cultured control, control group, DMSO, DXR, A. oncocalyx or onco A. Additionally,
caprine cumulus-oocyte-complex (COCs) were in vitro maturated (IVM) in the groups:
control alone or supplemented with DMSO; DXR; A. oncocalyx or onco A. Morphology,
survival, apoptosis and chromatin configuration were assessed. Finally, for phase III,
porcine COCs were IVM in the presence of DXR; A. oncocalyx or onco A and oocyte
competence was analyzed (experiment 1). Also, porcine embryos were in vitro cultured
in the same treatments and embryo development was evaluated (experiment 2). In phase
I, A. oncocalyx and onco A, in a concentration-dependent manner, and DXR decreased
(P<0.05) the percentage of morphologically normal follicles. DXR, A. oncocalyx 1.2 and
onco A 1 increased (P<0.05) the percentage of apoptosis. DXR decreased (P<0.05) the
cellular proliferation. On the other hand, in phase II, DXR showed a reduction in the
percentage of intact follicles, antrum formation, growth rate and proliferation (P < 0.05)
compared to control. DXR showed higher apoptosis indicators (P < 0.05). After IVM of
caprine COCs, DXR, A. oncocalyx and onco A treatments had a greater percentage (P <
0.05) of abnormal oocytes and a lower percentage of viable oocytes as compared with the
control (P < 0.05). Finally, in the phase III, in experiment 1; DXR, A. oncocalyx and onco
A reduced (P<0.05) oocyte viability and IVM efficiency. After IVF, all the drugs reduced
(P<0.05) the IVF efficiency and percentage of cleaved embryos, nevertheless, only DXR
decreased the percentage of blastocyst. In experiment 2; DXR and A. oncocalyx decreased
(P<0.05) the percentage of cleaved embryo, but had no effect on blastocyst formation. In
conclusion, A. oncocalyx and onco A affected in vitro caprine folliculogenesis in a
concentration-dependent manner. Onco A has a less harmful effect than DXR on goat
preantral follicle survival. Furthermore, A. oncocalyx and onco A do not exhibit a toxic
effect on caprine isolated secondary follicles and on maturation rates of COCs recovered
from caprine antral follicles. However, these substances negatively affected the oocyte
viability. Moreover, in the porcine model, the addition of DXR during IVM or IVC
negatively affected the IVF efficiency and cleavage rate. Additionally, the exposure of
porcine COCs to DXR only during IVM was more detrimental to oocyte viability and
blastocyst formation than A. oncocalyx and onco A.
Keywords: Auxemma oncocalyx. Oncocalyxone A. In vitro culture. In vitro maturation.
Embryos.
LISTA DE FIGURAS
FRAÇÃO DE AUXEMMA ONCOCALYX E ONCOCALYXONA A
AFETAM A SOBREVIVÊNCIA IN VITRO E O DESENVOLVIMENTO DE
FOLÍCULOS PRÉ-ANTRAIS CAPRINOS INCLUSOS EM TECIDO
CORTICAL OVARIANO
Figure 1 - TUNEL assay of caprine preantral follicles before (non-cultured
control) and after in vitro culture for 7 days in α-MEM+ alone or α-
MEM+ supplemented with DMSO, BMP-15, DXR, A. oncocalyx
(1.2 µg/mL) or onco A (1 µg/mL) …………………………………. 77
Figure 2 - AgNOR silver staining of caprine preantral follicles before (non-
cultured control) and after in vitro culture for 7 days in α-MEM+
alone or α-MEM+ supplemented with DMSO, BMP-15, DXR, A.
oncocalyx (1.2 µg/mL) or onco A (1 µg/mL) ……………………… 77
Figure 3 - PCNA test of caprine preantral follicles before (non-cultured
control) and after in vitro culture for 7 days in α-MEM+ alone or α-
MEM+ supplemented with DMSO, BMP-15, DXR, A. oncocalyx
(1.2 µg/mL) or onco A (1 µg/mL) ………………………………… 78
EFEITO DA TOXICIDADE DA FRAÇÃO DA AUXEMMA ONCOCALYX E
DO PRINCÍPIO ATIVO ONCOCALYXONA A NO CULTIVO IN VITRO
DE FOLÍCULOS SECUNDÁRIOS E NA MATURAÇÃO IN VITRO DE
OÓCITOS CAPRINOS
Figure 1 - Isolated secondary follicles before (a) and after 7 days of culture in
α-MEM+ alone (cultured-control) (b) or supplemented with DMSO
(c), DXR (d), A. oncocalyx (e) and onco A (f). Oocytes after in vitro
maturation in TCM199+ (control) (g) or supplemented with DMSO
(h), DXR (i), A. oncocalyx (j) or onco A (k) ………………………. 104
Figure 2 - Relative mean (± SEM) of BAX:BCL2 mRNA ratio in cultured
isolated secondary follicles for 7 days in α-MEM+ alone (cultured-
control) or supplemented with DMSO, DXR, A. oncocalyx and
onco A. Different letters denote significant differences (P < 0.05) .. 104
AUXEMMA ONCOCALYX E SEU COMPOSTO ATIVO
ONCOCALYXONA A PREJUDICAM A COMPETÊNCIA DE
DESENVOLVIMENTO OOCITÁRIO IN VITRO EM SUÍNOS, MAS SÃO
MENOS PREJUDICIAIS DO QUE A DOXORRUBICINA
Figure 1 - Experimental design and endpoints of experiment 1 and 2. In vitro
maturation (IVM), in vitro fertilization (IVF), in vitro embryo
culture (IVC), hours post insemination (hpi) ……………………… 123
Figure 2 - Percentage of cleaved (A) and blastocyst/cleaved (B) after previous
exposure (only during in vitro maturation) to DXR, A. oncocalyx or
onco A, only. a,b,c Distinct letters represent significant differences
among treatments (P < 0.05) (experiment 1) ……………………… 126
Figure 3 - Percentage of cleaved (A) and blastocyst / cleaved (B) after
exposure (only during in vitro embryo culture) to DXR, A.
oncocalyx or onco A. a,b Distinct letters represent significant
differences among treatments (P < 0.05) (experiment 2) ………….. 128
LISTA DE TABELAS
PROPRIEDADES DA PLANTA AUXEMMA ONCOCALYX E SEU
PRINCÍPIO ATIVO ONCOCALYXONA A
Table 1 - Main results of the use of A. oncocalyx and Onco A in several
species and cell types ……………………………………………… 57
FRAÇÃO DE AUXEMMA ONCOCALYX E ONCOCALYXONA A
AFETAM A SOBREVIVÊNCIA IN VITRO E O DESENVOLVIMENTO DE
FOLÍCULOS PRÉ-ANTRAIS CAPRINOS INCLUSOS EM TECIDO
CORTICAL OVARIANO
Table 1 - Percentage (mean ± SEM) of morphologically normal caprine
preantral follicles before (non-cultured control) and after in vitro
culture for 1 or 7 days in α-MEM+ alone or α-MEM+ supplemented
with DMSO, BMP15, DXR, A. oncocalyx (1.2; 12 and 34 µg/ml)
or onco A (1, 10 and 30 µg/ml) ……………………………………. 79
Table 2 - Percentage (mean ± SEM) of primordial and growing caprine
preantral follicles before (non-cultured control) and after in vitro
culture for 1 or 7 days in α-MEM+ alone or α-MEM+ supplemented
with DMSO, BMP15, DXR, A. oncocalyx (1.2; 12 and 34 µg/ml)
or onco A (1, 10 and 30 µg/ml) ……………………………………. 80
EFEITO DA TOXICIDADE DA FRAÇÃO DA AUXEMMA ONCOCALYX E
DO PRINCÍPIO ATIVO ONCOCALYXONA A NO CULTIVO IN VITRO
DE FOLÍCULOS SECUNDÁRIOS E NA MATURAÇÃO IN VITRO DE
OÓCITOS CAPRINOS
Table 1 - Oligonucleotide primers used for PCR analysis of goat secondary
follicles ……………………………………………………………. 103
Table 2 - Percentage of morphologically intact secondary follicles, and
antrum formation after in vitro culture for 7 days in α-MEM+
(control) or supplemented with DMSO, DXR, A. oncocalyx or onco
A ………………………………………………..………………… 105
Table 3 - Follicular diameter (on day 0 and 7) and growth rate (mean ± SEM)
of isolated secondary follicles after in vitro culture in α-MEM+
(control) or supplemented with DMSO, DXR, A. oncocalyx or onco
A …………………………………………………………………... 105
Table 4 - PCNA test and TUNEL assay of non-cultured or in vitro cultured
isolated secondary follicles for 7 days in α-MEM+ (control) or
supplemented with DMSO, DXR, A. oncocalyx or onco A ………. 106
Table 5 - Viable and non-viable oocytes rates, germinal vesicle (GV),
meiotic resumption and metaphase II (MII) rates, after in vitro
maturation in TCM199+ (control) or supplemented with DMSO,
DXR, A. oncocalyx or onco A of COCs recovered from antral
follicles ……………………………………………………………. 107
AUXEMMA ONCOCALYX E SEU COMPOSTO ATIVO
ONCOCALYXONA A PREJUDICAM A COMPETÊNCIA DE
DESENVOLVIMENTO OOCITÁRIO IN VITRO EM SUÍNOS, MAS SÃO
MENOS PREJUDICIAIS DO QUE A DOXORRUBICINA
Table 1 - Rates of viable oocytes, germinal vesicle (GV), meiotic resumption
and metaphase II (MII) rates, after in vitro maturation of porcine
oocytes in control medium alone or supplemented with DXR, A.
oncocalyx or onco A (experiment 1) …………………………..….. 124
Table 2 - Rates of viable oocytes, matured, penetrated, monospermy and
efficiency rates and number of spermatozoa per oocyte after
previous exposure (only during in vitro maturation) to DXR, A.
oncocalyx or onco A (experiment 1) ……………………………… 125
Table 3 Rates of viable oocytes, matured, penetrated, monospermy and
efficiency rates and number of spermatozoa per oocyte after 18hpi
exposure (only during in vitro embryo culture) to DXR, A.
oncocalyx or onco A (experiment 2) ………………………………. 127
LISTA DE ABREVIATURAS E SIGLAS
A. oncocalyx Auxemma oncocalyx
AgNOR
Argyrophilic proteins related to nucleolar organizer regions
(proteínas argirofílicas relacionadas com regiões organizadoras de
nucléolos)
ANOVA Analysis of variance (Análise de variância)
ANP Atrial natriuretic peptide
BAX BCL2 Associated X Protein
BCL2 B-cell lymphoma 2
BMP-15 Bone morphogenetic protein 15 (proteína morfogenética óssea 15)
BMPs Bone morphogenetic proteins
BSA Bovine serum albumin
CaCl2·2H2O Calcium chloride dehydrate
Calcein-AM Calcein acetoximetil
CAPES Coordenação de aperfeiçoamento de pessoal de nivel superior
Casp3 Caspase 3
cDNA Complementary DNA
cGMP Cyclic guanosine monophosphate
CH2Cl2 Dichloromethane
CNPq Conselho Nacional de Desenvolvimento Científico e Tecnológico
COCs / CCOs Cumulus oocyte complex (complexos cumulus-oócitos)
DAB 3,39-diaminobenzidine tetrahydrochloride
DMSO Dimethyl sulfoxide (dimetilsulfóxido)
DNA Deoxyribonucleic acid (ácido desoxirribonucléico)
DPBS Dulbecco’s phosphate-buffered saline
DSBs Double-strand breaks
dUTP Terminal deoxynucleotidyl transferase-mediated
DXR Doxorubicin (Doxorrubicina)
EGF Epidermal growth factor
EtOAc Ethyl acetate
EtOH Ethyl alcohol
FSH Follicle stimulating hormone
FUNCAP Fundação Cearense de Apoio ao Desenvolvimento Científico e
Tecnológico
GAPDH Glyceraldehyde-3-phosphate-dehydrogenase
GV Germinal vesicle
GVBD (RVG) Germinal vesicle break down (ruptura da vesícula germinativa)
H2O2 Hydrogen peroxide
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)
HL-60 Human promyelocytic leukemia line
hpi Hours post insemination
IGF-I Insulin growth factor I
IVF / FIV In vitro fertilization (fertilização in vitro)
IVM / MIV In vitro maturation (maturação in vitro)
IVP In vitro production
KCl Potassium chloride
LH Luteinizing hormone
mDPBS Modified DPBS
MEM Minimal essential medium (meio essencial mínimo)
MeOH Methanol
MI Metaphase 1
MII Metaphase 2
Na2HPO4 Sodium hydrogen phosphate
NaCl Sodium chloride
NCSU-23 North Carolina State University Medium-23
NMR Nuclear magnetic resonance
NOR Nucleolar organizer regions
Onco A Oncocalyxone A (oncocalyxona A)
PAF Paraformaldehyde
PAR Poly (ADP-ribose) chain
PARP Poly (ADP-ribose) polymerase
PCNA Proliferating cell nuclear antigen
PKG cGMP-dependent protein kinase
PPIA Peptidylprolyl Isomerase A
qPCR Quantitative PCR
rFSH Recombinant FSH
RNA Ribonucleic acid
RNAm Messenger RNA
S phase Synthesis
SEM Standard error of the mean
TCM-199+ Tissue culture medium 199
Topo II Topoisomerase II
TOPOs Topoisomerases
TPF TUNEL positive follicles
TUNEL Terminal deoxynucleotidil transferase-mediated deoxyuridine
Triphosphate biotin nick end-labeling
α-MEM Alpha minimal essential medium (meio essencial mínimo alfa)
SUMÁRIO
1 INTRODUÇÃO ......................................................................................... 20
2 REVISÃO DE LITERATURA ................................................................. 22
2.1 FOLICULOGÊNESE E CARATERIZAÇÃO FOLICULAR .................... 22
2.2 ATRESIA FOLICULAR ............................................................................. 24
2.3 TOXICIDADE E FUNÇÃO REPRODUTIVA FEMININA ...................... 24
2.4 SISTEMAS DE CULTIVO IN VITRO ........................................................ 26
2.4.1 Cultivo in situ e isolado de folículos pré-antrais ..................................... 26
2.4.2 Técnicas de avaliação do cultivo in vitro .................................................. 27
2.5 DOENÇAS TUMORAIS NEOPLÁSICAS ................................................ 29
2.5.1 Terapêutica do câncer ............................................................................... 29
2.6 FITOTERAPIA ........................................................................................... 30
3 JUSTIFICATIVA ...................................................................................... 33
4 HIPÓTESES CIENTÍFICA ...................................................................... 35
5 OBJETIVOS .............................................................................................. 36
5.1 OBJETIVO GERAL .................................................................................... 36
5.2 OBJETIVOS ESPECÍFICOS ...................................................................... 36
6
PROPRIEDADES DA PLANTA AUXEMMA ONCOCALYX E SEU
PRINCÍPIO ATIVO ONCOCALYXONA A .......................................... 37
7
FRAÇÃO DE AUXEMMA ONCOCALYX E ONCOCALYXONA A
AFETAM A SOBREVIVÊNCIA IN VITRO E O
DESENVOLVIMENTO DE FOLÍCULOS PRÉ-ANTRAIS
CAPRINOS INCLUSOS EM TECIDO CORTICAL OVARIANO ...... 59
8
EFEITO DA TOXICIDADE DA FRAÇÃO DA AUXEMMA
ONCOCALYX E DO PRINCÍPIO ATIVO ONCOCALYXONA A NO
CULTIVO IN VITRO DE FOLÍCULOS SECUNDÁRIOS E NA
MATURAÇÃO IN VITRO DE OÓCITOS CAPRINOS ......................... 84
9
AUXEMMA ONCOCALYX E SEU COMPOSTO ATIVO
ONCOCALYXONA A PREJUDICAM A COMPETÊNCIA DE
DESENVOLVIMENTO OOCITÁRIO IN VITRO EM SUÍNOS, MAS
SÃO MENOS PREJUDICIAIS DO QUE A DOXORRUBICINA ........ 108
10 CONCLUSÕES .......................................................................................... 133
11 PERSPECTIVAS ....................................................................................... 134
REFERÊNCIAS ......................................................................................... 135
20
1 INTRODUÇÃO
As plantas são reconhecidas pelo seu potencial terapêutico e representam uma
excelente fonte de matéria-prima para a produção de novas drogas (Bahmani et al., 2016).
Assim, o estudo das atividades farmacológicas das plantas é de grande importância a fim
de provar sua eficiência e, em muitos casos, validar as suas utilizações populares (Schmitt
et al., 2003).
Dentre os diferentes tipos de plantas existentes, A Auxemma oncocalyx (A.
oncocalyx) tem sido amplamente utilizada na medicina popular no tratamento adjuvante
para ferimentos (Braga, 1976). Diversos estudos sugerem algumas atividades biológicas
desta planta, tais como atividade analgésica, antioxidante, anti-inflamatória e anti-tumoral
(Ferreira et al., 2004; Pessoa et al., 1992). O extrato da A. oncocalyx pode ser obtida a
oncocalyxona A (rel-8a-hydroxy-5-hydroxy-methyl-8ab-methyl-2-methoxy-7,8,8a,9-
tetrahydro-1,4 anthracenediona, onco A) que é o princípio ativo possuindo alta atividade
antioxidante (Ferreira et al., 2003) e antiproliferativa contra as células tumorais (Costa-
Lotufo et al., 2002a). A onco A tem sido sugerida como uma droga alternativa para o
tratamento do câncer (Barreto et al., 2013). No entanto, a maioria dos medicamentos
utilizados para a terapia de câncer tende a ser tóxico para a saúde reprodutiva feminina,
acarretando falha ovariana prematura (Turan et al., 2013). Entretanto, ainda não é
conhecido o efeito da Auxemma oncocalyx e do seu princípio ativo sobre a fertilidade
feminina, incluindo os seus possíveis efeitos sobre a sobrevivência e o desenvolvimento
dos folículos ovarianos. Uma forma de investigar este parâmetro é a utilização da técnica
de cultivo folicular in vitro.
O cultivo in vitro de folículos pré-antrais, também conhecido como "Ovário
artificial", é uma etapa importante na biotecnologia de manipulação in vitro de oócitos
inclusos em folículos pré-antrais (MOIFOPA). Esta biotecnologia é uma importante
ferramenta para a elucidação dos mecanismos básicos envolvidos na foliculogênese
ovariana (Arunakumari et al., 2010). Além disso, permite a realização de ensaios in vitro
para investigar os efeitos benéficos/tóxicos de drogas sobre os folículos ovarianos, antes
de sua utilização efetiva em experimentos com humanos e/ou animais. Vale salientar que
a utilização de material humano para experimentação laboratorial envolve várias questões
éticas. Neste sentido, alguns autores utilizam modelos animais para a pesquisa. Um
exemplo é o uso do tecido ovariano de cabra, a fim de verificar o efeito de diversas
21
substâncias sobre o desenvolvimento folicular, devido às semelhanças entre os ovários
dessa espécie com a humana (Faustino et al., 2011). Os suínos, são também modelos
animais muito utilizados para estudos de toxicidade sobre a maturação, fertilização e o
cultivo embrionário (Santos et al., 2014).
Para uma melhor compreensão da importância desta tese, na revisão de literatura
a seguir será realizada uma breve abordagem da foliculogênese e caracterização dos
folículos ovarianos, população e atresia folicular, cultivo in vitro de folículos pré-antrais
(ovário artificial), estado atual da técnica de MOIFOPA, diferentes aplicações do ovário
artificial, com ênfase na sua importância para o teste da eficiência/toxicidade de drogas
e, finalmente, a importância dos fitoterápicos utilizados no tratamento do câncer, com
ênfase na planta Auxemma oncocalyx e seu princípio ativo, onco A.
22
2 REVISÃO DE LITERATURA
2.1 FOLICULOGÊNESE E CARACTERIZAÇÃO FOLICULAR
Na maioria das espécies, a foliculogênese é um evento iniciado ainda na vida pré-
natal e é definida como o processo de formação, crescimento e maturação folicular,
obedecendo à uma sequência de eventos característicos, que começam com o
estabelecimento da população folicular no ovário e termina com a ovulação. Durante esse
processo há uma intensa proliferação das células da granulosa e um aumento do volume
e diâmetro folicular, como resultado do acúmulo de água, íons, carboidratos e lipídios
(Amsterdam et al., 1989).
O folículo é considerado a unidade morfológica e funcional do ovário mamífero,
e tem duas funções principais: endócrina e gametogênica. A unidade folicular é composta
por um oócito circundado por células da granulosa e/ou tecais, sendo um elemento
essencial na promoção de um ambiente ideal para maturação, viabilidade, crescimento e
liberação de um oócito maduro no processo de ovulação (Cortvrindt and Smitz, 2001).
De acordo com o seu estágio de desenvolvimento, os folículos podem ser classificados
em pré-antrais (primordial, transição, primário e secundário) e antral (terciário e pré-
ovulatório) (Silva et al., 2004).
Os folículos primordiais são constituídos por um oócito primário (núcleo no
estágio de prófase da primeira divisão meiótica) circundados por uma camada de células
da pré-granulosa planas e uma membrana. Os folículos primordiais são os folículos de
menor tamanho e os mais numerosos no ovário mamífero (90% dos folículos) e
constituem a reserva de folículos quiescentes (Beckers et al., 1996). Eles podem ser
eliminados pelo processo de atresia ou continuar seu crescimento até ovulação
(McLaughlin and McIver, 2009).
Durante a fase inicial do crescimento dos folículos primordiais os folículos que
apresentam células da granulosa pavimentadas e cubicas são denominados de folículo de
transição (Silva et al., 2004). Aqueles que mantém seu crescimento ativo, se tornam
folículos primários, caracterizado por possuir um oócito circundado por uma camada de
células da granulosa cubóides (Picton, 2001).
23
As células da granulosa cubicas continuam a dividir-se e formam camadas
concêntricas. Com duas ou mais camadas de células ao redor do oócito, os folículos são
denominados de folículos secundários. Próximo à parte externa da membrana basal,
proliferam as células da teca que darão origem à teca interna e externa que são
responsáveis, juntamente como oócito, pelo funcionamento do folículo (Young and
McNeilly, 2010).
Quando os folículos secundários crescem, inicia-se na sequência a formação de
uma cavidade antral dando origem aos folículos terciários, que após um período de
desenvolvimento, caso escapem da atresia, poderão dar origem aos folículos maduros pré-
ovulatórios ou folículos de Graaf (Picton, 2001). A formação do antro faz com que as
células da granulosa se diferenciem em dois grupos: as células da granulosa murais, que
estão em contato com a membrana basal e têm uma função endócrina, e as células do
cumulus, que estão intimamente relacionadas com o oócito, e formam o complexo-
cumulus-oócito (CCO), que auxiliam no metabolismo e na maturação oocitária
(Gonçalves et al., 2008).
Nos folículos antrais, o antro é repleto com fluido folicular que atua como fonte
de oxigênio, tampão ácido-básico, hidratos de carbono, fatores de crescimento,
hormônios e outras substâncias (Sutton et al., 2003). O oócito completa o seu crescimento
quando o folículo que o contém entra na fase antral avançada, mas continua a maturar
(maturação nuclear e citoplasmática) até o final da foliculogênese. No citoplasma, as
alterações que ocorrem são destinadas à aquisição da capacidade de ser fertilizado pelo
espermatozoide, bloquear a polispermia, descondensar a cromatina do espermatozoide e
permitir a formação dos pró-núcleos masculinos e femininos, bem como as primeiras
divisões embrionárias (Ferreira et al., 2009). A nível nuclear, uma série de eventos
moleculares associados ocorrem em cascata com a retomada da meiose I: ruptura da
vesícula germinativa (RVG), a progressão na divisão meiótica, extrusão do primeiro
corpo polar e metáfase II (MII) (Tripathi et al., 2010). Além disso, ocorre a expansão das
células do culmulus.
Finalmente, o processo de foliculogênese termina quando o CCO é liberado de um
folículo maduro por ocasião da ovulação. Após a ovulação, a parede folicular
remanescente o sofre um processo de luteinização formando corpo lúteo.
24
2.2 ATRESIA FOLICULAR
O processo de atresia usualmente ocorre de forma diferenciada nos folículos pré-
antrais e antrais. Em folículos pré-antrais, os primeiros sinais de morte folicular surgem
no oócito, em que pode-se observar a retração da cromatina nuclear e a fragmentação
oocitária (Morita and Tilly, 1999). Após a formação do folículo antral ocorre uma
alteração na sensibilidade do oócito e das células da granulosa. A partir deste estágio, o
oócito torna-se mais resistente à atresia e as primeiras alterações indicativas de atresia são
observadas nas células da granulosa.
A atresia pode ocorrer por necrose e/ou apoptose (Saumande, 1981). A necrose é
iniciada por mecanismos não-celulares, tais como a isquemia, depleção de ATP (Bhatia,
2004) e fatores traumáticos ocasionados por alterações no fornecimento de oxigênio e
nutrientes para o ovário, que resultam em danos celulares irreversíveis (Mccully et al.,
2004).
Já a apoptose é um processo de morte celular ativo, que ocorre de forma ordenada
e demanda energia para a sua execução. Além disso, a ativação deste processo é
geneticamente determinada, ou seja, é regulada pela expressão de genes específicos
(Mccully et al., 2004), em que, provavelmente o desbalanço entre os fatores que
promovem a sobrevivência e aqueles que induzem a apoptose irá determinar quais os
folículos que continuarão o seu desenvolvimento ou sofrerão atresia (Bhatia, 2004). A
apoptose é mediada por mecanismos intrínsecos ou extrínsecos (Johnson, 2003), como
estresse oxidativo, irradiação, ativação de genes promotores da apoptose, danos no DNA,
citocinas, ou ausência de fatores de crescimento (Johnson, 2003). Outros fatores que
levam a apoptose folicular são os agentes quimioterápicos.
2.3 TOXICIDADE E FUNÇÃO REPRODUTIVA FEMININA
Empresas farmacêuticas e químicas produzem novos químicos na forma de novas
drogas para o tratamento de pacientes com câncer. Essas drogas podem interferir com a
síntese, secreção, transporte, ligação ou eliminação de hormônios naturais, e tem o
potencial para alterar o desenvolvimento reprodutivo e a fertilidade, levando a desordens
reprodutivas (Kort et al., 2014). Qualquer droga que atue como um agente tóxico
reprodutivo, tem um efeito direto no ovário e deve também ser capaz de alterar
25
mecanismos epigenéticos no oócito, resultando em efeitos epigenéticos ao longo das
gerações (Kang and Roh, 2010).
O ovário mamífero contém folículos em diferentes estágios de desenvolvimento,
que variam sua susceptibilidade a diferentes compostos (Stefansdottir et al., 2014).
Durante a foliculogênese, os folículos ovarianos entram em um período de crescimento
contínuo até eles entrarem em atresia ou desenvolverem até o estágio de folículos
maduros, acompanhados por uma rápida proliferação das células da granulosa. O estado
de crescimento contínuo, acompanhado pela parada meiótica do oócito durante a vida
reprodutiva feminina, faz dos folículos alvos vulneráveis para tóxicos reprodutivos
(Stefansdottir et al., 2014). Embora a estrutura folicular atue como uma barreira protetora
envolvendo o oócito, ela não protege necessariamente dos efeitos mutagênicos diretos ou
indiretos (Rekhadevi et al., 2014). Alguns compostos tóxicos são capazes de passar
através da membrana basal e têm o potencial de afetar o oócito, direta ou indiretamente,
ao afetar as células somáticas. Se essas drogas são capazes de afetar o pool de folículos
primordiais, elas podem causar a falência ovariana pré-matura, levando à infertilidade
pela depleção da reserva ovariana de folículos primordiais (De Vos et al., 2010). Por outro
lado, se o alvo dessas drogas é folículos em crescimento, isso pode resultar em atresia
folicular com subsequentes distúrbios cíclicos, causando a depleção do pool de folículos
primordiais (Meirow et al., 2010).
Existem diferentes rotas pelas quais os químicos podem interferir no
desenvolvimento do oócito. Agentes quimioterápicos podem afetar o fuso do oócito
durante a divisão meiótica, causando alteração no cromossomo (Fragouli et al., 2011).
Também, eles podem causar erros nos checkpoints meióticos, resultando em mutações
que têm potencial para a formação de embriões com aneuploidia e provalmente aborto
(Barekati et al., 2008), ou em outros casos, passam para as gerações subsequentes
(Stefansdottir et al., 2014).
Compostos tóxicos podem tanto atuar especificamente no oócito, ou ter impactos
mais amplos sobre as células somáticas (Orisaka et al., 2009). Qualquer efeito sobre as
células da granulosa e da teca pode alterar a produção de hormônios, perturbando o eixo
hipotalâmico-hipofisário-gonadal e o desenvolvimento folicular normal, afetando a
maturação do oócito (Canipari, 2000).
26
2.4 SISTEMAS DE CULTIVO IN VITRO
Diferentes sistemas de cultivo in vitro têm sido desenvolvidos com o objetivo de
promover o crescimento de folículos pré-antrais ou antrais até seu completo
desenvolvimento, originando oócitos fertilizáveis ( Jin et al., 2010; Eppig and O’Brien,
1996; Eppig and Schroeder, 1989). Esses cultivos têm se tornado de grande importância
para o estudo e compreensão da foliculogênese, bem como para avaliar o efeito de
diferentes substâncias. Essa biotecnologia tem sido estabelecida com sucesso em vários
modelos animais (camundongo, rato, vaca, ovelha, cabra, porca e primatas) ( Xuying et
al., 2011; McLaughlin and Telfer, 2010; Telfer et al., 2008; Hirao et al., 1994).
Modelos de cultivo in vitro de folículos pré-antrais na forma isolada ou inclusos
em fragmentos de tecido ovariano, ou mesmo no ovário inteiro, permitem controlar de
forma mais precisa do que os testes in vivo, o efeito de diferentes drogas sobre a
foliculogênese. Potenciais aplicações incluem o estudo dos mecanismos de ação das
substâncias tóxicas e como elas levam a danos no oócito e células somáticas, interferem
na qualidade do oócito, no estabelecimento do pool de folículos primordiais e nas
interações parácrinas (Sun et al., 2004). O cultivo também pode revelar o alvo de um
determinado composto sobre um estágio específico de desenvolvimento folicular,
permitindo avaliar se o referido composto afeta a integridade cromossômica do oócito,
ou se ele tem a capacidade de alterar a sinalização hormonal dentro e/ou entre os folículos
(Stefansdottir et al., 2014).
Os métodos de cultivo disponíveis para pesquisa toxicológica variam de acordo
com a espécie, estágio folicular, período e composição do meio de cultivo. Cada sistema
de cultivo tem suas vantagens e desvantagens, exigindo uma análise cuidadosa antes de
escolher o melhor método para um estudo de toxicologia (Stefansdottir et al., 2014).
2.4.1 Cultivo in situ e isolado de folículos pré-antrais
Os folículos podem ser cultivados “in situ”, ou seja, inseridos no córtex ovariano,
ou “isolados”. Em adição, o cultivo pode ser realizado em dois passos, podendo ser
iniciado com o cultivo de folículos in situ, seguido de uma etapa de cultivo de folículos
isolados (Brien et al., 2003; Telfer et al., 2008). O cultivo de pequenos fragmentos de
córtex ovariano tem sido realizado para o estudo da ativação e crescimento de folículos
27
em diferentes espécies, como caprinos (Silva et al., 2004), bovinos (Braw-Tal and
Yossefi, 1997), babuínos (Wandji et al., 1997) e humanos (Zhang et al., 2004). Além da
praticidade, o cultivo in situ apresenta também como vantagem a manutenção do contato
celular (Abir et al., 2006) e da integridade tridimensional dos folículos. No entanto, neste
tipo de modelo, embora haja uma expressiva ativação folicular, poucos folículos
primários cultivados progridem até o estágio de folículo secundário (Fortune, 2003).
O cultivo de folículos isolados apresenta como vantagens a possibilidade do
acompanhamento individual dos folículos durante o cultivo, além de favorecer melhor a
perfusão do meio para o folículo (Abir et al., 2006).
Uma vez isolados, os folículos podem ser cultivados em sistema bidimensional ou
tridimensional. No sistema bidimensional, o folículo é colocado diretamente sobre uma
placa de cultivo (exemplo superfície plástica) (Gonçalves et al., 2008), ou sobre uma
camada de células somáticas ou de matriz extracelular (exemplo o alginato). Já na forma
tridimensional, os folículos são cultivados inseridos em uma matriz extracelular, como
por exemplo, o colágeno ( Hirao et al., 1994; Carroll et al., 1991) ou gel de alginato (Xu
et al., 2009; West et al., 2007), mantendo a morfologia folicular intacta.
O fato do folículo permanecer com a morfologia intacta é muito importante, uma
vez que existe uma comunicação entre o oócito e as células somáticas que o circundam
(Spears et al., 1994), através das junções do tipo gap, pelas quais circulam fatores
parácrinos essenciais para proporcionarem crescimento e maturação do oócito
(Carabatsos et al., 2000). A perda desse contato causa ovulação pré-matura e liberação de
oócito degenerado (Eppig et al., 2005).
2.4.2 Técnicas de avaliação da eficiência do cultivo in vitro
Há um grande interesse no desenvolvimento de tecnologias que permitam o
crescimento e maturação in vitro de oócitos inclusos em folículos pré-antrais (maior
população de folículos presentes no ovário), devido às muitas aplicações que podem ter
tanto na reprodução assistida em humanos, como na produção animal.
Para a avaliação da eficiência do cultivo in situ pode ser utilizada a histologia
clássica para a análise quantitativa de folículos inclusos em tecido ovariano, com a
finalidade de verificar modificações na morfologia das células da granulosa, de
28
pavimentosa para cúbica. Assim, a histologia clássica permite classificar os folículos pré-
antrais quanto ao seu estágio de desenvolvimento (primordial, transição, primário ou
secundário), e ainda, quanto às suas características morfológicas (normais ou atrésicos).
Outras técnicas, tais como imunohistoquímica, também são amplamente utilizadas na
análise do cultivo in situ. Estas técnicas possibilitam analisar a proliferação celular,
apoptose e a expressão de moléculas de interesse (Gonçalves et al., 2008). O PCNA e o
AgNOR são marcadores apropriados para estudar a proliferação das células da granulosa.
Uma técnica empregada para avaliar a viabilidade de folículos pré-antrais isolados
e oócitos após o cultivo in vitro é a microscopia de fluorescência (Silva et al., 2011; Bruno
et al., 2010), a qual utiliza marcadores fluorescentes, que quando excitados com radiação
de baixo comprimento de onda, absorvem energia e emitem luz de comprimento de onda
maior (Gonçalves et al., 2008). Os marcadores comumente utilizados são o etídio
homodímero-1 e calceína-AM, que permitem a detecção simultânea de células mortas e
vivas, respectivamente. O etídio homodímero-1 marca ácidos nucléicos em células não
viáveis, indicando a perda da integridade da membrana plasmática das células (Gonçalves
et al., 2008), enquanto a atividade enzimática (esterases) no citoplasma é detectada nas
células foliculares através do composto calceína-AM, que é clivado por enzimas esterases
em células vivas, resultando em um produto fluorescente (De Clerck et al., 1994). A
microscopia de fluorescência é empregada ainda no intuito de avaliar a configuração da
cromatina de oócitos oriundos de folículos pré-antrais, indicando assim o estágio meiótico
alcançado após terem sido cultivados e maturados in vitro (Saraiva et al., 2010)G. Para
tal finalidade, utiliza-se o Hoescht 33342, que penetra em células vivas e se intercala entre
as bases nitrogenadas do DNA.
A quantificação dos níveis de RNAm para as diferentes substâncias (ligantes e
receptores) que atuam durante a foliculogênese, também é considerada uma importante
ferramenta para auxiliar na compreensão desse processo, uma vez que permite detectar
alterações nos padrões de expressão gênica que ocorrem em resposta à fenômenos
relacionados à sobrevivência, ao crescimento e à diferenciação celular (Zamorano et al.,
1996). Dentre as técnicas comumente utilizadas para esta finalidade, pode-se destacar a
qPCR.
Outras ferramentas para a análise da eficiência do cultivo e da competência
oocitária são a fertilização in vitro (FIV) e a produção in vitro de embriões (PIV). A PIV
29
é uma excelente ferramenta para pesquisa de fenômenos biológicos que ocorrem durante
a maturação, fecundação e cultivo in vitro de oócitos, capacitação espermática e eventos
relacionados ao início do desenvolvimento embrionário na fase de pré-implantação.
Devido à sua capacidade de produzir um grande número de embriões, a PIV se tornou um
instrumento indispensável para outras biotécnicas como a clonagem, a manipulação de
genes e a transferência de núcleos (Gonçalves et al., 2007).
2.5 DOENÇAS TUMORAIS NEOPLÁSICAS
As doenças tumorais neoplásicas vêm sendo indicadas como a terceira causa de
morte mais frequente no Brasil (Machado and Melo-junior, 2009). No mundo, o câncer é
responsável por mais de 12 % de todos os óbitos, e é alvo de pesquisas para o
desenvolvimento ou descoberta de novas formas de tratamento (Saúde, 2008), uma vez
que a resistência adquirida aos medicamentos anticancerígenos já existentes é encontrada
em grande parte dos pacientes, além da ocorrência de inúmeros efeitos adversos que
limitam a eficácia do tratamento.
2.5.1 Terapêutica do câncer
Atualmente, o tratamento dos cânceres, em sua grande maioria, é considerado
como um dos problemas mais desafiadores da medicina. A partir do momento que a
neoplasia primária causa metástase pelo corpo do hospedeiro, o prognóstico se torna ruim,
sendo a quimioterapia antineoplásica a principal forma de tratamento neste estágio. Uma
vantagem deste tratamento é a de atingir igualmente as metástases disseminadas pelo
corpo. Entretanto, há desvantagens importantes a serem consideradas, principalmente
aquelas relacionadas aos seus efeitos colaterais, pois em sua grande maioria, estes
medicamentos apresentam baixo índice terapêutico, ou seja, dose terapêutica muito
próxima à dose tóxica (Chabner and Roberts, 2005). Desta maneira, a pesquisa, tanto
básica como aplicada, é fundamental e deve ser estimulada, para que medicamentos
antineoplásicos mais eficazes e seguros sejam descobertos, incluindo drogas que não
afetem a função reprodutiva, ou seja, não sejam tóxicas aos ovários.
Com o objetivo de tratar o câncer com maior eficácia, esquemas terapêuticos
utilizando cirurgia, radioterapia e quimioterapia têm sido cada vez mais prevalentes
30
(Reiner et al., 2009). Cada um destes tratamentos visa erradicar o câncer, normalmente
por meio da terapia combinada, em que é associado mais de um tipo de tratamento.
Através da cirurgia ou radioterapia, um terço dos pacientes consegue ser curado através
de medidas locais, que são eficazes quando o tumor ainda não sofreu metástase por
ocasião do tratamento. Todavia, nos demais casos, a neoplasia caracteriza-se pelo
desenvolvimento precoce de micrometástases, indicando a necessidade de uma
abordagem sistêmica, que pode ser efetuada, em cerca de 60-70% dos casos, com a
quimioterapia (Almeida et al., 2005). Esta medida terapêutica consiste na utilização de
medicamentos a fim de destruir as células cancerosas, bloqueando o seu
desenvolvimento. Entretanto, a maioria dos agentes quimioterápicos atua de forma não
específica, lesando tanto células malignas quanto normais (Almeida et al., 2005). Porém,
o corpo recupera-se destes inconvenientes após o tratamento, e o uso clínico desses
fármacos exige que os benefícios sejam confrontados com a toxicidade, na procura de um
índice terapêutico favorável (Almeida et al., 2005).
Muitas drogas usadas na quimioterapia do câncer, além de possuir toxicidade
contra células tumorais, exibem efeitos genotóxicos, carcinogênicos e teratogênicos sobre
células normais, revelando uma baixa especificidade dessas drogas contra os tecidos
tumorais, resultando em efeitos não desejáveis no tratamento. A Doxorrubicina (DXR) é
um fármaco amplamente utilizado em pacientes com câncer (Oktem and Oktay, 2007).
Estudos recentes revelam que a DXR induz toxicidade ovariana, que é observada pela
redução da taxa de ovulação, juntamente com uma redução no tamanho do ovário (Ben-
Aharon et al., 2010; Oktem and Oktay, 2007). Neste contexto, os compostos derivados
de plantas (fitoterápicos) também têm sido uma fonte alternativa de moléculas
clinicamente úteis no tratamento do câncer (Cragg and Newman, 2005).
2.6 FITOTERAPIA
A expressão fitoterapia é atribuída aos medicamentos originados exclusivamente
de material botânico integral ou seus extratos utilizados com o propósito de tratamento
médico (Dewick, 2009).
Antes a fitoterapia era utilizada principalmente por populações carentes, isso pelo
fato da boa disponibilidade e menor custo. A fitoterapia e predominante em países
31
emergentes, sendo bem estabelecida em culturas e tradições, especialmente na Ásia,
América Latina e África (Shale et al., 1999).
Existe um interesse crescente no uso de produtos naturais, principalmente os
derivados de plantas. De acordo com Gurib-Fakim (2006), os produtos naturais e seus
derivados representam mais de 50% de todas as drogas utilizadas no mundo, e as plantas
medicinais contribuem com 25% deste total. Alguns exemplos de drogas obtidas a partir
de plantas são a Digoxina da Digitalis spp., Quinina e Quinidina obtidas da Cinchona
spp., Vincristina e Vinblastina oriundas da Catharanthus roseus, Atropina procedente de
Atropa belladona e Morfina e Codeína provenientes de Papaver somniferum (Rates,
2001).
A possibilidade de utilizar as plantas medicinais como fonte de substâncias
medicamentosas reside na capacidade de produzirem, a partir de seu metabolismo,
substâncias químicas que exercem alguma atividade sobre outros organismos vivos.
Baseado nessas atividades e que se procuram os efeitos terapêuticos para o tratamento de
doenças tanto em animais como em humanos (Boukandou et al., 2015). As plantas podem
sintetizar dois tipos de metabólitos: primários e secundários. A extensa e diversificada
flora do Brasil e um recurso natural de imenso potencial para a obtenção de metabólitos
secundários, muitos dos quais podem ser utilizados com finalidade terapêutica (da Silva
et al., 2016). De acordo com Gurib-Fakim (2006), as atividades biológicas das plantas
são atribuídas a esses metabólitos. As propriedades antifúngica, antibacteriana,
antineoplasica, imunomoduladora e antiparasitaria das plantas têm sido bastante
exploradas (Silva et al., 2016).
Algumas dessas plantas têm uma longa história de uso no tratamento de câncer. O
maior impacto recente de drogas derivadas de plantas foi provavelmente nesta área, em
que Taxol, Vinblastina, Vincristina e Camptotecina melhoraram drasticamente a eficácia
da quimioterapia contra alguns dos piores cânceres. Na verdade, mais de 60% dos agentes
anticancerígenos utilizados são derivados da natureza (Cragg and Newman, 2005).
Apesar deste vasto conhecimento, ainda são limitadas as investigações cientificas visando
determinar o potencial terapêutico das plantas (Duarte, 2006).
Estudos têm demonstrado que as populações locais da região do semiárido
brasileiro possuem um vasto conhecimento sobre a utilidade medicinal de determinadas
espécies de plantas, como por exemplo, a Auxemma oncocalyx (A. oncocalyx), também
32
conhecida como Pau-Branco, o que pode contribuir para a conservação da biodiversidade
e sua função dentro do ecossistema (Albuquerque and Oliveira, 2007).
A Auxemma oncocalyx é uma planta nativa da caatinga do Nordeste brasileiro, e
vem sendo bastante utilizada pela medicina popular. Seu composto ativo oncocalyxona
A (onco A) é conhecida por ter diversas propriedades bioquímicas, como antioxidante,
anti-inflamatório, anti-plaquetário e anti-cancerígeno. Mais informações sobre a planta e
seu composto ativo encontrasse no artigo de revisão (Capítulo 1).
33
3 JUSTIFICATIVA
Os fitoterápicos sofrem uma grande restrição quanto ao seu uso e aceitação,
devido ao reduzido número de estudos que comprovam sua ação biológica e segurança
quanto a efeitos tóxicos agudos, crônicos ou sobre a reprodução (Sharapin, 1999). Dentre
os critérios de segurança necessários, estão os estudos sobre a toxicidade reprodutiva dos
produtos fitoterápicos, que incluem uma avaliação das ações sobre a fertilidade e a
performance reprodutiva para os produtos administrados, durante a gametogênese e
fecundação.
Vários métodos in vitro para avaliar a toxicidade de substâncias foram
padronizados utilizando-se cultivos celulares. Um dos modelos experimentais utilizados
para avaliação da toxicidade in vitro, que surge como alternativa previa aos estudos in
vivo, é a biotécnica de Manipulação de Oócitos Inclusos em Folículos Pré-Antrais
(MOIFOPA/ Ovário artificial). A MOIFOPA consiste no isolamento, conservação
(resfriamento e criopreservação) e/ ou cultivo in vitro de folículos pré-antrais, visando a
ativação, crescimento e maturação in vitro dos folículos primordiais até o estágio pré-
ovulatório. Além de ter importantes aplicações para a pesquisa fundamental e reprodução
assistida animal e humana, esta biotécnica também representa uma excelente alternativa
para incrementar e auxiliar no desenvolvimento de pesquisas relacionadas à indústria
farmacêutica (Figueiredo, 2008). Portanto, a importância do presente trabalho visa dar
continuidade às pesquisas relacionadas ao ovário artificial, testando a sua aplicação no
teste de toxicidade de substâncias de interesse terapêutico empregadas em humanos.
O uso de material humano é bastante problemático na pesquisa, devido a
dificuldades éticas, e até mesmo de obtenção de material de pesquisa. Assim, diversos
autores têm utilizado animais em suas pesquisas antes de sua aplicação em humanos. Um
exemplo disto é a utilização de tecido ovariano de cabras com objetivo de verificar o
efeito de diferentes substâncias no desenvolvimento folicular. Isso seria possível devido
ao fato desse animal ter uma foliculogênese semelhante à humana, além da própria
estrutura ovariana que também é semelhante (Amorim et al., 2004) Por outro lado, a
espécie suína representa um modelo ideal para o teste de toxicidade de competência
oocitária e qualidade embrionária. Em comparação com as outras espécies, a espécie
suína é um modelo animal bastante utilizado como um modelo para oócitos humanos em
34
testes de toxicidade (Gerritse et al., 2008; Munn et al., 1986). Além disso, a vantagem de
utilizar ovários de porcas é que os ovários são obtidos a partir de animais em idade
semelhante, raça e nutrição controlada.
Uma das principais vantagens da utilização de modelos animais in vitro e
possibilidade de testar substâncias como novos antibióticos, hormônios, fatores de
crescimento e quimio e fitoterápicos poderão ter seus efeitos testados (benéfico ou tóxico)
sobre os oócitos in vitro. A utilização desta biotécnica como método laboratorial para
testes de drogas traz importantes consequências para o bem-estar animal, uma vez que
milhares de animais serão poupados de serem utilizados em experimentos/ testes no que
concerne aos testes in vivo (Figueiredo, 2008).
Dentre as plantas medicinais estudas por diversos autores, podemos destacar a
Auxemma oncocalyx (Pau-Branco-do-Sertão). Conforme já descrito anteriormente, esta
planta possui diversas atividades biológicas. O extrato hidroalcoólico dessa planta
mostrou ação antitumoral, analgesica e antinflamatória (Ferreira et al., 2004; Lino et al.,
1996; Pessoa et al., 1992). Estudos de quinonas isoladas, como o caso da oncocalyxona
A, observaram fortes atividades como antiagregante plaquetaria, antioxidante,
antinflamatória, analgesica, antitumoral e antifungica (Sun et al., 2016; Lee et al., 2015;
Ferreira et al., 2003; Leyva et al., 2000). Além disso, essa planta vem sendo utilizada pela
medicina popular por possuir diversas propriedades medicinais. A casca, por exemplo, e
muito utilizada para auxiliar na cicatrização de ferimentos (Pessoa, 1994; Braga, 1976).
Entretanto, apesar desses vários estudos, ainda não é conhecido o efeito dessa planta sobre
a fertilidade feminina.
35
4 HIPÓTESE CIENTÍFICA
Diante do exposto, foi formulada a seguinte hipótese científica:
Auxemma oncocalyx e onco A apresentam um efeito menos tóxico do que o
controle (tóxico) positivo DXR sobre a sobrevivência e crescimento folicular (espécie
caprina), maturação oocitária (espécies caprina e suína) e desenvolvimento
embrionário inicial in vitro (espécie suína).
36
5 OBJETIVOS
5.1 OBJETIVO GERAL
Avaliar o efeito da Auxemma oncocalyx e seu composto ativo a oncocalyxona A
sobre o cultivo in vitro de folículos pré-antrais, maturação oocitária e qualidade
embrionária.
5.2 OBJETIVOS ESPECÍFICOS
Avaliar o efeito da concentração-resposta da A. oncocalyx (1,2; 12 ou 34 μg/ml) e
onco A (1; 10 ou 30 μg/ml) sobre a sobrevivência, ativação, crescimento folicular e
oocitário após o cultivo in vitro de folículos pré-antrais caprinos inclusos em fragmentos
de tecido ovariano (Fase I);
Investigar o efeito da A. oncocalyx e onco A, utilizando as concentrações definidas
na Fase I, sobre a sobrevivência folicular, formação de antro e o crescimento de folículos
secundários isolados caprinos cultivados in vitro, bem como sobre a viabilidade e a
maturação nuclear de oócitos recuperados de folículos antrais caprinos (Fase II);
Avaliar o efeito da exposição da A. oncocalyx e onco A durante a maturação in
vitro de oócitos (Experimento 1) ou durante o cultivo in vitro de embriões (Experimento
2) sobre a maturação oocitária desenvolvimento embrionário inicial na espécie suína
(Fase III).
37
6 PROPRIEDADES DA PLANTA AUXEMMA ONCOCALYX E SEU PRINCÍPIO
ATIVO ONCOCALYXONA A
“Properties of the plant Auxemma oncocalyx and its active principle oncocalyxone A”
Periódico: Phytotherapy research (submetido) (ISSN: 1099-1573)
Factor de impacto: 2.694
38
RESUMO
Atualmente, existe uma constante necessidade de pesquisar novas drogas, sendo as
plantas cada vez mais reconhecidas por seu potencial terapeutico. Assim, o estudo das
atividades farmacológicas de plantas é crucial para identificar sua eficácia, e em muitos
casos, validar a utilização popular de plantas medicinais. Auxemma oncocalyx (A.
oncocalyx) é uma árvore pertencente à família Boraginaceae, endêmica do nordeste do
Brasil. Esta planta vem sendo amplamente utilizada na medicina popular, e seus extratos
hidroalcóolicos contém principalmente a Oncocalixona A (Onco A). Nesta revisão, serão
abordadas a ecologia e biologia de A. oncocalyx. Adicionalmente, as propriedades
biológicas de A. oncocalyx e Onco A, como ação anti-inflamatória e analgésica, efeito
antiplaquetário e antioxidante, toxicidade e potencial anticancerígeno também serão
discutidas.
Palavras-chave: Auxemma oncocalyx. Oncocalyxona A. toxicidade. Terapia de câncer.
Propriedades biológicas.
39
Title: Properties of the plant Auxemma oncocalyx and its active principle Oncocalyxone
A
Leiva-Revilla J. *1, Lunardi F. O. 1, Araújo V. R. 1, Celestino J. J. H. 2, Rodrigues A. P.
R. 1, Figueiredo J.R1.
1 Faculty of Veterinary Medicine, LAMOFOPA, PPGCV, Universidade Estadual do
Ceará, Fortaleza-CE, Brazil. Av. Paranjana, 1700. Itaperi. 60740000 - Fortaleza, CE –
Brasil. Telephone: (+55 85) 31019852
2 Institute of Health Sciences, Universidade da Integração Internacional da Lusofonia
Afro-Brasileira. Acarape-CE, Brazil. Rodovia CE 060 Km51. 62785000 - Acarape, CE –
Brasil. Telephone: (+55 85) 33731593
* Corresponding author; Av. Paranjana, 1700. Itaperi. 60740000 - Fortaleza, CE – Brasil.
Telephone: (+55 85) 31019852. Fax: (+55 85) 31019840. e-mail address:
40
ABSTRACT
Nowadays, there is a constant need to search for new drugs, and plants have become
increasingly recognized for their therapeutic potential. Thus, the study of the
pharmacological activities of plants is crucial to verify the effectiveness and, in many
cases, to validate the popular uses of these medicinal plants. Auxemma oncocalyx (A.
oncocalyx), is a tree that belongs to the Boraginaceae family, and it is native of the
northeast of Brazil. This plant has been widely used in folk medicine and the
hydroalcoholic extract contains its principal component, the Oncocalyxone A (Onco A).
In this review, the ecology and biology of the A. oncocalyx is evaluated. In addition, the
biological properties of A. oncocalyx and Onco A, such as their anti-inflammatory and
analgesic action, antiplatelet and antioxidant effect, toxicity and anticancer potential are
also discussed.
Keywords: Auxemma oncocalyx, Oncocalyxone A, toxicity, cancer therapy, biological
proprieties
41
1. Introduction
Plants have become increasingly recognized for their therapeutic potential,
representing an excellent source of raw material in the production of new drugs (Gossell-
Williams et al., 2006). Thus, the study of the pharmacological activities of plants is of
paramount importance in order to prove the effectiveness, and in many cases to validate
the popular uses of these medicinal plants (Schmitt et al., 2003).
Among these plants we can quote Auxemma oncocalyx, popularly known as "Pau-
Branco", which is a tree that belongs to the Boraginaceae family. It is a plant native of
the Caatinga (semi-arid forest occurring only in Brazil) (Maia, 2004), and it is mainly
found in the state of Ceará and Rio Grande do Norte (Braga, 1976). This plant has been
widely used in folk medicine. The shell, for example, is widely used in the adjunctive
treatment of injuries such as wound healing (Braga, 1976; Pessoa, 1994). Moreover, it
has a forage value as food for vertebrates (caprine, murine and birds) and invertebrates
(Coleoptera, Diptera, Lepidoptera and Hemiptera), mainly due to the high protein and
lipid content of its fruits (Tigre, 1970). Additionally, this plant has a high ornamental
value, particularly in afforestation, and agroforestry, being used as a windbreak crop. It
is also used in reforestation of degraded areas (Maia, 2004), besides being used in
woodworking.
The hydroalcoholic extract of the stem has shown an antitumoral, analgesic,
antioxidant and anti-inflammatory action (Ferreira et al., 2004, 2003; Lino et al., 1996).
On the other hand, the branches have presented properties against Trypanosoma spp.
(Braga, 1976).
Pharmacological studies have shown an antiplatelet action and vasoconstriction
in conductance vessels from the methanolic extract of the heartwood of the stem. This
42
action is attributed to its active principle, the Oncocalyxone A (Onco A) (Sousa et al.,
2002).
Pessoa and Lemos (Pessoa and Lemos, 1997) isolated allantoin from the
hydroalcoholic extract of the A. oncocalyx. Furthermore, the rel-hydroxy-8a-hydroxy-5-
methyl-8ab-methyl-7-methoxy-2,8.8-0.9-tetrahydro-1,4-anthracenedione, also known as
Onco A, which represents 80% of the A. oncocalyx fraction (Pessoa et al., 1995, 1993),
was also isolated from the same extract. Other components and derivatives such as 6-
chloro-oncocalixona A, 11-O-acetyl-oncocalyxone A, and 8,11-O-diacetyl-oncocalyxone
have been isolated from the ethanol extract (Pessoa et al., 2004). Several studies have
shown that Onco A and these derivatives have a cytotoxicity against tumor cells (Pessoa
et al., 2004, 2003).
After the increasing rate of studies about the A. oncocalyx and its isolated
compounds, it becomes necessary to know more about the biological properties of this
plant. Given the importance of this plant as a possible chemotherapeutic drug, in the
present work we review the most relevant outcomes obtained to date, with an overview
of the biology of the plant and its biological properties.
2. Ecology and biology of Auxemma oncocalyx
A. oncocalyx (Boraginaceae) is a common tree found in the state of Ceará and Rio
Grande do Norte, Northeast of Brazil (Braga, 1976). This tree has between 6 to 8 meters
tall whereas the diameter of the trunk is 30 to 40 cm. It is characterized by small, dense
and white flowers, being this a peculiarity that attributes to its popular name (Maia, 2004).
The leaves are simple, alternate, elliptic, serrated from the middle to the apex and with
membranous consistency. Its fruits are glabrous drupes of 2.5 cm (Lima, 1989). Nozella
43
(Nozella, 2006) studied the nutritional value of native tree-shrub species of the semi-arid
region of northeast of Brazil, which are considered an important source of proteins for
the animals of this region, mainly during the dry season. Among these species, he
evaluated the A. oncocalyx, and according to the results of tannin concentrations, it has
been considered safe for animal nutrition (Nozella, 2006). Previous investigations of
Auxemma species resulted in isolation of eight compounds classified as cordiachromes
(Pessoa et al., 1995) and hydroquinones (da Costa et al., 1999; Pessoa et al., 1995, 1993).
The cordiachromes are a class of meroterpenoids present in A. oncocalyx and other plants
such as Auxemma glazioviana (da Costa et al., 1999). Some authors suggest that this
cordiachromes have antimycobacterial activity (Dettrakul et al., 2009), which helps the
tree against fungi and termite infestation (da Costa et al., 1999). On the other hand,
hydroquinones play an important role in electron transport, photosynthesis, and also, they
act as antioxidants (Dewick, 2009). Marques et al. (Marques et al., 2000) reported the
isolation and structural elucidation based on spectral analysis of three anthracene
derivatives such as auxenone, oncocalyxonol and auxemim.
The quinone fraction (QF) is prepared from the ground heartwood methanolic
extract through exhaustive aqueous extraction followed by lyophilization. The
hydrosoluble fraction contained around 80% of Onco A (Ferreira et al., 2004; Pessoa et
al., 1993), which was previously characterized in another study (Pessoa et al., 1993).
Allantoin is isolated from the hydroalcoholic extract of the stem (Pessoa et al., 1995)
Allantoin is a compound that has various pharmacological activities, like wound healing,
and stimulating cellular mitosis and promoter of epithelial stimulation. Allantoin is very
used in cosmetic and pharmaceutical preparations (Qunaibi et al., 2009). Araújo et al.,
(Araújo et al., 2010) suggested that the mechanism induced by allantoin in the wound
44
healing process occurs via the regulation of inflammatory response and stimulus of
fibroblastic proliferation and extracellular matrix synthesis.
Many biological effects have been attributed to this plant, and most of them relates
to the Onco A. So far, studies have presented various properties of Onco A, such as anti-
inflammatory, antiplatelet, antioxidant and anti-carcinogenic as described in Table 1.
These properties will be better described below.
3. Biological proprieties of Auxemma oncocalyx and Oncocalyxone A
3.1 Anti-inflammatory and analgesic
Although widely used by the population as an anti-inflammatory and analgesic
drug, few scientific reports exist testing the action of A. oncocalyx for these purposes.
The quinones present in the fraction of A. oncocalyx, which contains 80% of Onco A
(Pessoa et al., 1993), are possibly responsible for the analgesic and anti-inflammatory
activity.
The reduction of induced paw edema and inhibition of induced abdominal
contractions in mice was observed in a dose dependent-manner (1 and 5 mg/kg body) of
QF, indicating an action on the inflammatory process, possibly due to the blockade of
prostaglandin synthesis (Ferreira et al., 2004). In the same experiment, the analgesic
ability of the QF was evaluated by an induction of acetic acid in mice and through the use
of the formalin test, which is considered as a good model for chronic pain (Dubuisson
and Dennis, 1977). It was observed that the acetic acid produced a painful reaction with
an acute inflammation in the peritoneal area. This study showed that, when these animals
were treated with the QF of A. oncocalyx, there was a dose-dependent inhibition of
45
abdominal contractions induced by acetic acid, and a positive response to formalin, thus,
showing the analgesic properties of the QF of A. oncocalyx.
3.2 Antiplatelet and antioxidant
The antiplatelet effect of Onco A has been previously described (Ferreira et al.,
2008, 1999). Ferreira et al. (Ferreira et al., 2008) tested the effect of Onco A in human
platelet cells, and showed that there was a reversal inhibitory effect concentration-
dependent. According to these authors, Onco A inhibits ATP liberation, and increase
cGMP levels without affecting cAMP and nitric oxide (NO) levels, causing the inhibition
of platelet aggregation. Onco A inhibited induced-aggregation probably by interfering
with a similar step of platelet activation (Haslam et al., 1999). However, Onco A had no
effect in NO production in human platelets, suggesting that the increase in cGMP levels
observed in this study was not dependent on a NO mechanism. This information suggests
that Onco A might by acting in two ways, downstream of the activation of soluble
guanylate cyclase (sGC) or, in a similar way of NO-independent activators of sGC, which
act by a synergistic mechanism that combine an increased production and reduced
degradation of cGMP (Ferreira et al., 2008).
Another reported action of Onco A, although with fewer studies, is its antioxidant
activity. Recently, interest in antioxidants action in biological systems has grown steadily,
possibly because it is associated with preventing tissue damage and release of free radicals
(Saeidnia and Abdollahi, 2013). In general, antioxidants are substances that prevent
deleterious damage from oxidation by inhibiting lipid peroxidation, or by sequestering
free radicals and chelating metal ions (Ferreira et al., 2003).
Toxicological studies have shown that synthetic antioxidants are capable of
causing harmful effects in animals and humans (Bouayed and Bohn, 2010). Thus, this
46
indicates the importance of studying the use of natural antioxidants, such as Onco A, in
biological systems.
The QF hepatotoxicity in rats was evaluated by induction with Carbon
tetrachloride (CCl4). CCl4 is known to induce intoxication through the production of free
radicals and lipid peroxidation. Mice treated with the QF showed a higher
hepatoprotective activity, possibly because of its antioxidant activity (Ferreira et al.,
2003). Onco A caused an inhibition of the cytochrome P-450 activity. Moreover, it was
able to stop the lipid peroxidation process, stabilized the hepatocellular membrane, and
improve protein synthesis (Ferreira et al., 2003). From all these data, Ferreira et al.
(Ferreira et al., 2008) suggested that Onco A could be a promising component for the
development of anti-thrombotic drugs.
3.3 Toxicity
Several authors reported the toxic effect of A. oncocalyx and Onco A. The effect
of different concentrations (1 – 100 µg/mL) of the quinone fraction of A. oncocalyx
(containing 80% of Onco A) on sea urchin eggs demonstrated that QF was capable of
inhibiting the cleavage of these eggs in a concentration-dependent manner. The beginning
of the destruction of the embryos started at the blastocyst stage with a concentration of
10 µg/mL, and there was a total destruction of the embryos (100%) with a concentration
of 30 µg/mL (Costa-Lotufo et al., 2002b). In another study, the cytotoxicity of Onco A
and other compounds in CEM leukemia cells and SW1573 lung tumor cells using
concentrations between 1 and 18 µg/mL was verified, demonstrating that all the
compounds caused cell death and inhibition of cell growth at concentration above 5
µg/mL in CEM cells. DNA damage of CEM cells was seen at concentrations of 5 µg/mL
for all four compounds, and a significant deleterious effect on DNA was observed as from
47
a concentration of 2 mg/mL of Onco A (Pessoa et al., 2004). Another study evaluated the
effect of different substances, among them Onco A and Onco C, in different
concentrations (0.4; 0.8; 1.6; 3.1; 6.2; 12.5 e 25 µg/mL) on human cells lines (CEM
leukemia, SW1573 lung tumor and CCD922 normal skin fibroblasts). This study showed
that both of them produced cytotoxicity with mean half maximal inhibitory concentration
(IC50) values of 0.8–2, 7–8 and 12–13 mg/mL against CEM, SW1573 and CCD922
respectively (Pessoa et al., 2000). Leyva et al. (Leyva et al., 2000) showed that
oncocalyxones A and C, both isolated from A. oncocalyx, were also cytotoxic to
multidrug resistant lung tumor cell lines (SW 1573, SW1573-S1, SW 1573-2R160),
which were moderately or even highly resistant to the conventional anticancer drugs
doxorubicin (DXR) and mitoxantrone. The cytotoxicity associated with these compounds
can be attributed to redox cycling and subsequent development of oxidative stress (Monks
and Lau, 1992). Thus, the cellular damage can occur by DNA alkylation (Bolton et al.,
2000). Consequently, quinones have a high toxicity related to their antimitotic properties.
Pessoa et al. (Pessoa et al., 2003) showed that the Onco A at the concentration of 0.5
g/mL was similar to 0.01 µg/mL DXR with regard to cytotoxicity in lymphocytes.
Lima (Lima, 2008) studied the effect of an aqueous extract of the leaves of A.
oncocalyx on the growth of bacterial culture. The study showed that this extract inhibited
the growth of gram-positive microorganisms, such as Bacillus subtilis and
Staphylococcus aureus. This antibacterial effect showed another toxic capacity of the A.
oncocalyx (Lima, 2008).
3.4 Anticancer
Several studies have reported the antitumoral activity of A. oncocalyx fraction and
Onco A. Moraes et al. (Moraes et al., 1997) was the first one to report the antitumoral
48
activity of the hidroalcoholic extract of A. oncocalyx. The study evaluated the anti-
cancerigenous effect of the extracts of 72 samples of plant species from northeastern
Brazil. Among many of the studied plants, A. oncocalyx showed an inhibitory activity
against Walker malignant tumor cells.
Other studies compared the cytotoxicity of Onco A with two conventional
anticancer agents, DXR and mitoxantrone, in a panel of human tumor cell lines. They
found that the IC50 was between 1.2 + 0.5 and 18 + 3.2 µg/mL depending on the cultured
cell line, and when multidrug resistant cell type were tested, Onco A showed a very high
potency when compared with DXR and Mitoxantrone (Leyva et al., 2000).
Pessoa et al. (Pessoa et al., 2000) showed that Onco A had an antitumoral activity
at a concentration between 0.8-2 µg/mL in leukemia cells. The antitumoral activity was
verified as the ability of Onco A to inhibit tumor cell line proliferation in the MTT [3-
(4’-5’- dimethylthiazol-2’-yl)-2.5-diphenyl-tetrazolium bromide] assay and this
cytotoxicity was related to the induction of DNA damage and the inhibition of DNA
synthesis. Finally, these authors suggested that this compound had moderate anticancer
potential.
There are several methods for testing genotoxic and cytotoxic potential. The
cytogenetic analysis represents an ideal tool to determine the DNA damage induced by
interaction of cells with exogenous substances. DNA damage can induce chromosomal
aberrations that can be used as mutagenic markers (Bahia et al., 1999).
Most anticancer compounds act at lower concentrations i.e., 1 µg/mL or 1 µM,
depending on the cultured cell line (Pessoa et al., 2000). Onco A can act between 0.8 and
18 µg/mL (Leyva et al., 2000; Pessoa et al., 2004, 2000). However, in cytotoxicity level,
derivatives from A. oncocalyx fraction can be less cytotoxic and less reactive against
49
leukemia cell DNA (Pessoa et al., 2004) than DRX, which is a widely used drug in cancer
treatment (Minotti et al., 2004).
To try to explain the effect of Onco A on cell growth, Pessoa et al. 15 evaluated
this effect in different phases of lymphocyte cell division (G1, G1/S and S). Onco A
showed similar cytotoxic results in G, G1/S and S phases when compared with DXR, but
only DXR showed genotoxicity. Genotoxicity can cause the occurrence of DNA
alterations leading to the possible formation of other tumors. The effect of Onco A was
seen in the DNA synthesis, in the transition G1/S. These results suggest that Onco A
possible interfere in the mechanisms involved in cell division and in the formation of the
spindle (Pessoa et al., 2003).
Many drugs used in cancer chemotherapy, in addition to having toxicity against
tumor cells, exhibit genotoxic, carcinogenic and teratogenic effects on normal cells,
showing a low specificity of these drugs against tumor tissue resulting in undesirable
effects of the treatments. For example, recent studies reveal that DXR induced ovarian
toxicity, which is observed by the reducing of the ovulation rate, together with a reduction
in the size of the ovary (Bar-Joseph et al., 2010; Ben-Aharon et al., 2010; Oktem and
Oktay, 2007). It its known that DXR elicits apoptosis by various mechanisms in a variety
of cells. It can be accumulated in both nucleus and mitochondria and induce chromosomal
obliteration by inhibiting topoisomerase-II. DXR can also interfere with mitochondrial
function and initiate an intrinsic pathway of apoptosis via the mitochondria by reducing
the mitochondrial membrane potential (MMP) and releasing cytochrome C (Bar-Joseph
et al., 2010) on cytoplasmic space. A oncocalyx and Onco A can be acting in a similar
pathway of DXR, but without causing genotoxicity (Pessoa et al., 2003), which may lead
to a more effective anticancer drug.
50
Barreto et al. (Barreto et al., 2013) described a new magnetic nano-system for
cancer therapy (MO-20), which facilitates the release of drugs at specific sites. This
system uses Onco A as a possible anticancer drug. The results showed potential future
applications of this technology (MO-20) with Onco A for cancer treatments.
4. Final Considerations
There are several properties of A. oncocalyx and Onco A, like anti-inflammatory,
analgesic, antiplatelet, antioxidant, cytotoxic and antitumor. It is important to emphasize
that Onco A has a cytotoxic effect on cancer cells in vitro without causing genotoxicity.
However, a study showed that Onco A caused embryo destruction and inhibition of
proliferation of tumor cells. Thus, further studies are needed to better understand the
mechanisms of A. oncocalyx and Onco A, especially in the field of anticancer activity and
toxic effect on organs and cells.
5. Conflicts of Interest
We wish to confirm that there are no known conflicts of interest associated with
this publication and there has been no significant financial support for this work that could
have influenced its outcome.
6. Bibliography
Araújo, L.U., Grabe-guimarães, A., Furtado, C.V., Martins, C., Silva-Barcellos, M.,
2010. Profile of Wound Healing induced by allantoin. Acta cirúrgica Bras. 25,
51
460–466.
Bahia, M.O., Estefhane, B., Burbano, R.R., Amorim, M.I.M., Dubeauo, H., 1999.
Genotoxic effects of mercury on in vitro cultures of human cells. An. Acad Bras.
Cienc 71, 437–443.
Bar-Joseph, H., Ben-Aharon, I., Rizel, S., Stemmer, S.M., Tzabari, M., Shalgi, R., 2010.
Doxorubicin-induced apoptosis in germinal vesicle (GV) oocytes. Reprod. Toxicol.
30, 566–72.
Barreto, A.C.H., Santiago, V.R., Freire, R.M., Mazzetto, S.E., Denardin, J.C., Mele, G.,
Cavalcante, I.M., Ribeiro, M.E.N.P., Ricardo, N.M.P.S., Gonçalves, T., Carbone,
L., Lemos, T.L.G., Pessoa, O.D.L., Fechine, P.B.A., 2013. Magnetic nanosystem
for cancer therapy using oncocalyxone A, an antitomour secondary metabolite
isolated from a Brazilian plant. Int. J. Mol. Sci. 14, 18269–18283.
Ben-Aharon, I., Bar-Joseph, H., Tzarfaty, G., Kuchinsky, L., Rizel, S., Stemmer, S.M.,
Shalgi, R., 2010. Doxorubicin-induced ovarian toxicity. Reprod. Biol. Endocrinol.
8, 20.
Bolton, J.L., Trush, M.A., Penning, T.M., Dryhurst, G., Monks, T.J., 2000. Role of
Quinones in Toxicology. Chem. Res. Toxicol. 13, 135–160.
Bouayed, J., Bohn, T., 2010. Exogenous Antioxidants—Double-Edged Swords in
Cellular Redox State: Health Beneficial Effects at Physiologic Doses versus
Deleterious Effects at High Doses. Oxid. Med. Cell. Longev. 3, 228–237.
Braga, R., 1976. Plantas do Nordeste, especialmente do Ceará, 3rd ed. Mossoró.
52
Costa-Lotufo, L.V., Ferreira, M.A.D., Lemos, T.L.G., Pessoa, O.D.L., Viana, G.S.B.,
Cunha, G.M.., 2002. Toxicity to sea urchin egg development of the quinone
fraction obtained from Auxemma oncocalyx. Brazilian J. Med. Biol. Res. 35, 927–
930.
da Costa, G.M., Lemos, T.L.G., Pessoa, D.L., Monte, F.J.Q., Braz-filho, R., 1999.
Glaziovianol , a New Terpenoid Hydroquinone from Auxemma glazioviana. J.
Nat. Prod. 62, 1044–1045.
Dettrakul, S., Surerum, S., Rajviroongit, S., Kittakoop, P., 2009. Biomimetic
Transformation and Biological Activities of Globiferin , a Terpenoid
Benzoquinone from Cordia globifera. J. Nat. Prod. 72, 861–865.
Dewick, P.M., 2009. Medicinal Natural Products−A Biosynthetic Approach.
Dubuisson, D., Dennis, S.G., 1977. The formalin test: A quantitative study of the
analgesic effects of morphine, meperidine, and brain stem stimulation in rats and
cats. Pain 4, 161–174.
Ferreira, M.A.D., do Nascimento, N.R.F., de Sousa, C.M., Pessoa, O.D.L., de Lemos,
T.L.G., Ventura, J.S., Schattner, M., Chudzinski-Tavassi, A.M., 2008.
Oncocalyxone A inhibits human platelet aggregation by increasing cGMP and by
binding to GP Ib-alpha glycoprotein. Br. J. Pharmacol. 154, 1216–1224.
Ferreira, M.A.D., Nunes, O.D.R.H., Fontenele, J.B., Pessoa, O.D.L., Lemos, T.L.G.,
Viana, G.S.., 2004. Analgesic and anti-inflammatory activities of a fraction rich in
oncocalyxone A isolated from Auxemma oncocalyx. Phytomedicine 11, 315–322.
53
Ferreira, M.A.D., Nunes, O.D.R.H., Fujimura, A.H.Y., Pessoa, O.D.L., Lemos, T.L.G.,
Viana, G.S.B., 1999. Inhibition of platelet activation by quinones isolated from
Auxemma oncocalyx Taub. Res Commun Mol Pathol Pharmacol 106, 97–107.
Ferreira, M.A.D., Nunes, O.D.R.H., Leal, L.K.A.M., Pessoa, O.D.L., de Lemos, T.L.G.,
Viana, G.S.D.B., 2003. Antioxidant effects in the quinone fraction from Auxemma
oncocalyx TAUB. Biol. Pharm. Bull. 26, 595–599.
Gossell-Williams, M., Simon, O.R., West, M.E., 2006. The Past and Present Use of
Plants for Medicines. West Indian Med J 55, 217–218.
Haslam, R.J., Dickinson, N.T., Jang, E.K., 1999. Cyclic nucleotides and
phosphodiesterases in platelets. Thromb Haemost 82, 412–423.
Leyva, A., Pessoa, O., Boogaerdt, F., Sokaroski, R., Lemos, T.G., Wetmore, L.A.,
Huruta, R.R., Moraes, M.O., 2000. Oncocalyxones A and C, 1,4-Antracenediones
from Auxemma oncocalyx: Comparison with Anticancer 1,9-Anthracenediones.
Anticancer Res. 20, 1029–1032.
Lima, D.A., 1989. Plantas da caatinga.
Lima, P.M., 2008. Avaliação da atividade de extratos de folhas de Momordica
charantia, Auxemma oncocalyx e Ziziphus joazeiro sobre bactérias e lavras de
Culex quinquefasciatus.
Lino, C.S., Pessoa, O.D.L., Lemos, T.L.C., Viana, G.S.B., 1996. Estudo da atividade
analgésica e antiedematogênica do extrato hidroalcoólico de Auxemma oncocalyx
e oncocalyxona A, in: Simpósio De Plantas Medicinais Do Brasil. p. 95.
Maia, G.M., 2004. Caatinga: árvores e arbustos e suas utilidades. D Z 413.
54
Marques, W.B., dos Santos, H.S., Pessoa, O.D.L., Braz-Filho, R., Lemos, T.L.G., 2000.
Anthracene derivatives from Auxemma oncocalyx. Phytochemistry 55, 793–797.
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., Gianni, L., 2004. Anthracyclines :
Molecular Advances and Pharmacologic Developments in Antitumor Activity and
Cardiotoxicity. Pharmacol. Rev. 56, 185–229.
Monks, T.J., Lau, S.S., 1992. Toxicology of quinone-thioethers. Crit. Rev. Toxicol. 22,
243–270.
Moraes, M.O., Fonteles, M.C., Moraes, M.E.A., Machado, M.I.L., Matos, F.J.A., 1997.
Screening for anticancer activity of plants from the Northeast of Brazil. Fitoterapia
68, 234–239.
Nozella, E.F., 2006. Valor nutricional de espécies arbóreo-arbustivas nativas da
caatinga e utilização de tratamentos físico-químicos para redução do teor de
taninos. Tese (Doutorado – Programa Pós-graduação em Ciéncias. Área Conc.
Energ. Nucl. na Agric. – Cent. Energ. Nucl. na Agric. da Univ. São Paulo.
Oktem, O., Oktay, K., 2007. Quantitative assessment of the impact of chemotherapy on
ovarian follicle reserve and stromal function. Cancer 110, 2222–9.
Pessoa, C., Lemos, T.L.G., Pessoa, O.D.L., Moraes, M.O., Costa-lotufo, L.V., Leyva,
A., 2004. Cytotoxicity of derivatives of oncocalyxone A from Auxemma
oncocalyx Taub. ARKIVOC vi, 89–94.
Pessoa, C., Silveira, E.R., Lemos, T.L.G., Wetmore, L.A., Moraes, M.O., Leyva, A.,
2000. Antiproliferative Effects of Compounds Derived from Plants of Northeast
Brazil. Phyther. Res. 14, 187–191.
55
Pessoa, C., Vieira, F.M.A.C., Lemos, T.G., Moraes, M.O., Lima, P.D.L., Rabenhorst,
S.H.B., Leyva, A., Burbano, R.R., 2003. Oncocalyxone A from Auxemma
oncocalyx lacks genotoxic activity in phytohemagglutinin-stimulated lymphocytes.
Teratog. Carcinog. Mutagen. Suppl 1, 215–20.
Pessoa, O.D., Lemos, T.L.G., 1997. Allantoin and fatty acid composition in Auxemma
oncocalyx. Rev. Bras. Farmácia 78, 9–10.
Pessoa, O.D., 1994. Contribuição ao conhecimento químico de plantas nativas do
nordeste: Auxemma oncocalyx Taub.
Pessoa, O.D., Lemos, T.L.G., Carvalho, M.G., Braz-Filho, R., 1995. Cordiachromes
from Auxemma oncocalyx. Phytochemistry 40, 1777–1786.
Pessoa, O.D.L., Lemos, T.L.G., Silveira, E.R., Braz-Filho, R., 1993. Novel
cordiachromes isolated from Auxemma oncocalyx. Nat. Prod. Res. 2, 145–150.
Qunaibi, E.A., Disi, A.M., Taha, M.O., 2009. Phenytoin enhances collagenization in
excision wounds and tensile strength in incision wounds. Pharmazie 64, 584–586.
Saeidnia, S., Abdollahi, M., 2013. Toxicological and pharmacological concerns on
oxidative stress and related diseases. Toxicol. Appl. Pharmacol. 273, 442–55.
Schmitt, A.C., Almeida, A.B.P.., Silveira, T.A., Iwakura, C.T., Mendes, K.F., Silva,
M.., 2003. Avaliação da atividade antimicrobiana in vitro da planta Bryophyllum
pinnatum Kurz (“Folha-da-fortuna”) colhida em Varzea Grande, Mato
Grosso/Brazil. Acta Sci. Vet. 31, 55–58.
56
Sousa, C.M., Nascimento, N.R.F., Lemos, T.L.G., Pessoa, O.D.L., Ferreira, M.A.D.,
2002. Avaliação da Atividade Antiagregante Plaquetária da oncocalixona A (Onco
a) e vasoconstritora da Fração quinona da Auxemma oncocalyx, in: Reunião Anual
Da Sociedade Brasileira De Química. p. 24.
Tigre, C.B., 1970. Silvicultura para as matas xerófilas: defesa dos recursos naturais
renováveis, DNOCS. Fortale.
57
Table 1. Main results of the use of A. oncocalyx and Onco A in several species and cell
types
Substance Researched
form
Tested
species Cell type Main result Reference
A. oncocalyx In vivo Rat Animal
analgesic and
anti-
inflammatory
activity
Lino et al.,
1996
A. oncocalyx In vitro Human
Walker
malignant
tumor cells
Anti-tumor
activity
Moraes et al.,
1997
A. oncocalyx In vitro Rat Hepatocytes
Decrease in
serum GOT and
GPT levels
(hepatoprotective
effect) and
Inhibition of
platelet activation
Ferreira et
al., 1999
Onco A In vitro Human Tumor cells Cytotoxic activity Leyva et al.,
2000
Onco A In vitro Human
CEM
leukemia,
SW1573 lung
tumour and
CCD922
normal skin
fibroblasts.
Antiproliferative
activity
Pessoa et al.,
2000
Onco A In vivo Rat Brain Inhibiting
lipoperoxidation
Ferreira et
al., 2001
A. oncocalyx In vivo Sea urchin Eggs
Concentration-
dependent
inhibition of sea
urchin eggs
development
Costa-Lotufo
et al., 2002
Onco A In vitro Human Platelet cells
Inhibits human
platelet
aggregation
Sousa et al.,
2002
Onco A In vitro Human lymphocytes Cytotoxic but not
genotoxic activity
Pessoa et al.,
2003
A. oncocalyx In vivo Mice and rats Animal Antioxidant
activity
Ferreira et
al., 2003
A. oncocalyx In vivo Mice Animal
Anti-
inflammatory and
antinociceptive
activity
Ferreira et
al., 2004
Onco A
In vitro
Human
Leukaemia
cells
Cytotoxicity
Pessoa et al.,
2004
58
A. oncocalyx In vitro Bacteria
Bacillus
subtilis,
Enterobacter
aerogenes,
Escherichia
coli, Klebsiella
pneumoniae,
Pseudomonas
aeruginosa,
Salmonella
cholerasuis and
Staphylococcus
aureus
Inhibition of
gram-positive
bacteria
Lima., 2008
Onco A In vitro Human Platelet cells
Inhibits human
platelet
aggregation by
increasing cGMP
and by binding to
GP Ibα
glycoprotein
Ferreira et
al., 2008
59
7 FRAÇÃO DE AUXEMMA ONCOCALYX E ONCOCALYXONA A AFETAM A
SOBREVIVÊNCIA IN VITRO E O DESENVOLVIMENTO DE FOLÍCULOS
PRÉ-ANTRAIS CAPRINOS INCLUSOS EM TECIDO CORTICAL
OVARIANO
“Fraction of Auxemma oncocalyx and Oncocalyxone A affects the in vitro survival and
development of caprine preantral follicles enclosed in ovarian cortical tissue”
Periódico: Forschende Komplementärmedizin (aceito) (ISSN: 1661-4119)
Qualis B2
60
RESUMO
Introdução: A. oncocalyx e seu componente principal (Onco A) possuem fortes ações
antioxidantes e antitumorais, entretanto, não existem estudos a respeito da ação de ambas
as substâncias durante a foliculogênese. Materiais e Métodos: Fragmentos de tecido
ovariano caprino foram fixados (controle fresco não cutivado) ou cultivados por 1 ou 7
dias em α-MEM+ isolado (controle cultivado) ou supementado com DMSO (0.5% v/v),
BMP-15 (100 ng/ml), doxorrubicina (DXR; 0.3 ug/ml) ou diferentes concentrações de A.
oncocalyx (1.2, 12 ou 34 µg/ml) ou Onco A (1, 10 ou 30 µg/ml). Foi avaliada a morfologia
e crescimento folicular, apoptose (ensaio de TUNEL), proliferação celular (AgNOR e
PCNA). Resultados: A. oncocalyx e Onco A (de modo concentração-dependente) e DXR
reduziram (P<0,05) a quantidade de folículos morfologicamente normais, sem efeito
(P>005) sob o crescimento folicular. A. oncocalyx reduziu o percentual de folículos
normais quando comparado ao grupo onco A (P<0,05). DXR, A. oncocalyx 1,2 e Onco A
1 aumentaram (P<0,05) o percentual de folículos marcados positivamente para TUNEL.
DXR reduziu significativamente (P>0,05) o número de regiões organizadoras de
nucléolos. Conclusão: A. oncocalyx e onco A afetaram o desenvolvimento folicular in
vitro no modelo caprino de modo dose-dependente. Onco A (1 µg/ml) possuem menor
efeito nocivo quando comparado a DXR na sobrevivência de folículos pré-antrais
caprinos.
Palavras-chave: Auxemma oncocalyx. Boraginaceae. Cultivo in vitro. Oncocalyxona A;
Folliculogenesis. Tecido cortical.
61
Title: Fraction of Auxemma oncocalyx and Oncocalyxone A affects the in vitro survival
and development of caprine preantral follicles enclosed in ovarian cortical tissue
Short title: “Effect of Auxemma oncocalyx and Oncocalyxone A on preantral follicles”
Leiva-Revilla J.1,*, Lima L.F. 1, Castro S.V. 1, Campello C.C. 1, Araújo V.R. 1, Celestino
J.J.H. 2, Pessoa O.D.L. 3, Silveira E.R. 3, Rodrigues A.P.R. 1, Figueiredo J.R. 1
1 Faculty of Veterinary Medicine, LAMOFOPA, PPGCV, Universidade Estadual do
Ceará, Fortaleza-CE, Brazil. Av. Paranjana, 1700. Itaperi. 60740000 - Fortaleza, CE –
Brasil. Telephone: (+55 85) 31019852
2 Institute of Health Sciences, Universidade da Integração Internacional da Lusofonia
Afro-Brasileira. Acarape-CE, Brazil. Rodovia CE 060 Km51. 62785000 - Acarape, CE –
Brasil. Telephone: (+55 85) 33731593
3 Departamento de Química Orgânica e Inorgânica. Universidade Federal do Ceará,
Centro de Ciências, Av. Mister Hull S/N Pici 60455-760 - Fortaleza, CE - Brasil - Caixa-
postal: 12200 Telephone: (+55 85) 33669441
* Corresponding author; Av. Paranjana, 1700. Itaperi. 60740000 - Fortaleza, CE – Brasil.
Telephone: (+55 85) 31019852. Fax: (+55 85) 31019840. e-mail address:
62
ABSTRACT
Background: Auxemma oncocalyx (A. oncocalyx) and its main component
Oncocalyxone A (onco A), have a high level of antioxidant and anti-tumoral activity, but
there are no studies on the action of both of these drugs regarding folliculogenesis.
Materials and methods: Caprine ovarian tissue fragments were fixed (non-cultured
control) or cultured for 1 or 7 days in α-MEM+ alone (cultured control) or supplemented
with DMSO (20% v/v), BMP-15 (100 ng/ml), doxorrubicin (DXR; 0.3 g/ml) or different
concentrations of A. oncocalyx (1.2, 12 or 34 µg/ml) or onco A (1, 10 or 30 µg/ml). We
analyzed follicular morphology and growth, apoptosis (TUNEL assay), cell proliferation
(AgNOR and PCNA) Results: A. oncocalyx and onco A (concentration-dependent
manner) and DXR decreased (P<0.05) morphologically normal follicles, with no effect
(P>005) over follicular growth. A. oncocalyx reduced (P<0.05) the percentage of normal
follicles compared to the onco A., DXR, A. oncocalyx 1.2 and onco A 1 increased
(P<0.05) the percentage of TUNEL positive follicles. DXR decreased (P<0.05) the
number of nucleolar organizer regions. Conclusion: A. oncocalyx and onco A affected in
vitro caprine folliculogenesis in a concentration-dependent manner. Onco A (1 µg/ml)
has a less harmful effect than DXR on goat preantral follicle survival.
Keywords: Auxemma oncocalyx; Boraginaceae; in vitro culture; Oncocalyxone A;
Folliculogenesis; Cortical tissue.
63
1. Introduction
Cancer is a target of research for the development or discovery of new forms of
treatments [1]. Many drugs used in cancer chemotherapy, in addition to showing toxicity
against tumor cells, exhibit genotoxic, carcinogenic and teratogenic effects on normal
cells. The low specificity of these drugs against tumor tissue results in undesirable effects.
Doxorubicin (DXR) is a widely used drug for cancer patients [2]. It induces ovarian
toxicity by reducing the ovulation rate, along with a reduction in the size of the ovary and
other side effects [2–4].
Plants are excellent sources of raw material when searching for new drugs.
Moreover, plants have a long history of use in the treatment of cancer [5]. Over 60% of
currently used anti-cancer agents are derived from natural sources, including plants,
marine organisms and micro-organisms [6,7].
AuxemmA. oncocalyx (A. oncocalyx) is a common tree found in the state of Ceará
in Northeast Brazil [8]. It has been widely used in folk medicine as an adjunctive
treatment of injuries such as wounds and cuts [8,9]. Some studies have suggested that this
plant has biological activities such as analgesic, anti-oxidant, anti-tumor and anti-
inflammatory effects [9–12]. Oncocalyxone A (onco A) has been isolated from the stem
heartwood of the plant, which has a high antioxidant activity [9] and an antiproliferative
effect in tumor cell cultures [13].
In other studies, onco A has been suggested as a possible anticancer compound
since it has presented antitumor and cytotoxic activity in human leukemia cells, and other
cell cancer lines, without causing genotoxicity [14]. Therefore, this compound may be
presented as a possible therapeutic agent [15,16]. On the other hand, a study conducted
with sea urchin embryos observed a fraction of onco A induced destruction of the
64
embryos at the same concentrations (1 to 30 µg/ml) which inhibited tumor cell
proliferation, indicating that this compound could be very toxic [13]. However, the effect
of the use of these substances with antitumoral potential on fertility and ovarian follicle
function, for example, is still unknown. Toxicity can be evaluated both in vivo and in
vitro. In vitro studies permit testing drug toxicity while avoiding the ethical concerns and
restrictions of in vivo experiments. Within the criteria required to safely study the effects
of phytotherapeutics on reproductive toxicity, one way to evaluate this parameter is by
the utilization of in vitro preantral follicle culture. This method enables the testing of the
beneficial or toxic effects of drugs on ovarian follicles in vitro before their use in
experiments involving live humans or animals [17].
Thus, the aim of this study was to evaluate the effect of the concentration-response
curve of the A. oncocalyx and onco A and determine the minimum toxic concentration on
the survival, growth and development of goat preantral follicles in vitro cultured
(Experiment 1), and to evaluate the effects of the minimum toxic concentration of A.
oncocalyx and onco a on apoptosis and proliferation of goat pre-antral follicles in vitro
cultured (Experiment 2)”.
2. Materials and Methods
2.1. Source of ovaries
Ovaries (n = 10: Experiment 1; n = 6: Experiment 2) from eight adult mixed breed
goats were obtained at a local slaughterhouse. The ovaries were washed in 70% alcohol
for approximately 10 s then twice in minimal essential medium (MEM) supplemented
with 100 µg/ml penicillin and 100 µg/ml streptomycin plus HEPES (MEM-HEPES). The
ovaries were transported to the laboratory in thermo flasks at 4 ºC within 1 h [18].
65
2.2. Isolation of onco A from A. oncocalyx
Auxemma oncocalyx was collected in August 2012 at Acarape, state of
Ceará, which is located in Northeast Brazil. The plant was identified by Dr. Maria Iracema
B. Loiola of the Department of Biology of the Universidade Federal do Ceará. A voucher
specimen (No. 18459) has been deposited in the Herbarium Prisco Bezerra (EAC),
Universidade Federal do Ceará.
The air-dried and powdered heartwood (2.5 kg) of A. oncocalyx was extracted
with EtOH (2 x each) at room temperature. The combined extracts were evaporated under
reduced pressure to yield the crude extract (100 g), which was fractionated over silica gel
and eluted with CH2Cl2, CH2Cl2/ EtOAc (7:3 and 1:1), EtOAc, EtOAc/ MeOH (9.5:0,5
and 1:1) to yield after solvent evaporation the correspondent fractions: 6.60, 5.99, 8.01,
3.36, 50.08 and 25.96 g, respectively. The fraction EtOAc/MeOH 9.5:0.5 (50.0 g) was
subjected to a silica gel (200 g) chromatography column using CH2Cl2/ EtOAc 1:1 (200
mL), 7:3 (500 mL), EtOAc (1000 mL) and EtOAc/ MeOH 9.5:0.5 (400 mL) to afford 60
fractions of approximately 30 mL. After comparative analysis by TLC, these fractions
were pooled into 3 main fractions: F1(1-20; 8.2 g), F2(21-54; 25.2 g) and F3(55-60; 16.7
g). F2(21-54; 25.2 g) was subjected twice to chromatography over silica gel eluted with
CH2Cl2/EtOAc 1:1, 7:3, EtOAc, EtOAc/MeOH 9.5:0.5 and MeOH. Fractions
CH2Cl2/EtOAc 7:3 and EtOAc furnished a dark solid which was purified by addition of
acetone followed by filtration. This material (5.5 g), a deep red powder, mp 207–208o
was identified as rel-8a-hydroxy-5-hydroxymethyl-2-methoxy-8ab-methyl-7,8,8a,9-
tetrahydro-1,4-anthracenedione), named oncocalyxone A, as previously described by
Pessoa et al., 1993.
66
1H NMR (200 MHz, DMSO-d6): 6.00 (s, H-3), 6.03 (br d, H-6), 2.52 (br d, J 17.2 Hz, H-
7eq), 2.60 (dd, J 17.2, 3.9 Hz, H-7ax), 3.57 (br s, H-8), 2.90 (d, J 18.4 Hz, H-9ax), 2.34
(d, J 18.4 Hz, H-9eq), 6.50 (s, H-10), 4.16 (br s, 2H-11), 0.74 (s, 3H-12), 3.78 (s, OMe).
13C NMR (50.3 MHz, DMSO-d6): 181.2 (C-1), 159.8 (C-2), 106.4 (C-3), 186.1 (C-4),
134.6 (C-4a), 146.7 (C-5), 128.4 (C-6), 32.0 (C-7), 70.1 (C-8), 38.9 (C-8a), 29.2 (C-9),
133.0 (C-9a), 111.8 (C-10), 135.5 (C-10a), 61.6 (C-11), 21.3 (C-12), 56.7 (OMe).
2.3. In vitro culture of goat ovarian tissue
Ovarian tissue samples from each ovarian pair were cut into fragments
approximately 3 x 3 x 1 mm using a needle and scalpel under sterile conditions. One
fragment (non-cultured control) was immediately fixed in Carnoy’s solution for 12 h for
histological studies. The other fragments of ovarian cortex were transferred to 24-well
culture dishes containing 1 ml of culture medium. In vitro culture was performed at 39
°C in 5% CO2 in a humidified incubator and all media were incubated for 2 h prior to use.
The basic culture medium (cultured control) consisted of α-MEM (pH 7.2 – 7.4)
supplemented with 10 ng/ml of insulin, 5.5 µg/ml transferrin, 5 ng/ml selenium, 2 mM
glutamine, 2 mM hipoxanthine and 1.25 mg/ml bovine serum albumin (BSA) and was
called α-MEM+. The culture medium was replaced every 2 days with fresh medium. All
chemicals used in the present study were purchased from Sigma Chemical Co. (St. Louis,
MO, USA) unless otherwise indicated.
2.4. Experimental design
For Experiment 1, the fragments were randomly divided into 11 groups according
to the following treatments: non-cultured control, α-MEM+ alone (cultured control) or
supplemented with: human recombinant bone morphogenetic protein 15 (BMP-15) at 100
67
ng/ml (R&D Systems; Minneapolis, MN, USA); Dimethyl sulfoxide (DMSO) at 20%
v/v; Doxorubicin (DXR) at 0.3 g/ml; Auxemma oncocalyx (A. oncocalyx) at 1.2, 12 or
34 g/ml; or Oncocalixone A (onco A) at 1, 10 or 30 g/ml. The fraction of A. oncocalyx
contains 80% of onco A [12], therefore in each concentration of A. oncocalyx there was
an equal proportion of onco A. A. oncocalyx and onco A were diluted with DMSO as a
vehicle. Each treatment was repeated five times using the ovaries of five different
animals. The BMP-15 concentration was chosen based on previous studies conducted in
our laboratory [19].
Based on the results from Experiment 1, immunohistochemistry and cell
proliferation analysis were performed in Experiment 2. The ovarian fragments were
randomly divided into 7 groups according to the following treatments: non-cultured
control, α-MEM+ alone (cultured control) or supplemented with BMP-15 (100 ng/ml),
DMSO (20% v/v), DXR (0.3 g/ml), A. oncocalyx (1.2 g/ml) or onco A (1 g/ml). Each
treatment was repeated three times.
2.5. Morphological analysis and assessment of in vitro follicular growth
To evaluate the morphology of caprine follicles in the non-cultured control or after
one or seven days of culture, the tissue fragments were fixated and dehydrated in a graded
series of ethanol, clarified with xylene and embedded in paraffin wax. For each piece of
ovarian cortex, 7 µm sections were mounted on slides, stained with periodic acid Schiff
and hematoxylin, and examined by light microscopy at 400× magnification (Nikon
Eclipse E200).
The follicles were classified as primordial (one layer of flattened granulosa cells
around the oocyte) and growing, i.e. transitional (one layer of flattened granulosa cells
and at least 3 cuboidal granulosa cells around the oocyte), primary (a complete layer of
68
cuboidal granulosa cells around the oocyte) or secondary (oocyte surrounded by two or
more layers of cuboidal granulosa cells). Degenerated follicles were defined as those with
a retracted oocyte pyknotic nucleus and/or were surrounded by disorganized granulosa
cells which were detached from the basement membrane. To evaluate follicular
activation and growth, only intact follicles with a visible oocyte nucleus were recorded
and the proportion of primordial and growing follicles were calculated on day 0 (non-
cultured control) and after one or seven days of culture in all tested treatments.
Follicle and oocyte diameter were recorded. Two perpendicular diameters were
recorded from edge to edge, of the follicle or oocyte, and the average of these two values
was reported as follicle and oocyte diameter, respectively. Each follicle was examined in
every section in which it appeared and matched with the same follicle on adjacent
sections to avoid double counting, thus ensuring that each follicle was only counted once,
regardless of its size.
2.6. Assessment of apoptosis by TUNEL assay
For determination of DNA fragmentation, a terminal deoxynucleotidyl
transferase-mediated dUTP biotin nick end labeling (TUNEL) in situ detection kit (R&D
Systems, Minneapolis, MN, USA) was applied. The fragments were fixed in 4%
paraformaldehyde buffered with PBS. Subsequently, the blocks were sectioned at a
thickness of 5 µm following de-paraffinization and boiled for antigen retrieval in 0.01 M
citric acid. The blockade of exogenous peroxidase and nonspecific blocking were
performed in a humid chamber. The TUNEL kit was prepared following the guidelines
given by the manufacturer. The incubation of TUNEL consisted of the addition of a
TUNEL mixture for 1 h at 37 °C (moist chamber) and, after washing, 50 ml Convert POD
was added for 30 min at 37 °C (moist chamber). The staining of the nucleus of apoptotic
69
cells appeared brown whereas normal cells were lighter in color. At least 30 follicles per
treatment were evaluated.
2.7. Assessment of cell proliferation
2.7.1. AgNOR silver staining
To estimate the cell proliferation index AgNOR staining was performed to
quantify the number of argyrophilic nucleolar organizer regions (NOR). For this purpose,
ovarian tissue fixed in 4% paraformaldehyde solution was sectioned at 5 µm. After
reduction with 1% potassium iodide, slides were stained with 50% silver nitrate solution
in a colloid solution (2:1) in a darkroom and counterstained with 0.1% safranin. For
quantification, the follicles were visualized under a light microscope (1000X
magnification; Nikon Eclipse E200) and the NOR of all the nuclei of all the visible
granulosa cells were counted. In the non-cultured group and groups after 7 days of culture,
granulosa cells from 30 growing preantral follicles were evaluated per group.
2.7.2. Proliferating cell nuclear antigen (PCNA)
Ovarian fragments were fixed in 4% paraformaldehyde and 5 µm paraffin sections
were mounted to microscope slides. Paraffin sections were heated at 65 °C for 45 min.
Following de-paraffinization, sections were rehydrated in a series of graded ethanol/water
solutions then boiled in 0.01 M citric acid (pH 6.0) at 95–100 °C for 5 min followed by
incubation in 3% hydrogen peroxide (H2O2) for 10 min. The tissues were blocked with
avidin and biotin and incubated with a Rb Pab-PCNA ab 2426 (abcam) overnight at 4 °C.
After rinsing thoroughly with PBS, the sections were incubated with goat pAB-Rb IgG
antibody (Biotin) for 30 min at room temperature. PCNA expression in sections was
detected by the reaction of peroxidase with 3,39-diaminobenzidine tetrahydrochloride
70
(DAB) and analyzed using a light microscope (400X maginification, Nikon Eclipse
E200). When at least one granullosa cell was marked in brown, it was considered as a
positive PCNA follicle. At least 20 follicles per treatment were evaluated.
2.8. Statistical analyses
Data were initially evaluated for homocedasticity and normal distribution of the
residues by Bartlett’s and Shapiro-Wilk tests, respectively. Confirmed both requirements
underlying analysis of variance, the effects of medium, time and medium by time
interaction were analyzed using PROC MIXED of SAS (2002), including repeated
statement to account for autocorrelation between sequential measurements. The model
was Yij=µ+Mi+Tj+(R*T)ij+eij, where Yij is the observation of the ith medium at the jth
time of culture, µ is the overall mean, Ri is the ith medium, Tj is the jth time of culture,
(R*T)ij is the medium by time interaction term and eij is the random residual effect.
Comparisons amongst media or times were further analyzed by Student-Newman-Keuls
test, being the results expressed as mean ± standard deviation. TUNEL and PCNA data
were analyzed by chi-square test and the results were expressed as percentages. A
probability of P<0.05 indicated a significant difference.
3. Results
3.1. Morphologically normal preantral follicles and follicle and oocyte diameter before
and after in vitro culture
A total of 3,150 preantral follicles were analyzed by classical histology. The
percentage of morphologically normal preantral follicles in the non-cultured control
treatment and after 1 or 7 days of in vitro culture is shown (Table 1). After 1 and 7 days
71
of culture there was a reduction (P<0.05) in the percentage of normal follicles in all
treatments compared to the non-cultured control. When compared to α-MEM+, the
percentage of morphological normal follicles was higher (P<0.05) on days 1 and 7 in the
BMP-15 treatment. However, the percentage of morphological normal follicles was
similar (P>0.05) between the DMSO and α-MEM+ treatments. On the other hand, the
treatments with DXR, A. oncocalyx and onco A at all concentrations were lower (P<0.05)
than α-MEM+ on days 1 and 7. The A. oncocalyx 1.2 (day 1), onco A 1 (days 1 and 7) and
onco A 10 (day 1) treatments showed a higher (P<0.05) percentage of morphologically
normal follicles than DXR. On day 1, the treatments with A. oncocalyx 12 and 34, and on
day 7, those with A. oncocalyx 12 and 34 and onco A 30 showed a lower (P<0.05)
percentage of morphologically normal follicles compared to the DXR treatment.
Comparing the concentration of A. oncocalyx with its equivalent of onco A, there was a
lower percentage of normal follicles in the A. oncocalyx treatments. Among the different
concentrations of A. oncocalyx and onco A, it was observed that after 1 and 7 days of
culture there was a concentration-dependent effect with a decrease in the percentage of
normal follicles along with an increase in A. oncocalyx or onco A concentrations. Also,
with the progression of the culture from day 1 to day 7, there was a reduction (P<0.05) in
the percentage of normal follicles in all treatments. Finally, there was no difference
(P>0.05) in follicle and oocyte diameter among treatments (data not shown).
3.2. Activation of caprine primordial follicles after in vitro culture
The percentages of preantral follicle activation in the non-cultured control and
after 1 or 7 days of in vitro culture are shown (Table 2). After 7 days of culture, a lower
(P<0.05) percentage of primordial follicles and an increase (P<0.05) in the percentage of
growing follicles was observed in all treatments compared to the non-cultured control,
72
except the DMSO treatment. From day 1 to day 7, a significant reduction in the percentage
of primordial follicles and a significant increase in the percentage of growing follicles
were observed in all treatments. Overall, irrespective of culture period, the
supplementation of α-MEM+ with DMSO, BMP-15, DXR, A. oncocalyx and onco A did
not significantly affect either the percentage of primordial or growing follicles.
3.3 TUNEL assay
The percentage of TUNEL positive follicles (TPF; Fig. 1) was similar (P>0.05) in
the α-MEM+, DMSO and BMP-15 treatments compared to the non-cultured control. In
contrast, DXR, A. oncocalyx 1.2 and onco A 1 showed a higher (P<0.05) percentage of
TPF compared to the non-cultured control, DMSO and BMP-15 treatments. Moreover,
the addition of onco A 1 did not increase (P>0.05) the percentage of TPF compared to the
α-MEM+ treatment.
3.4. Assessment of proliferation with AgNOR and PCNA
The mean number of nucleolar organizer regions (NOR) per treatment is shown
(Fig. 2). DXR was the only treatment that had a lower (P<0.05) number of NOR than the
non-cultured control, α-MEM+, BMP-15 and onco A 1 treatments. It is important to
emphasize that BMP-15 was the only treatment that increased (P<0.05) the percentage of
NOR compared to the α-MEM+ treatment. On the other hand, the PCNA test showed no
statistical difference (P>0.05) among all treatments (Fig. 3).
73
4. Discussion
The present study demonstrated for the first time the effect of A. oncocalyx
and its isolated compound, onco A, on ovarian preantral folicles. After 7 days of culture,
a concentration-dependent effect was observed of both A. oncocalyx and onco A, of which
a higher concentration was related to a smaller percentage of morphologically normal
follicles when compared to the α-MEM+ cultured control. However, both compounds did
not affect either the percentage of primordial or growing follicles, showing that the effect
of this drugs is not stage-specific, and they cause the degeneration of both categories
equally, as it has been seen with other toxic compounds such as Areca catechu [20]. In a
study testing different concentrations (1 to 100 µg/ml) of a quinone fraction of A.
oncocalyx (containing 80% of onco A) in sea urchin eggs, it was found that the cleavage
of eggs was inhibited in a concentration-dependent manner. The early destruction of
embryos at the blastula stage occurred when a concentration of 10 µg/ml was used, and a
total destruction (100%) of embryos occurred with a concentration of 30 µg/ml,
associated with a rupture of the embryo membranes [21]. The cytotoxicity of onco A was
also observed on human tumor cell lines [15,16,22] and normal skin fibroblasts [22] at
concentrations varying from 0.4 to 25 µg/ml. In addition, onco A inhibited leukemia cell
line CEM growth at concentrations greater than 2 µg/ml and showed a significant
deleterious effect on DNA [15,16,22]. The cytotoxicity associated with these compounds
can be attributed to redox cycling and subsequent development of oxidative stress [23].
Thus, cellular damage can occur by DNA alkylation [24]. Consequently, quinones might
have a high toxicity related to their antimitotic properties [15].
In the present study, the fraction of A. oncocalyx had a higher toxicity than onco
A on folliculogenesis. Several studies [14–16,21,22] have already shown in vitro
74
cytotoxic effects of the quinone fraction of A. oncocalyx, represented mainly by onco A.
However, Ferreira et al. [9] showed an antioxidant effect of the fraction of A. oncocalyx
on mice in vivo. It is believed that this effect can be due to prevention of the process of
lipid peroxidation and enhancement of protein synthesis [9]. Moreover, the fraction of A.
oncocalyx contains 80% of onco A [12], leaving the other 20% of other substances that
can be more toxic than onco A alone. Pessoa et al. [25] listed some compounds of this
fraction, such as cordiachromes, allantoin, sitosterol, 3b-O-b-D-glucopyranosylsitosterol
and acetyl derivative. It is known that the cordiachromes are an unusual class of
meroterpenoids that have been isolated from a quinone [26]. Cordiachromes were also
isolated from the trunk heartwood of another Northeastern Brazilian tree (Auxemma
glazioviana; [27]). The wood of this tree, as is that of A. oncocalyx, is resistant to fungi
and termite attacks, and thus is often used for civil construction [25,27]. In folk medicine,
cuts and wounds were treated with the trunk bark [8,25]. It has been suggested that this
property can be related to the cordiachromes present in the quinone fraction [26]. These
properties can influence the toxicity of the plant and may explain the difference between
the fraction of A. oncocalyx and onco A.
The results showed that onco A was less harmful than DXR on follicle survival
as well as the proliferation of granulosa cells. It is known that onco A and DXR both have
anti-carcinogenic effects. The fraction of A. oncocalyx and onco A in different lineages
of cells, especially in tumor cell lines [14,16,22], showed a similar effect when compared
to DXR. It was shown that both DXR and onco A present cytotoxicity in the G, G1/S and
S phases of cell division, with the only difference being that DXR presents genotoxicity
in these cells [14]. In this study, DXR caused a decrease in both the percentage of
morphologically normal follicles and the proliferation of granulosa cells and also
increased follicular DNA fragmentation. Likewise, the TUNEL assay showed an increase
75
in apoptotic cells in the groups treated with the A. oncocalyx 1.2 and onco A 1 treatments
when compared to the non-cultured control. Only the onco A 1 treatment was able to
maintain a percentage of TUNEL positive follicles similar to the α-MEM+ cultured
control. A study conducted by Pessoa et al. [14] showed that onco A at a concentration
of 0.5 g/ml had a similar effect as 0.1 mg/ml DXR with regard to cytotoxicity in
lymphocytes. Many drugs used in cancer chemotherapy, in addition to having toxicity
against tumor cells, exhibit genotoxic, carcinogenic and teratogenic effects on normal
cells, showing a low specificity of these drugs against tumor tissue, resulting in
undesirable side effects. Nevertheless, DXR is a widely used drug in cancer treatment
[28]. Recent studies revealed that DXR induced ovarian toxicity, which was observed by
a reduction in ovulation rate and the size of the ovary [2–4]. DXR elicits apoptosis by
various mechanisms in a variety of cells. It can be accumulated in both the nucleus and
mitochondria and induces chromosomal destruction by inhibiting topoisomerase-II [29].
DXR can also interfere with mitochondrial function and initiate an intrinsic pathway of
apoptosis by reducing the mitochondrial membrane potential and releasing cytochrome
C [3].
It is important to highlight that the DMSO treatment (i.e., the vehicle used for the
dilution of DXR, A. oncocalyx and onco A) was similar to the α-MEM+ cultured control.
This result shows that DMSO by itself was not responsible for the negative effect of the
tested drugs. On the other hand, in this study BMP-15 served as a positive control for its
ability to maintain follicular viability, increase granulosa cell proliferation and prevent
DNA fragmentation. Celestino et al. [19] showed that BMP-15 (100 ng/ml) maintained
the integrity and promoted the growth of caprine preantral follicles cultured in vitro for 7
days. It is known that BMP-15, along with the other BMPs (2 and 5), acts in granulosa
76
cells, promoting follicle survival through maintenance of cell proliferation and prevention
of precocious luteinization and/or atresia [30].
In conclusion, A. oncocalyx and onco A affected caprine folliculogenesis in vitro
in a concentration-dependent manner. In addition, the less harmful effect of onco A (1
µg/ml) than DXR on goat preantral follicle survival may encourage future studies
involving the use of this drug for cancer treatment in women.
5. Conflict of interest
We wish to confirm that there are no known conflicts of interest associated with
this publication and there has been no significant financial support for this work that could
have influenced its outcome.
6. Acknowledgments
This research was financially supported by CNPq, CAPES and FUNCAP. The
authors thank Denise Damasceno Guerreiro, Naiza de Sá Arcangela, Renato Felix da
Silva, Francisco Léo Nascimento de Aguiar and Keith Haag for assistance with this study.
77
78
79
Table 1. Percentage (mean ± SEM) of morphologically normal caprine preantral follicles
before (non-cultured control) and after in vitro culture for 1 or 7 days in α-MEM+ alone
or α-MEM+ supplemented with DMSO, BMP15, DXR, A. oncocalyx (1.2; 12 and 34
µg/ml) or onco A (1, 10 and 30 µg/ml).
Treatments Culture time
Non-cultured control 88.00 ± 1.83
D1 D7
α-MEM+ cultured control 74.67 ± 2.98 *A 54.67 ± 1.83 *B
BMP-15 82.00 ± 5.06 *†Aa 69.79 ± 2.40 *†Ba
DMSO 71.33 ± 3.80 *Ab 54.00 ± 4.35 *Bb
DXR 45.33 ± 5.06 *†Ae 32.67 ± 5.48 *†Bd
A oncocalyx 1.2 55.33 ± 1.83 *†Ad 27.33 ± 4.35 *†Bde
A oncocalyx 12 34.67 ± 3.80 *†Af 20.67 ± 3.65 *†Bf
A oncocalyx 34 24.00 ± 1.49 *†Ag 14.00 ± 2.79 *†Bg
Onco A 1 64.00 ± 4.35 *†Ac 48.00 ± 5.06 *†Bc
Onco A 10 58.67 ± 6.06 *†Ad 32.67 ± 6.41*†Bd
Onco A 30 42.67 ± 5.48 *†Ae 24.67 ± 3.80 *†Bef
* Differs significantly from non-cultured control. † Differs significantly from α-MEM+.
Distinct capital letters represent significant differences between columns (days of
culture). Different lowercase letters represent significant differences between lines
(experimental treatments).
80
Table 2. Percentage (mean ± SEM) of primordial and growing caprine preantral follicles before (non-cultured control) and after in vitro
culture for 1 or 7 days in α-MEM+ alone or α-MEM+ supplemented with DMSO, BMP15, DXR, A. oncocalyx (1.2; 12 and 34 µg/ml) or onco
A (1, 10 and 30 µg/ml).
Treatments Primordial follicles Growing follicles
Culture Time
Non-cultured
control
65.95 ± 4.92 34.05 ± 4.92
D1 D7 D1 D7
α-MEM+ cultured
control
56.25 ± 4.64 A 19.56 ± 5.18*B 43.75 ± 4.64 B 80.44 ± 5.18*A
BMP-15 41.72 ± 7.86*Ab 9.10 ± 3.80*Bb 58.28 ± 7.86*Ba 90.90 ± 3.80*Aa
DMSO 59.14 ± 8.78 Aa 22.19 ± 10.67*Bab 40.86 ± 8.78Bb 77.81 ± 10.67*Aab
DXR 40.38 ± 18.95*Ab 21.69 ± 7.63*Bab 59.62 ± 18.95*Ba 78.31 ± 7.63*Aab
A oncocalyx 1.2 49.41 ± 5.06 *Aab 14.44 ± 3.38*Bab 50.59 ± 5.06*Bab 85.56 ± 3.38*Aab
A oncocalyx 12 38.65 ± 6.80*†Aab 22.29 ± 6.19*Bab 61.35 ± 6.80*†Ba 77.71 ± 6.19*Aab
A oncocalyx 34 47.14 ± 6.39*Aab 28.67 ± 7.94*Ba 52.86 ± 6.39*Bab 71.33 ± 7.94*Ab
Onco A 1 51.90 ± 5.63*Aab 23.96 ± 9.85*Bab 48.10 ± 5.63*Bab 76.04 ± 9.85*Aab
Onco A 10 49.19 ± 6.07*Aab 18.72 ± 8.78*Bab 50.81 ± 6.07*Bab 81.28 ± 8.78*Aab
Onco A 30 37.56 ± 4.59*†Ab 24.48 ± 10.52*Bab 62.44 ± 4.59*†Ba 75.52 ± 10.52*Aab
* Differs significantly from non-cultured control. † Differs significantly from α-MEM+ cultured control. Distinct capital letters represent
significant differences between columns (days of culture). Different lowercase letters represent significant differences between lines
(experimental treatments).
81
7. References
1. Cragg GM, Grothaus PG, Newman DJ: New Horizons for Old Drugs and Drug
Leads. J Nat Prod 2014;77:703–723.
2. Oktem O, Oktay K: Quantitative assessment of the impact of chemotherapy on
ovarian follicle reserve and stromal function. Cancer 2007 Nov 15;110:2222–9.
3. Bar-Joseph H, Ben-Aharon I, Rizel S, Stemmer SM, Tzabari M, Shalgi R:
Doxorubicin-induced apoptosis in germinal vesicle (GV) oocytes. Reprod Toxicol
2010 Dec;30:566–72.
4. Ben-Aharon I, Bar-Joseph H, Tzarfaty G, Kuchinsky L, Rizel S, Stemmer SM, et
al.: Doxorubicin-induced ovarian toxicity. Reprod Biol Endocrinol 2010 Jan;8:20.
5. Graham JG, Quinn ML, Fabricant DS, Farnsworth NR: Plants used against cancer
– an extension of the work of Jonathan Hartwell. J Ethnopharmacol 2000;73:347–
377.
6. Newman DJ, Cragg GM, Snader KM: Natural Products as Sources of New Drugs
over the Period 1981 - 2002. J Nat Prod 2003;66:1022–1037.
7. Cragg GM, Newman DJ: Plants as a source of anti-cancer agents. J
Ethnopharmacol 2005 Aug 22;100:72–9.
8. Braga R: Plantas do Nordeste, especialmente do Ceará. ed 3rd Mossoró, 1976.
9. Ferreira MAD, Nunes ODRH, Leal LKAM, Pessoa ODL, de Lemos TLG, Viana
GSDB: Antioxidant effects in the quinone fraction from Auxemma oncocalyx
TAUB. Biol Pharm Bull 2003;26:595–599.
10. Pessoa C, Mendes CS, Pessoa LO, Sabino SH, Lemos T., Moraes MO: Avaliação
da atividade antitumoral de Auxemma oncocalyx Taub. (Pau Branco).; in : VII
Annual Meeting of the Federação de Sociedades de Biologia Experimental,
Caxambu, MG, Brazil. 1992, pp 26– 29.
11. Lino CS, Pessoa ODL, Lemos TLC, Viana GSB: Estudo da atividade analgésica e
antiedematogênica do extrato hidroalcoólico de Auxemma oncocalyx e
oncocalyxona A; in : Simpósio De Plantas Medicinais Do Brasil. 1996, p 95.
12. Ferreira MAD, Nunes ODRH, Fontenele JB, Pessoa ODL, Lemos TLG, Viana
GS.: Analgesic and anti-inflammatory activities of a fraction rich in oncocalyxone
A isolated from Auxemma oncocalyx. Phytomedicine 2004;11:315–322.
13. Costa-lotufo LV, Cunha GMA, Farias PAM, Viana GSB, Cunha KMA, Pessoa C,
82
et al.: The cytotoxic and embryotoxic effects of kaurenoic acid , a diterpene
isolated from Copaifera langsdorffii oleo-resin. Toxicon 2002;40:1231–1234.
14. Pessoa C, Vieira FMAC, Lemos TG, Moraes MO, Lima PDL, Rabenhorst SHB, et
al.: Oncocalyxone A from Auxemma oncocalyx lacks genotoxic activity in
phytohemagglutinin-stimulated lymphocytes. Teratog Carcinog Mutagen 2003
Jan;Suppl 1:215–20.
15. Leyva A, Pessoa O, Boogaerdt F, Sokaroski R, Lemos TG, Wetmore LA, et al.:
Oncocalyxones A and C, 1,4-Antracenediones from Auxemma oncocalyx:
Comparison with Anticancer 1,9-Anthracenediones. Anticancer Res
2000;20:1029–1032.
16. Pessoa C, Lemos TLG, Pessoa ODL, Moraes MO, Costa-lotufo LV, Leyva A:
Cytotoxicity of derivatives of oncocalyxone A from Auxemma oncocalyx Taub.
ARKIVOC 2004;vi:89–94.
17. Figueiredo JR, Rodrigues APR, Silva JRV, Santos RR: Cryopreservation and in
vitro culture of caprine preantral follicles. Reprod Fertil Dev 2011 Jan;23:40–7.
18. Chaves RN, Duarte ABG, Matos MHT, Figueiredo JR: Sistemas de cultivo in vitro
para o desenvolvimento de oócitos imaturos de mamíferos. Rev Bras Reprod Anim
2010;34:37–49.
19. Celestino JJH, Lima-Verde IB, Bruno JB, Matos MHT, Chaves RN, Saraiva MV
a, et al.: Steady-state level of bone morphogenetic protein-15 in goat ovaries and
its influence on in vitro development and survival of preantral follicles. Mol Cell
Endocrinol 2011 May 16;338:1–9.
20. Shrestha J, Shanbhag T, Shenoy S, Amuthan A, Prabhu K, Sharma S, et al.:
Antiovulatory and abortifacient effects of Areca catechu (betel nut) in female rats.
Indian J Pharmacol 2010;42:306–311.
21. Costa-Lotufo LV, Ferreira MAD, Lemos TLG, Pessoa ODL, Viana GSB, Cunha
GM.: Toxicity to sea urchin egg development of the quinone fraction obtained
from Auxemma oncocalyx. Brazilian J Med Biol Res 2002;35:927–930.
22. Pessoa C, Silveira ER, Lemos TLG, Wetmore LA, Moraes MO, Leyva A:
Antiproliferative Effects of Compounds Derived from Plants of Northeast Brazil.
Phyther Res 2000;14:187–191.
23. Monks TJ, Lau SS: Toxicology of quinone-thioethers. Crit Rev Toxicol
1992;22:243–270.
83
24. Bolton JL, Trush MA, Penning TM, Dryhurst G, Monks TJ: Role of Quinones in
Toxicology. Chem Res Toxicol 2000 Mar;13:135–160.
25. Pessoa OD., Lemos TLG, Carvalho MG, Braz-Filho R: Cordiachromes from
Auxemma oncocalyx. Phytochemistry 1995;40:1777–1786.
26. Löbermann F, Weisheit L, Trauner D: Intramolecular Vinyl Quinone Diels-Alder
Reactions: Asymmetric Entry to the Cordiachrome Core and Synthesis of d
Synthesis of (-) - Isoglaziovianol. Org Lett 2013;15:4324–4326.
27. da Costa GM, Lemos TLG, Pessoa DL, Monte FJQ, Braz-filho R: Glaziovianol , a
New Terpenoid Hydroquinone from Auxemma glazioviana. J Nat Prod
1999;62:1044–1045.
28. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L: Anthracyclines : Molecular
Advances and Pharmacologic Developments in Antitumor Activity and
Cardiotoxicity. Pharmacol Rev 2004;56:185–229.
29. Tokarska-schlattner M, Zaugg M, Zuppinger C, Wallimann T, Schlattner U: New
insights into doxorubicin-induced cardiotoxicity : The critical role of cellular
energetics. J Mol Cell Cardiol 2006;41:389–405.
30. Knight PG, Glister C: Focus on TGF- b Signalling TGF- b superfamily members
and ovarian follicle development. Reproduction 2006;132:191–206.
84
8 EFEITO DA TOXICIDADE DA FRAÇÃO DA AUXEMMA ONCOCALYX E
DO PRINCÍPIO ATIVO ONCOCALYXONE A NO CULTIVO IN VITRO DE
FOLÍCULOS SECUNDÁRIOS E NA MATURAÇÃO IN VITRO DE OÓCITOS
DE CAPRINOS
“Toxicity effect of the Auxemma oncocalyx fraction and its active principle
oncocalyxone A on in vitro culture of caprine secondary follicles and in vitro oocyte
maturation.”
Periódico: Semina: Ciências Agrárias (aceito) (ISSN: 1679-0359)
Qualis B1
85
RESUMO
O extrato da Auxemma oncocalyx (A. oncocalyx) e seu componente, oncocalyxona A
(onco A), possui atividade antitumoral, podendo afetar a fertilidade. Entretanto, estudos
sobre a ação dessas substâncias em relação à foliculogênese caprina são desconhecidos.
O objetivo desse estudo foi avaliar o efeito da A. oncocalyx e onco A no cultivo in vitro de
folículos secundários isolados (Experimento 1) e na maturação in vitro (MIV) de oócitos
de folículos antrais caprinos crescidos in vivo (Experimento 2). Folículos secundários
isolados foram distribuídos em seis grupos, em que o controle não-cultivado foi
imediatamente fixado em paraformaldeído 4%. Os folículos restantes foram cultivados
durante 7 dias em α-MEM+ sozinho (controle) ou suplementado com DMSO,
doxorrubicina (DXR), A. oncocalyx ou onco A. Após o cultivo, os folículos foram
avaliados quanto à formação de antro, taxa de crescimento, apoptose (TUNEL) e
proliferação celular (PCNA), bem como a expressão dos genes BCL2 e BAX. Além disso,
os complexos cumulus-oócitos (CCOs) foram aspirados e distribuídos em cinco
tratamentos para MIV: o controle em meio de maturação (TCM 199+), e os demais
tratamentos suplementados com DMSO, DXR, A. oncocalyx ou onco A. Depois da MIV,
a configuração da cromatina e viabilidade oocitária foram avaliadas. Após 7 dias de
cultivo, observou-se redução na percentagem de folículos morfologicamente intactos, na
formação de antro, na taxa de crescimento e no número de células PCNA positivas
(P<0,05). Depois do cultivo, no tratamento DXR foi observada maior percentagem de
folículos TUNEL positivos (P<0,05) e também aumento na taxa de RNAm BAX: BCL2
(P<0,05). Após MIV dos CCOs, nos tratamentos com DXR, A. oncocalyx e onco A,
observou-se maior (P<0,05) percentagem de oócitos anormais e menor de oócitos viáveis
quando comparados ao grupo controle (P<0,05). No entanto, apenas nos tratamentos
DXR e onco A aumentou a percentagem de oócitos viáveis com configuração da
cromatina anormais (P<0,05). Não houve diferenças nas taxas de maturação entre o grupo
controle e os tratamentos DXR, A. oncocalyx e onco A. De acordo com nossas condições
de cultivo, pode-se concluir que a A. oncocalyx e onco A não apresentaram efeitos tóxicos
sobre folículos secundários isolados e as taxas de maturação dos CCOs recuperados a
partir de folículos antrais. No entanto, estas substâncias afetam negativamente a
viabilidade oocitária. Assim, o uso de biotecnologias como o cultivo de folículos
86
secundários in vitro e MIV de oócitos para testes de toxicidade são métodos apropriados
para avaliar possíveis efeitos das drogas na foliculogênese.
Palavras-chave: Auxemma oncocalyx. Doxorrubicina. Oncocalyxona A. Foliculogênese.
Ovócitos
87
Efeito da toxicidade da fração da Auxemma oncocalyx e do princípio ativo oncalyxone A
no cultivo in vitro de folículos secundários e na maturação in vitro de oócitos de caprinos.
Toxicity effect of the Auxemma oncocalyx fraction and active principle oncalyxone A
on in vitro culture of caprine secondary follicles and in vitro oocyte maturation.
Leiva-Revilla J.a,, Cadenas J.a, Vieira L. a, Macedo V. a, Campello C.C. a, Aguiar F.L. a,
Celestino J.J.H. b, Pessoa O.D.L. c, Apgar G.A. d, Rodrigues A.P.R. a, Figueiredo J.R. a*,
Maside C. a.
a Laboratory of Manipulation of Oocytes and Preantral Follicles (LAMOFOPA),
Universidade Estadual do Ceará, Fortaleza-CE, Brazil.
b Institute of Health Sciences, Universidade da Integração Internacional da Lusofonia
Afro-Brasileira. Acarape-CE, Brazil.
c Departamento de Química Orgânica e Inorgânica. Universidade Federal do Ceará,
Centro de Ciências. Fortaleza-CE, Brazil
d Professor of Department of Animal Science, Food and Nutrition, Southern Illinois
University-Carbondale, USA
* Correspondence should be addressed to:
Laboratório de Manipulação de Oócitos e Folículos Pré-Antrais (LAMOFOPA).
Universidade Estadual do Ceará (UECE). Av. Silas Munguba, 1700, Campus do Itaperi.
Fortaleza – CE – Brasil. CEP: 60740 903
Tel.: +55.85. 3101.9852; Fax: +55.85.3101.9840
E-mail address: [email protected]
88
ABSTRACT
The extract of Auxemma oncocalyx (A. oncocalyx) and its main component i.e.,
oncocalyxone A (onco A), have anti-tumoral activity, and might affect fertility. Studies
on the action of these substances regarding caprine folliculogenesis are lacking. The aim
of this study was to evaluate the effect of A. oncocalyx and onco A on the in vitro culture
of isolated secondary follicles (Experiment 1) and on the in vitro maturation (IVM)
(Experiment 2) of oocytes from caprine antral follicles grown in vivo. Isolated secondary
follicles were distributed in six groups; the non-cultured control was immediately fixed
in Paraformaldehyde 4%. The remaining follicles were cultured for 7 days in α-
MEM+ alone (control) or supplemented with DMSO, doxorubicin (DXR), A.
oncocalyx or onco A. After culture, follicles were evaluated for antrum formation, growth
rate, apoptosis (TUNEL) and cellular proliferation (PCNA), as well as gene expression
of BCL2 and BAX. Additionally, cumulus oocyte complexes (COCs) were aspirated and
allocated into five treatments for IVM: control, cultured only in maturation base medium
(TCM 199+); or supplemented with DMSO; DXR; A. oncocalyx or onco A. After IVM,
oocyte chromatin configuration and viability were assessed. After 7 days of culture, there
was a reduction in the percentage of morphologically intact follicles, antrum formation,
growth rate and number of PCNA positive granulosa cells (P < 0.05). After culture, the
DXR treatment had a higher percentage of TUNEL positive follicles and relative
BAX:BCL2 mRNA ratio’s (P < 0.05). After IVM of the COCs, DXR, A. oncocalyx and
onco A treatments had a greater percentage (P < 0.05) of abnormal oocytes and a lower
percentage of viable oocytes as compared with the control group (P < 0.05). However,
only DXR and onco A treatments increased the percentage of alive oocytes with abnormal
chromatin configuration (P < 0.05). There were no differences in maturation rates
between the control group and DXR, A. oncocalyx and onco A treatments. In conclusion,
under our culture conditions, A. oncocalyx and onco A do not exhibit a toxic effect on
isolated secondary follicles and on maturation rates of COCs recovered from antral
follicles. However, these substances negatively affected the oocyte viability. Thus, the
use of culture biotechnologies as an in vitro secondary follicle culture and in vitro oocyte
maturation toxicity testing are appropriated methods to evaluate the possible effects of
drugs in folliculogenesis.
89
Keywords: Auxemma oncocalyx; Doxorubicin; Oncocalyxone A; Folliculogenesis;
Oocytes.
90
1. Introduction
In vitro manipulation of oocytes enclosed in preantral follicles allows drug
toxicity testing, by avoiding the ethical concerns and restrictions of in vivo experiments.
Therefore, one way to safely study the effects of drugs on reproduction, is by the
utilization of in vitro preantral follicle culture. This technique enables the testing of
beneficial or toxic effects on ovarian follicles in vitro before their use in experiments
involving live subjects (FIGUEIREDO et al., 2011).
Cancer research is continuously seeking to develop or discover new treatments
(CRAGG et al., 2014). Many drugs used in cancer chemotherapy, in addition to showing
toxicity against tumor cells, exhibit genotoxic, carcinogenic and teratogenic effects on
normal cells. One of the most commonly used is Doxorubicin (DXR) (OKTEM; OKTAY,
2007). Normally used in treatment against bladder, breast, lung, ovary cancer and others
(CHOW et al., 2010), it transgresses the cell membrane and accumulates in both the
nucleus mitochondria, by inducing oxidative stress and chromosomal obliteration through
inhibition of topoisomerase II (MAILER; PETIRING, 1976). However, DXR induces
ovarian toxicity by reducing the ovulation rate, along with a reduction in the size of the
ovary and other side effects (OKTEM; OKTAY, 2007; BAR-JOSEPH et al., 2010; BEN-
AHARON et al., 2010). The poor specificity of these drugs against tumor tissue highlights
the need of developing new drugs with fewer side effects (OKTEM; OKTAY, 2007) and
more specificity.
Plants are excellent sources of raw material when searching for new drugs, and
commonly used in the treatment of cancer (GRAHAM et al., 2000). In addition, over 60%
of currently anti-cancer agents are derived from natural sources, including plants, marine
organisms and micro-organisms (NEWMAN et. al., 2003; CRAGG; NEWMAN, 2005).
Auxemma oncocalyx (A. oncocalyx) is a common tree found in the state of Ceará in
Northeast Brazil (BRAGA, 1976). It has been widely used in folk medicine as an
adjunctive treatment for injuries (BRAGA, 1976; FERREIRA et al., 2003). Some studies
have suggested that this plant has biological activities such as analgesic, anti-oxidant,
anti-tumor and anti-inflammatory effects (PESSOA et al., 1992; LINO et al., 1996;
FERREIRA et al., 2003, 2004). Oncocalyxone A (onco A) has been isolated from the
stem heartwood of the plant, which has a high antioxidant activity (FERREIRA et al.,
91
2003) and an antiproliferative effects in tumor cell cultures (COSTA-LOTUFO et al.,
2002).
In previous studies, onco A has been suggested as a possible anticancer compound
since it has presented antitumor and cytotoxic activity in human leukemia cells, and other
cell cancer lines, without causing genotoxicity (LEYVA et al., 2000; PESSOA et al.,
2003, 2004). However, the effect of A. oncocalyx and onco A on in vitro folliculogenesis
is not known.
Hence, the aim of this study was to investigate the effect of A. oncocalyx and onco
A on the in vitro survival and growth of isolated goat secondary follicles (Experiment 1)
as well as on the viability and nuclear maturation of oocytes recovered from antral
follicles (Experiment 2).
2. Materials and methods
2.1. Source of ovaries
Ovaries (n =130) from 65 cycled mixed breed adult goats, with body condition
score 3 (30 and 35 for experiment 1 and 2, respectively) were obtained at a local
slaughterhouse located in Mossoro, Rio Grande do Norte state, northeast region, with
latitude: 05º 11' 15" S and longitude 37º 20' 39" W. The ovaries were washed in 70%
alcohol for approximately 10 s and then twice in minimal essential medium (MEM)
supplemented with 100 µg/mL penicillin and 100 µg/mL streptomycin plus HEPES
(MEM-HEPES). The ovaries were transported to the laboratory at 4 or 33 °C (experiment
1 or 2, respectively) in a thermal container, within 4 h. All chemicals used in the present
study were purchased from Sigma Chemical Co. (St. Louis, MO, USA), unless otherwise
indicated.
2.2. Obtainment of onco A from A. oncocalyx
Auxemma oncocalyx was collected in August 2012 at Acarape, state of Ceará,
which is located in Northeast Brazil. The plant was identified by Dr. Maria Iracema B.
Loiola of the Department of Biology of Federal University of Ceará. A voucher specimen
(No. 18459) has been deposited in the Herbarium Prisco Bezerra (EAC), Federal
University of Ceará.
92
The air-dried and powdered heartwood (2.5 kg) of A. oncocalyx was extracted
with EtOH (2 x each) at room temperature. The combined extracts were evaporated under
reduced pressure to yield the crude extract (100 g), which was fractionated over silica gel
and eluted with CH2Cl2, CH2Cl2/ EtOAc (7:3 and 1:1), EtOAc, EtOAc/ MeOH (9.5:0.5
and 1:1) to yield after solvent evaporation the correspondent fractions: 6.60, 5.99, 8.01,
3.36, 50.08 and 25.96 g, respectively. The fraction EtOAc/MeOH 9.5:0.5 (50.0 g) was
subjected to a silica gel (200 g) chromatography column using CH2Cl2/ EtOAc 1:1 (200
mL), 7:3 (500 mL), EtOAc (1000 mL) and EtOAc/ MeOH 9.5:0.5 (400 mL) to afford 60
fractions of approximately 30 mL. After comparative analysis by TLC, these fractions
were pooled into 3 main fractions: F1 (1-20; 8.2 g), F2 (21-54; 25.2 g) and F3 (55-60;
16.7 g). F2 (21-54; 25.2 g) was subjected twice to chromatography over silica gel eluted
with CH2Cl2/EtOAc 1:1, 7:3, EtOAc, EtOAc/MeOH 9.5:0.5 and MeOH. Fractions
CH2Cl2/EtOAc 7:3 and EtOAc furnished a dark solid, which was purified by addition of
acetone followed by filtration. This material (5.5 g), a deep red powder, mp 207–208o
was identified as rel-8a-hydroxy-5-hydroxymethyl-2-methoxy-8ab-methyl-7,8,8a,9-
tetrahydro-1,4-anthracenedione), named onco A, as previously described by PESSOA et
al., 1993.
1H NMR (200 MHz, DMSO-d6): 6.00 (s, H-3), 6.03 (br d, H-6), 2.52 (br d, J 17.2
Hz, H-7eq), 2.60 (dd, J 17.2, 3.9 Hz, H-7ax), 3.57 (br s, H-8), 2.90 (d, J 18.4 Hz, H-9ax),
2.34 (d, J 18.4 Hz, H-9eq), 6.50 (s, H-10), 4.16 (br s, 2H-11), 0.74 (s, 3H-12), 3.78 (s,
OMe). 13C NMR (50.3 MHz, DMSO-d6): 181.2 (C-1), 159.8 (C-2), 106.4 (C-3), 186.1
(C-4), 134.6 (C-4a), 146.7 (C-5), 128.4 (C-6), 32.0 (C-7), 70.1 (C-8), 38.9 (C-8a), 29.2
(C-9), 133.0 (C-9a), 111.8 (C-10), 135.5 (C-10a), 61.6 (C-11), 21.3 (C-12), 56.7 (OMe).
It is noteworthy that the fraction of A. oncocalyx contains 80 % of onco A
(FERREIRA et al., 2004), therefore the concentration of A. oncocalyx was in equal
proportion of onco A. A. oncocalyx and onco A were diluted with DMSO as a vehicle.
The concentrations of A. oncocalyx and onco A were chosen based on previous studies
performed in our laboratory (unpublished data).
2.3. Experimental design
For Experiment 1, isolated secondary follicles were randomly distributed in the
following six treatments: I) non-cultured control; II) cultured in α-MEM+ (control); III)
93
α-MEM+ supplemented with 20% v/v dimethyl sulfoxide (DMSO); IV) α-MEM+
supplemented with 0.3 g/mL DXR (positive toxicity control); V) α-MEM+
supplemented with 1.2 g/mL A. oncocalyx or VI) α-MEM+ supplemented with 1 g/mL
onco A. The culture was replicated seven times, and a total of 60 follicles (at least) were
used in each treatment. Cultured follicles were evaluated for antrum formation capacity,
growth rate, apoptosis (TUNEL) and cellular proliferation (PCNA). In addition, both non-
cultured and cultured isolated secondary follicles from the five treatments after culture
were selected for Bcl2 and Bax gene expression.
For experiment 2, COCs were allocated into five treatments to perform in vitro
maturation: I) TCM-199+ (control) II) TCM-199+ supplemented with 20% v/v DMSO;
III) TCM-199+ supplemented with 0.3 g/mL DXR; IV) TCM-199+ supplemented with
1.2 g/mL A. oncocalyx or V) TCM-199+ supplemented with 1 g/mL onco A. The
culture (maturation) was replicated three times, and a total of 75 (at least) COCs were
used in each treatment. After 24 h of in vitro maturation, oocyte chromatin configuration
and viability were assessed by fluorescence microscopy.
2.4. Isolation, selection and culture of secondary follicles
After transportation, fat and connective tissue surrounding the ovaries were
removed. Cortical slices (1 to 2 mm thick) were cut with a surgical blade (under sterile
conditions) and placed in a holding medium consisting of HEPES-MEM. Secondary
follicles that were approximately 200 µm in diameter were visualized using a
stereomicroscope (SMZ 645, Nikon, Tokyo, Japan) with ocular micrometer (100 X
magnification) and manually dissected from strips of ovarian cortex using 26-gauge (26
G) needles. After isolation, follicles were transferred to 100 µL drops containing fresh
culture medium under mineral oil for further evaluation of follicular quality. Follicles
with a visible and centrally located oocyte that were surrounded by granulosa cells and
had an intact basement membrane and no antrum formation were selected as secondary
follicles for culture.
After selection, follicles were individually cultured in 100 µL drops of culture
media and allocated into different treatments (67, 58, 59, 59 and 58 respectively for
control, DMSO, DXR, A. oncocalyx and onco A treatments) described further in the
experimental design (item 2.5). The base culture media consisted in α-MEM
94
supplemented with 3 mg/mL bovine serum albumin (BSA), 10 ng/mL insulin, 5.5 µg/mL
transferrin and 5 ng/mL selenium, 2 mM glutamine, 2 mM hypoxanthine, 50 µg/mL
ascorbic acid and 100 ng/mL FSH (α-MEM+). The culture was carried out at 39 °C, in
5% CO2 in air for 7 days. Fresh media were prepared and pre-equilibrated for 2 h prior to
use. Every other day, 60 µL of medium were replenished in each drop.
2.5. Assessment of follicle development
During culture, follicles were classified according to their morphology. Follicles
showing darkness of the oocytes and surrounding cumulus cells or those with misshapen
oocytes were classified as degenerated. At day 7 of culture, follicular diameter and antrum
formation were evaluated only in healthy follicles. The follicular diameter was
determined as the mean of two perpendicular measures of each follicle, using an ocular
micrometer (100 X magnification) inserted into a stereomicroscope (SMZ 645, Nikon,
Tokyo, Japan). Antrum formation was defined as a visible translucent cavity within the
granulosa cell layers.
2.6. Assessment of apoptosis by TUNEL assay
For determination of DNA fragmentation, a terminal deoxynucleotidyl
transferase-mediated dUTP biotin nick end labeling (TUNEL) detection kit (R&D
Systems, Minneapolis, MN, USA) was utilized. The follicles were fixed in 4%
paraformaldehyde buffered with PBS. Subsequently, the blocks were sectioned at a
thickness of 5 µm following de-paraffinization and boiled for antigen retrieval in 0.01 M
citric acid. The blockade of exogenous peroxidase and nonspecific blocking were
performed in a humid chamber. The TUNEL kit was prepared following the guidelines
provided by the manufacturer. The incubation of TUNEL consisted of the addition of a
TUNEL mixture for 1 h at 37 °C (moist chamber) and, after washing, 50 mL Convert
POD was added for 30 min at 37 °C (moist chamber). Follicles were considered TUNEL
positive when oocyte nucleus was stained brown.
2.7. Proliferating cell nuclear antigen (PCNA) assessment
Follicles were fixed in 4% paraformaldehyde and 5 µm paraffin sections were
mounted to microscope slides. Paraffin sections were heated at 65 °C for 45 min.
95
Following de-paraffinization, sections were rehydrated in a series of graded ethanol/water
solutions then boiled in 0.01 M citric acid (pH 6.0) at 95–100 °C for 5 min followed by
incubation in 3% hydrogen peroxide (H2O2) for 10 min. The tissues were blocked with
avidin and biotin and incubated with a Rb Pab-PCNA (1:3000 - 2426 Abcam) overnight
at 4 °C. After rinsing thoroughly with PBS, the sections were incubated with caprine
pAB-Rb IgG antibody (Biotin) for 30 min at room temperature. PCNA expression was
detected by the reaction of peroxidase with 3,39-diaminobenzidine tetrahydrochloride
(DAB) and analyzed using a light microscope (400X maginification, Nikon Eclipse
E200). PCNA assessment was evaluated by counting positive cells/total cells for each
follicle to obtain an index of positive cells. Between 34 and 427 granulosa cells per
follicle were evaluated.
2.8. Quantitative real-time PCR analysis for BAX, BCL2 in isolated secondary follicles
For RNA isolation, three pools of 10 isolated secondary follicles were collected
from each experimental group after 7 days of culture (Exp.1). The samples were stored
in microcentrifuge tubes (1.5 mL) with 100 µL Trizol at -80 ºC. Total RNA from follicles
were isolated and purified with Trizol® Plus Purification kit (Invitrogen, São Paulo,
Brazil). The RNA preparations were treated with DNase I and Pure Link RNA Mini Kit
(Invitrogen, São Paulo, Brazil). Complementary DNA (cDNA) was synthesized from the
isolated RNA using Superscript II RNase H-Reverse Transcriptase (Invitrogen, São
Paulo, Brazil). The qPCR reaction was performed in a final volume of 20 µL, containing
1 µL of each cDNA, 1 x Power SYBR Green PCR Master Mix (10 µL) (PE Applied
Biosystems, Foster City, CA, USA), 5.5 µL of ultrapure water, and 0.5 µM of both sense
and anti-sense primers. The gene-specific primers used for the amplification of different
transcripts are shown in Table 1. Transcript levels in follicular cells were normalized to
the content of peptidylprolyl Isomerase A (PPIA) and glyceraldehyde-3-phosphate-
dehydrogenase (GAPDH). Primer specificity and amplification efficiency were verified
for each gene. The qPCR cycling conditions consisted of an initial denaturation and
polymerase activation step at 94 ºC for 15 min, followed by 40 cycles of 15 s at 94 ºC, 30
s at 60 ºC, and 45 s at 72 ºC, and then a final extension for 10 min at 72 ºC. After
amplification, melting curve analysis was performed between 60 ºC and 95 ºC for all
genes. All amplifications were carried out in a Bio-Rad iQ5 (Hercules, CA, USA). The
96
delta-delta-CT method was used to transform threshold cycle values into normalized
relative expression levels (LIVAK; SCHMITTGEN, 2001).
2.9. In vitro maturation of caprine oocytes recovered from antral follicles
In the laboratory, approximately 399 cumulus oocytes complexes (COCs) from
70 ovaries were collected by slicing of ovaries. Oocytes with a compact cumulus mass
and a dark, evenly granulated cytoplasm were selected for IVM and washed three times
in base maturation medium (TCM-199+), consisting of TCM-199 supplemented with 1
µg/mL 17β- estradiol, 5 µg/mL LH, 0.5 µg/mL rFSH, 10 ng/mL EGF, 1 mg/mL BSA, 22
µg/mL pyruvate, 50 ng/mL IGF-I, and 100 µmol/L cysteamine, previously pre-
equilibrated at 39°C and 5% CO2 .in air. Groups of COCs were cultured in 500 µL of
designed media into each well of a 4-well multidish (Nunc, Roskilde, Denmark) for 24 h
at 39 °C, in 5% CO2.
2.10. Assessment of oocyte chromatin configuration and viability
Following maturation, the COCs were denuded mechanically and oocytes were
washed in PBS, then incubated in 100 µL droplets containing 4 µM calcein-AM, 2 µM
ethidium homodimer-1 (Molecular Probes, Invitrogen, Karlsruhe, Germany), 0.5% of
glutaraldehyde and 10 µM Hoechst 33342 for 30 min.
The chromatin configuration was assessed by fluorescence microscopy (Nikon,
Eclipse 80i, Tokyo, Japan), and classified as abnormal chromatin configuration, when the
nucleus was pyknotic, compact or in a strange configuration; and normal chromatin
configuration was considered when the nucleus was in germinal vesicle (GV) or meiotic
resumption. Meiotic resumption was defined when the nucleus was in germinal vesicle
break down (GVBD), metaphase I (MI) or in metaphase II (MII) stages. Thereafter,
oocytes were also examined under a fluorescence microscope (Nikon, Eclipse 80i, Tokyo,
Japan) for evaluation of live/dead fluorescent staining. The emitted fluorescent signals of
calcein-AM and ethidium homodimer-1 were collected at 488 and 568 nm, respectively.
Oocytes were considered alive when the cytoplasm was stained positively with calcein-
AM (green) and chromatin was not labeled with ethidium homodimer-1 (red). Also,
oocytes were classified as viable when the cytoplasm was stained positively with calcein-
AM and they showed a normal chromatin configuration, as mentioned above. Moreover,
97
abnormal oocytes were divided in three categories: oocytes stained positively with
calcein-AM with abnormal chromatin were considered as alive with abnormal chromatin
configuration, or oocytes non stained with calcein-AM and stained with ethidium
homodimer were considered as non-alive; and finally non-alive plus alive with abnormal
chromatin configuration which formed the total number of abnormal oocytes.
2.11. Statistical analyses
For both experiments, data referring to continuous variables were initially
evaluated for homocedasticity and normal distribution of the residues by Bartlett’s and
Shapiro-Wilk tests, respectively. Confirmed both requirements underlying analysis of
variance, it was carried out considering a completely randomized design in a factorial
arrangement 5 x 2 (five treatments and two times of culture). When any main effect or
their interactions were significant, comparisons were further analyzed by Student-
Newman-Keuls test, being the results expressed as mean ± standard deviation. When
heterocedasticity was observed, even after transformation of data, non-parametric
Kruskal-Wallis test was applied. Data for discrete variables were analyzed by chi-square
test (or Fisher Exact Test when n<5) and results were expressed as percentages. In all
cases, a probability of P<0.05 indicated a significant difference.
3. Results and discussion
The present study utilized for the first time reproductive toxicity of in vitro
cultured isolated follicles and in vitro matured COC’s to assess the toxicity of A.
oncocalyx and its isolated compound onco A. In order to investigate the effects of
different drugs over folliculogenesis, there are various toxicological tests. In vitro cultures
have become a tool to analyze the effects of several components on the survival, growth
and maturation of follicles in many animal models (STEFANSDOTTIR et al., 2014). In
vitro experiments are of great importance as they provided appropriated information
about the effect of different compounds before in vivo testing. The in vitro culture of
caprine preantral follicles and the in vitro maturation of COCs showed to be appropriated
techniques to analyze the drugs effect over folliculogenesis.
98
A total of 301 secondary follicles were analyzed before and after in vitro culture
in different treatments (Figure 1). The effects of the treatments on the percentage of
morphologically intact follicles and antrum formation are shown (Table 2). After 7 days
of culture there was a lower (P < 0.05) percentage of morphologically intact follicles and
antrum formation in DXR treatment compared to the other treatments (control, DMSO,
A. oncocalyx and onco A). Follicular diameter and growth rate of follicles after 7 days of
in vitro culture are shown (Table 3). There was a significant increase in follicular diameter
from D0 to D7 in all treatments except for onco A and DXR. In addition, we observed
that DXR significantly reduced the growth rate when compared to the other treatments
(control, DMSO, A. oncocalyx and onco A). The in vitro follicle culture system used in
the present study was effective to investigate the impact of the studied drugs (DXR, A.
oncocalyx and onco A) on in vitro folliculogenesis. The control medium used ensured the
maintenance of appropriate rates of follicle survival (92.54 %), growth (4.19 ± 6.12) and
antrum formation (59.70 %). These data are in agreement with previous studies reporting
the in vitro culture of caprine preantral follicles for 6 days, using the same culture medium
(ARAÚJO et al., 2011; DUARTE et al., 2013). In this study, A. oncocalyx and onco A
did not alter the folliculogenesis parameters such as survival, antrum formation and
growth rate. On the contrary, DXR caused a toxic effect on all these folliculogenesis end
points. A. oncocalyx and onco A were less harmful to in vitro secondary follicles than
DXR, although both drugs were able to maintain follicular morphology, without affecting
neither antrum formation, nor follicular growth. It is known that onco A and DXR both
have anti-carcinogenic effects (PESSOA et al., 2004). The fraction of A. oncocalyx and
onco A in different lineages of cells, especially in tumor cell lines, had a similar effect
when compared to DXR (PESSOA et al., 2000, 2003, 2004). DXR and onco A have been
shown to exhibit cytotoxicity in the G, G1/S and S phases of cell division, however, only
DXR exhibited genotoxicity in these cells (PESSOA et al., 2003). This genotoxicity,
caused by DXR, could explain the decrease in the percentage of morphologically intact
follicles and antrum formation found in this study.
The percentage of TUNEL positive follicles (TPF) was higher (P < 0.05) for the
DXR treatment when compared to non-cultured control. There was no difference (P >
0.05) in the percentage of TPF among the other treatments. The number of PCNA positive
granulosa cells were lower (P <0.05) for the DXR treatment when compared to the other
treatments (control, DMSO, A. oncocalyx and onco A) (Table 4). Additionally, DXR was
99
the only treatment to cause a decrease (P < 0.05) in the relative BAX:BCL2 mRNA ratio
(Figure 2). More studies are needed to discern the mechanism of action of both drugs.
Recent studies revealed that DXR induced ovarian toxicity, which was observed by a
reduction in ovulation rate and the size of the ovary (OKTEM; OKTAY, 2007; BAR-
JOSEPH et al., 2010; BEN-AHARON et al., 2010). DXR elicits apoptosis by various
mechanisms in a variety of cells. It can be accumulated in both the nucleus and
mitochondria, and induces chromosomal destruction by inhibiting topoisomerase-II
(TOKARSKA-SCHLATTNER et al., 2006). DXR can also interfere with mitochondrial
function and initiate an intrinsic pathway of apoptosis by reducing the mitochondrial
membrane potential and releasing cytochrome C (BAR-JOSEPH et al., 2010).
In this study, there was a decrease (P < 0.05) in the percentage of viable oocytes
when they were treated with DXR, A. oncocalyx and onco A. The percentage of non-alive
oocytes was significantly higher (P < 0.05) in the onco A treatment than DXR and A.
oncocalyx treatments. The opposite was observed for the percentage of alive oocytes with
abnormal chromatin configuration. Compared to its vehicle (DMSO), onco A and DXR
treatments reduced (P < 0.05) the percentage of oocyte meiotic resumption, but they were
similar (P > 0.05) to the control treatment. In addition, the MII rates were similar (P >
0.05) among the treatments (Table 05). The in vitro maturation culture system used in the
present study was adequate to investigate the impact of the studied drugs (DXR, A.
oncocalyx and onco A) on in vitro maturation. The control medium used ensured the
maintenance of appropriate rates of viability (90.67 %) and meiotic resumption (92.65
%). These data are in agreement with previous studies made by our group, reporting the
in vitro maturation of caprine COCs, using the same culture medium. In this study, DXR,
A. oncocalyx and onco A negatively affected the oocyte viability (Figure 1). It is known
that DXR can induce cellular apoptosis. Moreover, a study evaluating different
concentrations (1 to 100 µg/mL) of a quinone fraction of A. oncocalyx (containing 80%
of onco A) in sea urchin eggs reported that the cleavage of eggs was inhibited in a
concentration-dependent manner, and when a concentration of 30 µg/mL was used it
caused a total destruction (100%) of embryos (COSTA-LOTUFO et al., 2002).
Only DXR and onco A caused a harmful effect on meiotic resumption. This
finding may be due to the higher sensitivity of the COCs to a toxic compound. The
presence of alive oocytes with abnormal chromatin configuration implies the occurrence
of apoptosis (BAR-JOSEPH et al., 2010). Moreover, only DXR and A. oncocalyx
100
exhibited an increase in oocytes with abnormal chromatin configuration, showing a less
harmful effect of onco A. This result may be due to the impurity of the fraction of A.
oncocalyx which contains 80% of onco A (FERREIRA et al., 2004), and 20% of other
substances that may be more toxic than onco A alone. Also, Pessoa et al. (PESSOA et al.,
2003), showed that even though onco A and DXR have cytotoxicity in lymphocytes, only
DXR present genotoxicity, proving to be more toxic. It is important to highlight that the
DMSO treatment (i.e., the vehicle used for the dilution of DXR, A. oncocalyx and onco
A) was similar to the α-MEM+ cultured control. This result shows that DMSO by itself
was not responsible for the negative effect of the tested drugs in any of the studied end
points.
4. Conclusions
In conclusion, under our culture conditions, A. oncocalyx and onco A do not have
a toxic effect on isolated secondary follicles and maturation rates on in vitro matured
COCs, however, these drugs affect the oocyte viability after in vitro maturation. In
addition, the less harmful effect of onco A than DXR on caprine secondary follicle
survival and oocytes with normal chromatin configuration may encourage future studies
involving the use of this drug for cancer treatment in women.
5. Acknowledgments
This research was financially supported by CNPq, CAPES and FUNCAP. The
authors thank Francisco Leo Aguiar, Victor Macedo Paes, Denise Damasceno Guerreiro,
Renato Félix da Silva and Naiza Arcângela Ribeiro de Sá for assistance with this study.
6. References
ARAÚJO, V. R.; SILVA, G. M.; DUARTE, A. B. G.; MAGALHÃES, D. M.;
ALMEIDA, A. P. Vascular endothelial growth factor-A165 (VEGF-A165) stimulates the
in vitro development and oocyte competence of goat preantral follicles. Cell Tissue Res,
v. 165, p. 273–281, 2011.
101
BAR-JOSEPH, H.; BEN-AHARON, I.; RIZEL, S.; STEMMER, S. M.; TZABARI, M.;
SHALGI, R. Doxorubicin-induced apoptosis in germinal vesicle (GV) oocytes.
Reproductive toxicology (Elmsford, N.Y.), v. 30, n. 4, p. 566–72, dez. 2010.
BEN-AHARON, I.; BAR-JOSEPH, H.; TZARFATY, G.; KUCHINSKY, L.; RIZEL, S.;
STEMMER, S. M.; SHALGI, R. Doxorubicin-induced ovarian toxicity. Reproductive
biology and endocrinology : RB&E, v. 8, p. 20, jan. 2010.
BRAGA, R. Plantas do nordeste, especialmente do ceará. 3rd. ed. [s.l: s.n.]
CHOW, W.-H.; DONG, L. M.; DEVESA, S. S. Epidemiology and risk factors for kidney
cancer. Nature Reviews Urology, v. 7, n. 5, p. 245–257, 2010.
COSTA-LOTUFO, L. V.; FERREIRA, M. A. D.; LEMOS, T. L. G.; PESSOA, O. D. L.;
VIANA, G. S. B.; CUNHA, G. M. . Toxicity to sea urchin egg development of the
quinone fraction obtained from Auxemma oncocalyx. Brazilian Journal of Medical and
Biological Research, v. 35, n. 8, p. 927–930, 2002.
CRAGG, G. M.; GROTHAUS, P. G.; NEWMAN, D. J. New Horizons for Old Drugs and
Drug Leads. Journal of natural products, v. 77, p. 703–723, 2014.
CRAGG, G. M.; NEWMAN, D. J. Plants as a source of anti-cancer agents. Journal of
ethnopharmacology, v. 100, n. 1–2, p. 72–9, 22 ago. 2005.
DUARTE, A. B. G.; ARAÚJO, V. R.; CHAVES, R. N.; DA SILVA, G. M.; LUZ, V. B.;
THOMAS, K. H.; MAGALHÃES-PADILHA, D. M.; ALMEIDA, A. P.; LOBO, C. H.;
CAMPELLO, C. C.; FIGUEIREDO, J. R. Insulin-like growth factor II ( IGF-II ) and
follicle stimulating hormone ( FSH ) combinations can improve the in vitro development
of grown oocytes enclosed in caprine preantral follicles. Growth Hormone & IGF
Research, v. 23, n. 1–2, p. 37–44, 2013.
FERREIRA, M. A. D.; NUNES, O. D. R. H.; FONTENELE, J. B.; PESSOA, O. D. L.;
LEMOS, T. L. G.; VIANA, G. S. . Analgesic and anti-inflammatory activities of a
fraction rich in oncocalyxone A isolated from Auxemma oncocalyx. Phytomedicine :
international journal of phytotherapy and phytopharmacology, v. 11, n. 4, p. 315–322,
2004.
FERREIRA, M. A. D.; NUNES, O. D. R. H.; LEAL, L. K. A. M.; PESSOA, O. D. L.;
DE LEMOS, T. L. G.; VIANA, G. S. D. B. Antioxidant effects in the quinone fraction
from Auxemma oncocalyx TAUB. Biological & pharmaceutical bulletin, v. 26, n. 5, p.
595–599, 2003.
FIGUEIREDO, J. R. De; CELESTINO, J. J. D. H.; FAUSTINO, L. R.; RODRIGUES,
A. P. R. In vitro culture of caprine preantral follicles: Advances, limitations and prospects.
Small Ruminant Research, v. 98, n. 1–3, p. 192–195, jun. 2011.
GRAHAM, J. G.; QUINN, M. L.; FABRICANT, D. S.; FARNSWORTH, N. R. Plants
used against cancer – an extension of the work of Jonathan Hartwell. Journal of
ethnopharmacology, v. 73, p. 347–377, 2000.
LEYVA, A.; PESSOA, O.; BOOGAERDT, F.; SOKAROSKI, R.; LEMOS, T. G.;
WETMORE, L. A.; HURUTA, R. R.; MORAES, M. O. Oncocalyxones A and C, 1,4-
Antracenediones from Auxemma oncocalyx: Comparison with Anticancer 1,9-
Anthracenediones. Anticancer Research, v. 20, n. 2A, p. 1029–1032, 2000.
LINO, C. S.; PESSOA, O. D. L.; LEMOS, T. L. C.; VIANA, G. S. B. Estudo da atividade
analgésica e antiedematogênica do extrato hidroalcoólico de Auxemma oncocalyx e
oncocalyxona A. In: Simpósio De Plantas Medicinais Do Brasil, Anais...1996.
102
LIVAK, K. J.; SCHMITTGEN, T. D. Analysis of Relative Gene Expression Data Using
Real- Time Quantitative PCR and the 2 -DDCT Method. Methods, v. 408, n. 25, p. 402–
408, 2001.
MAILER, K.; PETIRING, D. H. Inhibition of oxidative phosphorylation in tumor cells
and mitochondria by daunomycin and adriamycin. Biochemical Pharmacology, v. 25, p.
6–10, 1976.
NEWMAN, D. J.; CRAGG, G. M.; SNADER, K. M. Natural Products as Sources of New
Drugs over the Period 1981 - 2002. Journal of natural products, v. 66, p. 1022–1037,
2003.
OKTEM, O.; OKTAY, K. Quantitative assessment of the impact of chemotherapy on
ovarian follicle reserve and stromal function. Cancer, v. 110, n. 10, p. 2222–9, 15 nov.
2007.
PESSOA, C.; LEMOS, T. L. G.; PESSOA, O. D. L.; MORAES, M. O.; COSTA-
LOTUFO, L. V.;LEYVA, A. Cytotoxicity of derivatives of oncocalyxone A from
Auxemma oncocalyx Taub. ARKIVOC, v. vi, p. 89–94, 2004.
PESSOA, C.; MENDES, C. S.; PESSOA, L. O.; SABINO, S. H.; LEMOS, T. .;
MORAES, M. O. Avaliação da atividade antitumoral de Auxemma oncocalyx Taub. (Pau
Branco). In: VII Annual Meeting of the Federação de Sociedades de Biologia
Experimental, Caxambu, MG, Brazil., Anais...1992.
PESSOA, C.; SILVEIRA, E. R.; LEMOS, T. L. G.; WETMORE, L. A.; MORAES, M.
O.; LEYVA, A. Antiproliferative Effects of Compounds Derived from Plants of
Northeast Brazil. Phytotherapy research, v. 14, p. 187–191, 2000.
PESSOA, C.; VIEIRA, F. M. A. C.; LEMOS, T. G.; MORAES, M. O.; LIMA, P. D. L.;
RABENHORST, S. H. B.; LEYVA, A.; BURBANO, R. R. Oncocalyxone A from
Auxemma oncocalyx lacks genotoxic activity in phytohemagglutinin-stimulated
lymphocytes. Teratogenesis, carcinogenesis, and mutagenesis, v. Suppl 1, p. 215–20, jan.
2003.
PESSOA, O. D. L.; LEMOS, T. L. G.; SILVEIRA, E. R.; BRAZ-FILHO, R. Novel
cordiachromes isolated from Auxemma oncocalyx. Natural Product Research, v. 2, p.
145–150, 1993.
STEFANSDOTTIR, A.; FOWLER, P. A.; POWLES-GLOVER, N.; ANDERSON, R. A.;
SPEARS, N. Use of ovary culture techniques in reproductive toxicology. Reproductive
Toxicology, v. 49, p. 117–135, 2014.
TOKARSKA-SCHLATTNER, M.; ZAUGG, M.; ZUPPINGER, C.; WALLIMANN, T.;
SCHLATTNER, U. New insights into doxorubicin-induced cardiotoxicity : The critical
role of cellular energetics. Journal of molecular and cellular cardiology, v. 41, p. 389–
405, 2006.
103
7. Figures and tables
Table 1. Oligonucleotide primers used for PCR analysis of goat secondary follicles
Target gene Primer sequence (5'→3')
Sense (S) Genbank
accession nos. Antisense (AS)
GAPDH ATGCCTCCTGCACCACCA S GI: 298676424
(Ovis aries) AGTCCCTCCACGATGCCAA AS
PPIA TCATTTGCACTGCCAAGACTG S GI:548463626
(Capra hircus) TCATGCCCTCTTTCACTTTGC AS
BAX TTTTGCTTCAGGGTTTCATCCAGGA S GI:926714830
(Capra hircus) CAGCTGCGATCATCCTCTGCAG AS
BCL2 GTTTTCCGACGGCAACTTC S
GI:354549710
(Capra hircus)
104
Figure 1. Isolated secondary follicles before (a) and after 7 days of culture in α-MEM+
alone (cultured-control) (b) or supplemented with DMSO (c), DXR (d), A. oncocalyx (e)
and onco A (f). Oocytes after in vitro maturation in TCM199+ (control) (g) or
supplemented with DMSO (h), DXR (i), A. oncocalyx (j) or onco A (k).
Figure 2. Relative mean (± SEM) of BAX:BCL2 mRNA ratio in cultured isolated
secondary follicles for 7 days in α-MEM+ alone (cultured-control) or supplemented with
DMSO, DXR, A. oncocalyx and onco A. Different letters denote significant differences
(P < 0.05).
105
Table 2. Percentage of morphologically intact secondary follicles, and antrum formation
after in vitro culture for 7 days in α-MEM+ (control) or supplemented with DMSO, DXR,
A. oncocalyx or onco A.
Treatments (n) % Morphologically intact follicles % Antrum formation
Control (n = 67) 92.54 (62/67) A 59.70 (40/67) A
DMSO (n = 58) 89.66 (52/58) A 50.00 (29/58) A
DXR (n = 59) 55.93 (33/59) B 16.95 (10/59) B
A. oncocalyx (n = 59) 86.44 (51/59) A 57.63 (34/59) A
Onco A (n = 58) 84.48 (49/58) A 55.17 (32/58) A
A,B Distinct capital letters represent significant differences among experimental treatments (P <
0.05). n Total number of analyzed follicles per treatment
Table 3. Follicular diameter (on day 0 and 7) and growth rate (mean ± SEM) of isolated
secondary follicles after in vitro culture in α-MEM+ (control) or supplemented with
DMSO, DXR, A. oncocalyx or onco A
Treatments D0 D7 Growth rate
Control 156.87 ± 39.13 Ab 184.41 ± 53.16 Aa 4.19 ± 6.12 A
DMSO 155.26 ± 34.43 Ab 177.99 ± 53.41 Aa 2.96 ± 6.87 A
DXR 151.59 ± 38.55 Aa 148.12 ± 39.36 Ba -0.49 ± 3.80 B
A. oncocalyx 161.44 ± 38.24 Ab 188.87 ± 52.56 Aa 4.03 ± 6.62 A
Onco A 165.20 ± 44.77 Aa 178.05 ± 51.22 Aa 1.85 ± 6.79 A
A,B Distinct capital letters represent significant differences among treatments within the same day
of culture. a,b Different lowercase letters represent significant differences between days of culture
within the same treatment. (P < 0.05).
106
Table 4. PCNA test and TUNEL assay of non-cultured or in vitro cultured isolated
secondary follicles for 7 days in α-MEM+ (control) or supplemented with DMSO, DXR,
A. oncocalyx or onco A.
Treatments PCNA TUNEL
Non-cultured control 87.45 ± 7.32 A 16.67 % (1/6) B
Control 89.72 ± 8.83 A 33.33 % (2/6) AB
DMSO 94.20 ± 6.00 A 33.33 % (2/6) AB
DXR 16.54 ± 9.70 B 100.00 % (4/4) A
A. oncocalyx 93.20 ± 4.51 A 60.00 % (3/5) AB
Onco A 94.07 ± 6.71 A 50.00 % (3/6) AB
Distinct capital letters represent significant differences among experimental treatments (P < 0.05).
107
Table 5. Viable and non-viable oocytes rates, germinal vesicle (GV), meiotic resumption and metaphase II (MII) rates, after in vitro
maturation in TCM199+ (control) or supplemented with DMSO, DXR, A. oncocalyx or onco A of COCs recovered from antral follicles.
NON-VIABLE OOCYTES
VIABLE
OOCYTES
MATURATION RATES OF VIABLE OOCYTES
Treatments TOTAL Non-alive Alive # TOTAL GV
Meiotic
GVBD MI MII Resumption*
(n) % % % % % % % % %
Control 75 57.14 AB 42.86 AB 9.33 B 90.67 A 7.35 AB 92.65 AB 5.88 A 29.41 A 57.35 A
(4/7) (3/7) (7/75) (68/75) (5/68) (63/68) (4/68) (20/68) (39/68)
DMSO 84 69.23 AB 30.77 AB 15.48 B 84.52 A 4.23 B 95.77 A 8.45 A 30.99 A 56.34 A
(9/13) (4/13) (13/84) (71/84) (3/71) (68/71) (6/71) (22/71) (40/71)
DXR 77 46.43 B 53.57 A 36.36 A 63.64 B 14.29 A 85.71 B 2.04 A 36.73 A 46.94 A
(13/28) (15/28) (28/77) (49/77) (7/49) (42/49) (1/49) (18/49) (23/49)
A. oncocalyx 77 44.12 B 55.88 A 44.16 A 55.84 B 13.95 AB 86.05 AB 2.33 A 34.88 A 48.84 A
(15/34) (19/34) (34/77) (43/77) (6/43) (37/43) (1/43) (15/43) (21/43)
Onco A 86 71.79 A 28.21 B 45.35 A 54.65 B 17.02 A 82.98 B 4.26 A 31.91 A 46.81 A
(28/39) (11/39) (39/86) (47/86) (8/47) (39/47) (2/47) (15/47) (22/47)
A,B Distinct capital letters represent significant differences among treatments (P < 0.05)
n Total number of analyzed oocytes per treatment
* Includes GVBD, MI and MII oocytes
# Oocytes stained positively with calcein-AM (green) that presented an abnormal chromatin configuration (marked with Hoechst).
108
9 AUXEMMA ONCOCALYX E SEU COMPOSTO ATIVO ONCOCALYXONA A
PREJUDICAM A COMPETÊNCIA DE DESENVOLVIMENTO OOCITÁRIO
IN VITRO EM SUÍNOS, MAS SÃO MENOS PREJUDICIAIS DO QUE A
DOXORRUBICINA
“Auxemma oncocalyx and its active compound oncocalyxone A impair in vitro porcine
oocyte developmental competence but are less detrimental than Doxorubicin.”
Periódico: Planta medica (submetido) (ISSN: 0032-0943)
Qualis A2
109
RESUMO
Diversas drogas anticancerígenas, como a doxorrubicina (DXR), possuem menor
especificidade de ação, resultando em efeitos indesejáveis. Plantas são uma excelente
fonte de substâncias na pesquisa de novas drogas. Auxemma oncocalyx (A. oncocalyx) e
o seu componente, a oncocalixona A (Onco A) possuem atividade antitumoral e são
menos tóxicos em relação à DXR no que se refere aos parâmetros reprodutivos.
Entretanto, não existem estudos a respeito da ação dessas drogas no âmbito da
competência oocitária in vitro e desenvolvimento embrionário no modelo suíno. Com
isso, o objetivo deste estudo consistiu em avaliar os efeitos da adição de A. oncocalyx e
Onco A durante a maturação in vitro (MIV) de oócitos (Experimento 1) ou cultivo in
vitro de embriões (Experimento 2) no modelo suíno. Para o experimento 1, complexos-
cumulus-oócitos (CCOs) foram distribuídos no meio de MIV de modo isolado (controle)
ou suplementado com DXR (0,3 ug/mL), A. oncocalyx (1,2 ug/mL) e Onco A (1 ug/mL).
Em seguida, oócitos foram submetidos à fertilização in vitro (FIV) e posterior cultivo in
vitro de embriões. Para o segundo experimento, CCOs foram submetidos à MIV e FIV,
onde seus presumíveis zigotos foram cultivados com DXR, A. oncocalyx ou Onco A por
7 dias. A Viabilidade, maturação, fertilização e desenvolvimento embrionário foram
parâmetros avaliados em ambos os experimentos. No experimento 1, DXR, A.
oncocalyx e Onco A reduziram de modo significativo (P<0,05) a viabilidade oocitária e
eficácia da MIV. Onco A aumentou de modo significativo (P<0,05) a retomada da
meiose. Entretanto, os oócitos ficaram bloqueados no estágio de MII. Após a FIV, todas
as drogas reduziram de modo significativo (P<0,05) a viabilidade, eficiência da FIV e
percentual de zigotos clivados. No entanto, apenas DXR reduziu a percentagem de
blastocistos. No experimento 2, todas as drogas reduziram de modo significativo (P<0,05)
a percentagem de penetração, mas apenas DXR e Onco A reduziram (P<0,05) a eficiência
da FIV. DXR e A. oncocalyx reduziram de modo significativo (P<0,05) o percentual de
zigotos clivados, mas não afetaram a formação de blastocistos. Em conclusão, a adição
de DXR durante a MIV ou CIV afetam negativamente a eficácia da FIV e taxa de
clivagem. Em adição, a exposição dos CCOs à DXR somente durante a MIV foi mais
prejudicial à viabilidade oociátia e formação de blastocisto quando comparado à A.
oncocalyx e Onco A.
Palavras-chave: Auxemma oncocalyx. Oncocalyxone A. Doxorrubicina. Maduração in
vitro. Fertilização in vitro. Desenvolvimento embrionário.
110
Auxemma oncocalyx and its active compound oncocalyxone A impair in vitro porcine
oocyte developmental competence but are less detrimental than Doxorubicin
Leiva-Revilla J. 1, Maside C. 1, Vieira L. 1, Cadenas J.1, Ferreira A.A. 1, Paes V.M. 1, Agiar
F.L. 1, Celestino J.J.H. 2, Alves B. 1, Pessoa O.D.L. 3, Apgar G.A. 4, Toniolli R. 5,
Rodrigues A.P.R. 1, Figueiredo J.R. 1*.
1 Laboratory of Manipulation of Oocytes and Preantral Follicles (LAMOFOPA).
Universidade Estadual do Ceará, Fortaleza-CE, Brazil.
2 Institute of Health Sciences. Universidade da Integração Internacional da
Lusofonia Afro-Brasileira. Acarape-CE, Brazil.
3 Department of Organic and Inorganic Chemistry. Universidade Federal do Ceará, Centro
de Ciências. Fortaleza-CE, Brazil
4 Professor of Department of Animal Science, Food and Nutrition, Southern Illinois
University-Carbondale, USA
5 Laboratory of Swine Reproduction and Semen Technology. Universidade Estadual do
Ceará, Fortaleza-CE, Brazil.
* Corresponding address:
Laboratório de Manipulação de Oócitos e Folículos Pré-Antrais (LAMOFOPA).
Universidade Estadual do Ceará (UECE). Av. Silas Munguba, 1700, Campus do Itaperi.
Fortaleza – CE – Brasil. CEP: 60740 903
Tel.: +55.85. 3101.9852; Fax: +55.85.3101.9840
E-mail address: [email protected]
111
ABSTRACT
Most anticancer drugs like doxorubicin (DXR) have low specificity that results in
undesirable effects. Plants are excellent sources when searching for new drugs. Auxemma
oncocalyx (A. oncocalyx) and its main component oncocalyxone A (onco A) have anti-
tumoral activity and are less toxic than DXR in reproductive parameters. However, there
are no studies on the action of these drugs regarding the porcine in vitro oocyte
competence and embryo development. The aim of this study was to evaluate the effect of
A. oncocalyx and onco A exposure during in vitro maturation (IVM) of oocytes
(Experiment 1) or in vitro embryo culture (IVC) (Experiment 2) on the oocyte
developmental competence. For experiment 1, COCs were distributed in IVM medium
alone (control) or supplemented with DXR (0.3 g/mL), A. oncocalyx (1.2 g/mL) and
onco A (1 g/mL). Then, oocytes were submitted to in vitro fertilization (IVF) and in
vitro embryo culture. For experiment 2, COCs were submitted to IVM and IVF and the
presumptive zygotes were cultured with DXR, A. oncocalyx and onco A for 7 days.
Viability, maturation, fertilization and embryo developmental parameters were evaluated
in both experiments. In experiment 1; DXR, A. oncocalyx and onco A reduced (P<0.05)
oocyte viability and IVM efficiency. Onco A increased (P<0.05) the meiotic resumption,
however, oocytes were arrested at MI. After IVF, all the drugs reduced (P<0.05) viability,
IVF efficiency and percentage of cleaved embryos, nevertheless, only DXR decreased
the percentage of blastocyst. In experiment 2; all drugs reduced (P<0.05) the percentage
of penetration, but only DXR and onco A decreased (P<0.05) IVF efficiency. DXR and
A. oncocalyx decreased (P<0.05) the percentage of cleaved embryo, but had no effect on
blastocyst formation. In conclusion, the addition of DXR during IVM or IVC negatively
affected the IVF efficiency and cleavage rate. In addition, the exposure of COCs to DXR
only during IVM was more detrimental to oocyte viability and blastocyst formation than
A. oncocalyx and onco A.
Keywords: Auxemma oncocalyx; Oncocalyxone A; Doxorubicin; in vitro maturation; in
vitro fertilization; embryo development
112
Abbreviations
Auxemma oncocalyx A. oncocalyx
cGMP-dependent protein kinase PKG
Cumulus oocyte complexes COCs
Cyclic guanosine monophosphate cGMP
Double-strand breaks DSBs
Doxorubicin DXR
Germinal vesicle GV
Germinal vesicle break down GVBD
Hours post insemination hpi
In vitro embryo culture IVC
In vitro fertilization IVF
In vitro maturation IVM
Metaphase 1 MI
Metaphase 2 MII
Oncocalyxone A Onco A
Poly (AND-ribose) polymerase PARP
Topoisomerase II TOPO II
Topoisomerases TOPOs
113
1. Introduction
Cancer is a target of research for the development or discovery of new forms of
treatments [1]. Many drugs used in cancer chemotherapy, like doxorubicin (DXR), a
widely used drug for different cancer types[2], have low specificity that results in
undesirable effects. Studies show that DXR cause toxicity in both primordial follicles and
growing ovarian follicles, triggering follicular and oocyte apoptosis [3], and eventually
affect human fertility. Therefore, plants are excellent sources of raw material when
searching for new anticancer drugs [4].
AuxemmA. oncocalyx (A. oncocalyx) is a common tree found in the state of Ceará
in Northeast Brazil [5]. It has been widely used in folk medicine as an adjunctive
treatment of injuries such as wounds and cuts [5,6]. Some studies have suggested that this
plant has biological activities such as analgesic, antioxidant, antitumor and anti-
inflammatory effects [6–9].Oncocalyxone A (onco A) is A. oncocalyx’s active compound.
Onco A has high antioxidant activity [6] and an anti-proliferative effect on tumor cell
cultures [10]. Studies have suggested onco A as a possible anticancer compound since it
presents antitumor and cytotoxic activity in human leukemia cells, and other cell cancer
lines, without causing genotoxicity [11] as most anticancer drugs.
Little is known about reproductive toxicity of A. oncocalyx and onco A in
mammals. In recent pioneer studies conducted by our group with caprine preantral
follicles cultured in vitro enclosed in ovarian cortical tissue, A. oncocalyx and onco A
affected in vitro caprine early folliculogenesis in a concentration-dependent manner [12].
However, no toxic effect of A. oncocalyx and onco A was observed on in vitro
development of late caprine isolated secondary follicles. In contrast, these drugs affected
the cumulus-oocyte complexes (COCs) viability after in vitro maturation but not the
metaphase II rates (Leiva-Revilla et al., 2016 b – under review). In both studies, DXR
was used as positive (toxic) control and presented a more toxic effect than A. oncocalyx
and onco A. These results suggest that A. oncocalyx and onco A despite of having
anticancer effects they are, apparently, less harmful to reproductive parameters than
commercial drugs, such as DXR.
Normal embryonic development is preceded by a sequence of coordinate events
during maturation and fertilization. The mechanism of oocyte maturation encompasses
interactions between the oocyte and its surrounding cumulus cells, which synchronizes
114
meiosis with structural and molecular changes in the ooplasm, enabling the oocyte to
support proper fertilization and subsequent embryo development [13]. Consequently, it
is of high significance to study the toxic effect of new drugs over in vitro maturation,
fertilization and embryo development.
To the best our knowledge, there is no information about the influence of A.
oncocalyx and onco A on the in vitro embryo development in mammals, including pigs.
Compared to the other species, the porcine seems to be a suitable animal model for
humans, due to the ovarian similarities [14].In addition, the advantage of using pig ovaries
is that the ovaries are from animals at similar age, breed and controlled nutrition. Thus,
the porcine specie has been quite used as a model for human oocytes in toxicity tests [14].
Therefore, the aim of this study was to evaluate the effect of A. oncocalyx and onco A
exposure during in vitro maturation of oocytes (Experiment 1) or in vitro embryo culture
(Experiment 2) on the oocyte developmental competence, investigating the following end
points: oocyte viability, maturation rates and efficiency, in vitro fertilization parameters
and percentage of cleaved embryos and blastocyst formation.
2. Results
2.1. Experiment 1. Effect of A. oncocalyx and onco A on IVM of porcine COCs and
subsequent embryo development.
The rates of oocyte viability and maturation after exposure to DXR, A. oncocalyx
and onco A are shown (Table 01). Take into account the total number of COCs submitted
to IVM, the DXR, A. oncocalyx and onco A treatments showed a significant lower
percentage of oocyte viability and maturation than control. Except for oocyte viability, A.
oncocalyx and onco A showed similar results for the aforementioned endpoints being
both higher (P < 0.05) than DXR. However, when only viable oocytes were considered
to calculate the maturation rate no differences were observed among treated groups
(DXR, A. oncocalyx and onco A). To determine the meiotic resumption and MI rates only
viable oocytes were used. The percentage of meiotic resumption in the onco A treatment
and rate of MI in the A. oncocalyx and onco A treatments were similar to DXR but higher
(P < 0.05) than control.
115
The exposure of COCs to DXR, A. oncocaly and onco A during IVM reduced
significantly the IVF efficiency when compared to the control treatment (Table 2).
However, when only matured oocytes were taken into account the penetration and
monospermy rates as well as the number of spermatozoa/oocyte were similar (P > 0.05)
among the treatments.
When the COCs were exposed to the three tested drugs during IVM (Figure 2),
DXR, A. oncocalyx and onco A treatments showed lower (P < 0.05) cleaved rates
compared to control. This endpoint was higher in the onco A treatment than DXR and A.
oncocalyx treatments. With regard to blastocyst rate, lower (P < 0.05) values were
observed in the DXR treatment.
2.2. Experiment 2. Effect of A. oncocalyx and onco A on the in vitro culture of porcine
embryos.
Contrary to the experiment 1, where the COCs were exposed to the tested drugs
during IVM, in the experiment 2, only the in vitro presumptive zygotes were exposed to
DXR, A. oncocalyx and onco A for 18 hpi (Table 3). There was no difference (P > 0.05)
between control group and other treatments regarding to viability and maturation rates.
However, DXR and onco A showed a lower percentage (P <0.05) of viability than A.
oncocalyx. All the tested treatments reduced (P < 0.05) the penetration rate compared to
control treatment. Onco A, but not A. oncocalyx reduced significantly the monospermy
and IVF efficiency, and increased (P < 0.05) the number of spermatozoa/oocyte. The IVF
efficiency was also reduced (P < 0.05) when DXR was added to the control medium.
The exposure of presumptive zygotes to onco A did not change either the cleavage
or blastocyst rates comparing control (Figure 3). The addition of DXR and A. oncocalyx
to the control medium only reduced (P < 0.05) the cleavage rate.
3. Discussion and conclusion
To our knowledge, the present study demonstrated for the first time the effect of
A. oncocalyx and its isolated compound, onco A, on the in vitro maturation of porcine
oocytes and subsequent in vitro embryo development.
116
When the three tested drugs exposure occurred only during IVM (Experiment 1),
DXR, A. oncocalyx and onco A had a detrimental effect on the oocyte viability, being
DXR the most toxic with only 12.83 % viable oocytes after 44h of exposure. It is known
that DXR acts on several levels by different molecular mechanisms including an
interaction with iron, upsetting calcium homeostasis, altering the activity of intracellular
or intra-mitochondrial oxidant enzymes, and binding to topoisomerases (TOPOs)
promoting their dysfunction leading to DNA damage and apoptosis [17]. Specifically,
DXR acts by inhibiting Topoisomerase II (Topo II). In the female, Topo II is required for
chromosome separation during oocyte meiotic maturation, but is dispensable for
resumption of meiosis [18]. On the other hand, A. oncocalyx and onco A also disrupt
oocyte viability and caused damage in the chromatin configuration. Sbardelotto [19]
showed that, in human promyelocytic leukemia line (HL-60) cells, onco A activates first
the intrinsic apoptotic pathway by caspase 8, and then the extrinsic pathway by caspase 3
and 7. Contrary to DXR, onco A does not affect the TOPOs. However, in HL-60 cells,
onco A cleaved poly (ADP-ribose) polymerase (PARP) [19]. PARP binds and repair
DNA-strand breaks generated by genotoxic agents. Likewise, PARP is implicated in the
regulation of a wide range of important cellular processes including transcriptional
regulation, chromatin modification, cellular homeostasis, and cell proliferation and death
[20]. Therefore, cleaved PARP results in an oocyte proapoptotic protein [21]. A study
conducted in porcine showed that the cleavage of PARP1 was strongly implicated in
follicular development and atresia of fetal, neonatal, and adult porcine ovaries [20]. In
addition, PARP-1 synthesize PAR, which is required for assembly and function of the
bipolar spindle [22]. PARP-1 also mediates the regulation of centrosome duplication and
chromosomal stability. The inhibition of PARP-1 is associated with mislocalization of
centromeric and centrosomal proteins, defective chromatin modifications and genomic
instability characterized by loss of mitotic checkpoint integrity [23].
In the present study, the IVM efficiency was compromised in all treatments
compared to control treatment. Interestingly, onco A increased the meiotic resumption
rates. However, these oocytes were arrested at the MI stage. Anticancer drugs can cause
double-strand breaks (DSBs). These DSBs do not arrest mouse oocytes in the
G2/prophase but, instead, allow them to progress to the MI stage [24]. The exposure of
oocytes to genotoxic agents, such as PARP inhibitors, causes failures in the spindle
assembly checkpoint, leading to an oocyte meiotic arrest at MI [24]. Another study
117
showed that damage in the microtubules, main structural elements of the spindle, result
in oocytes arrest at the MI stage during in vitro maturation in mouse [25]. Our results
suggest that onco A might be affecting the oocyte chromatin configuration, through
PARP inhibition, leading to failures in the spindle assembly checkpoint and therefore
causing this meiotic arrest at the MI stage.
In the present study, the exposure of COCs to the tested drugs only during IVM
negatively affected the IVF efficiency. Even tough DXR, A. oncocalyx and onco A
reduced embryo cleavage rate, only DXR showed a more toxic effect on blastocyst
development. DXR elicits apoptosis by various mechanisms in a variety of cells. DXR is
capable to accumulate in both nucleus and mitochondria and induce chromosomal
obliteration by inhibiting Topo-II. In oocytes, it can interfere with mitochondrial function
and start the intrinsic pathway of apoptosis via the mitochondria by reducing the
mitochondrial membrane potential and releasing cytochrome C [26]. Impaired
mitochondrial function lead to improper fertilization and a reduction of embryo
development [27].
When DXR, A. oncocalyx and onco A were added only during the in vitro embryo
culture (Experiment 2), all drugs negatively affected the penetration rate evaluated after
18 hpi. However, DXR and onco A showed a detrimental effect on IVF efficiency.
Nonetheless, only onco A augmented the percentage of spermatozoa per oocyte. Ferreira
et al. [28] showed that onco A was able to inhibit platelet aggregation by increasing the
cyclic guanosine monophosphate (cGMP) levels in platelets by a synergistic mechanism,
combining increased production and reduced degradation of cGMP [28]. In porcine,
cGMP activates cGMP-dependent protein kinase (PKG). This pathway plays an essential
role in acrosome reaction, which enables the spermatozoa to penetrate the zona pellucida,
and therefore, to fuse with the oocyte plasma membrane [29]. Zhang [30] observed that
when a cGMP analog, atrial natriuretic peptide (ANP), was added during IVF of frozen-
thawed giant panda sperm with porcine salt-stored oocytes, it resulted in a higher
proportion of oocytes with spermatozoa in the zona pellucida and perivitelline space, and
a higher average number of spermatozoa/oocyte.
In experiment 2, DXR, A. oncocalyx and onco A negatively affected the cleavage
rate. Wang et al [31] showed that DXR blocked pre-implantation development in early
mouse embryos by altering apoptosis-related gene expression, Bcl2l1 and Casp3, and
118
inactivating DNA repair by PARP. In the same study, the authors found out that DXR
arrested zygotes at the 1-cell stage by disruption of DNA and of the cytoskeleton. In
addition, it is known that during blastocyst formation, the inhibition PARP suppresses
selective autophagic degradation of ubiquitinated proteins, which contributes to apoptosis
[32]. Thus, the interaction between PARP and autophagy influences the quality of in vitro
produced embryos in porcine [33]. Due to the fact that onco A affects PARP in HL-60
cells [19], and that A. oncocalyx contains 80% of onco A in its composition [9], both
drugs could be affecting embryonic competition by this pathway. Moreover, a study
evaluating different concentrations (1 to 100 µg/mL) of a quinone fraction of A. oncocalyx
in sea urchin eggs reported that the cleavage of eggs was inhibited in a concentration-
dependent manner [34]. Despite the fact that DXR, A. oncocalyx and onco A reduced
porcine embryo cleavage rate, they did not affect blastocyst development, showing that
porcine blastocyst tend to be more resistant to toxic agents [35].
In conclusion, the addition of DXR during IVM or IVC negatively affected the
IVF efficiency and cleavage rate. In addition, the exposure of COCs to DXR only during
IVM was more detrimental to oocyte viability and blastocyst formation than A. oncocalyx
and onco A.
4. Materials and methods
4.1. Culture media
All chemicals used in the present study were purchased from Sigma Chemical Co.
(St. Louis, MO, USA) unless otherwise indicated. The medium used for the collection of
cumulus-oocyte complexes (COCs) and for washing was Dulbecco’s phosphate-buffered
saline (DPBS) medium composed of 136.89 mM NaCl, 2.68 mM KCl, 8.1 mM Na2HPO4
and 1.46 mM CaCl2·2H2O supplemented with 4 mg/mL bovine serum albumin (BSA),
0.34 mM sodium pyruvate, 5.4 mM D-glucose and 70 µg/mL kanamycin (mDPBS). The
oocyte maturation medium was modified-TCM 199supplemented with 150 µM
cisteamine and 10 ng/m Lepidermal growth factor(TCM-199+) [15]. The basic medium
used for fertilization was essentially the same as that used by Abeydeera and Day [16].
This medium, designated as a modified Tris-buffered medium, consisted of 113.1 mM
NaCl, 3 mM KCl, 7.5 mM CaCl2·2H2O, 20 mM Tris (crystallized free base), 11 mM
119
glucose and 5 mM sodium pyruvate supplemented with 2 mM caffeine and 0.2% BSA.
The embryo culture medium was a sequential medium based on NCSU-23 supplemented
with 0.4% BSA[15].
4.2. Isolation of onco A from A. oncocalyx
The obtaining of the A. oncocalyx and onco A has previously been described by
Pessoa et al.[11]. Briefly, A. oncocalyx was collected and identified by Dr. Maria Iracema
B. Loiola of the Department of Biology of Federal University of Ceará. Onco A
(C17H18O5) was extracted from woody parts of A. oncocalyx (Boraginaceae) by
phytochemical extraction methods using organic solvents, and was isolated and purified
by crystallization and recrystallization. It is noteworthy that the fraction of A. oncocalyx
contains 80 % of onco A [9], therefore the concentration of A. oncocalyx was in equal
proportion of onco A. A. oncocalyx and onco A were diluted with DMSO as a vehicle.
The concentrations of A. oncocalyx and onco A were chosen based on previous studies
performed in our laboratory [12].
4.3. Experimental design
Experiment 1: Effect of A. oncocalyx and onco A on IVM of porcine COCs and
subsequent embryo development
In this experiment, the effect of DXR, A. oncocalyx and onco A on in vitro
maturation (IVM) of porcine COCs and subsequent embryo development was evaluated
(Figure 1). Immediately after oocyte recovery, COCs were allocated into four treatments
to carry out IVM: I) TCM-199+ alone (control), or supplemented with II) 0.3 g/mL
DXR; III) 1.2 g/mL A. oncocalyx or IV) 1 g/mL onco A. After IVM, oocyte chromatin
configuration and viability were assessed. Moreover, oocytes from each group were
pooled, exposed to spermatozoa and cultured for 18 hours post insemination (hpi) to
assess fertilization parameters or for 7 (168 hpi) days to evaluate embryo development.
Experiment 2: Effect of A. oncocalyx and onco A on the in vitro culture of porcine
embryos.
COCs were submitted to IVM and IVF as described for experiment 1 (control
group), and presumptive zygotes were randomly allocated into four treatments for in vitro
embryo culture (IVC): I) NCSU-23 alone (control) or supplemented with II) 0.3 g/mL
120
DXR; III) 1.2 g/mL A. oncocalyx or IV) 1 g/mL onco A. The presumptive zygotes
were cultured for 18 hpi to assess fertilization parameters or for 7 days (168 hpi) to
evaluate embryo development (Figure 1).
4.4. Oocyte collection and IVM
Ovaries were obtained from prepuberal gilts at a local slaughterhouse and were
transported in 0.9% NaCl containing 70 µg/mL kanamycin, at 33°C within 1 h. In the
laboratory, COCs were aspirated from medium-sized follicles (3 to 6 mm in diameter)
using an 18-gauge needle connected to a 10-mL disposable syringe. Oocytes with a
compact cumulus mass and a dark, evenly granulated cytoplasm were washed three times
in maturation medium, and 50–60 oocytes were transferred into each well of a 4-well
multidish (Nunc, Roskilde, Denmark) containing 500-µL of maturation medium
supplemented with 10 IU/mL pregnant mare's serum gonadotropin and 10 IU/mL human
chorionic gonadotropin for 20–22 h. The oocytes were then incubated for another 20–22
h in maturation medium without hormones. Oocyte maturation was carried out under
mineral oil at 39ºC in a humidified atmosphere of 5% CO2 in air. After maturation, COCs
were mechanically denuded in maturationmedium and washed twice in maturation
medium.
4.5. In vitro fertilization and embryo culture.
Denuded oocytes were washed three times in pre-equilibrated fertilization
medium and fertilized as previously described [15].Briefly, groups of 30 denuded oocytes
were then placed in 50-µL drops of fertilization medium in a 35x10-mm Petri dish under
mineral oil and held at 38.5ºC in an atmosphere of 5% CO2 in air for approximately 30
min until the addition of spermatozoa. Pool of freshly ejaculated semen diluted in
extender from a three boars was obtained from a local breeding station. The semen was
washed three times by centrifugation at 1900 x g for 3 min in mDPBS. The resulting
pellet was re-suspended in fertilization medium, and after the appropriate dilution, 50 µL
of this sperm suspension was added to a 50µL drop of fertilization medium containing
the oocytes. The spermatozoa:oocyte ratio was 2000:1. The gametes were co-incubated
at 38.5ºC in a humidified atmosphere of 5% CO2 in air for approximately 4 h.
Presumptive zygotes were removed from the fertilization medium and washed
three times in pre-equilibrated embryo culture medium. The zygotes were then transferred
121
to a 4-well multidish (30 zygotes per well), with each well containing 500 µL of the same
medium under mineral oil, and were cultured at 38.5ºC in a humidified atmosphere of 5%
CO2 in air. Presumptive zygotes were cultured for the first 2 days (Day 0 = day of
fertilization) in glucose-free NCSU-23 supplemented with 0.33 mM pyruvate and 4.5 mM
lactate and then in fresh NCSU-23 medium containing 5.5 mM glucose until day 7.
4.6. Assessment of oocyte chromatin configuration, viability, sperm penetration and
embryo development
To evaluate maturation and fertilization parameters, denuded oocytes and
presumptive zygotes were washed in PBS-BSA, and incubated in 500 µL droplets
containing 4 µM calcein-AM, 2 µM ethidium homodimer-1 (Molecular Probes,
Invitrogen, Karlsruhe, Germany), 0.5% of glutaraldehyde and 10 µM Hoechst 33342 for
15 min.
The maturation rate was assessed at 44h of IVM. The chromatin configuration
patterns were the following: abnormal chromatin configuration, germinal vesicle (GV) or
meiotic resumption. Meiotic resumption was defined when the nucleus was in germinal
vesicle break down (GVBD), metaphase I (MI) or in metaphase II (MII) stages.
Maturation efficiency was calculated by MII/total oocytes cultured. Thereafter, oocytes
were also examined under a fluorescence microscope (Nikon, Eclipse 80i, Tokyo, Japan)
for evaluation of live/dead fluorescent staining. The emitted fluorescent signals of
calcein-AM and ethidium homodimer-1 were collected at 488 and 568 nm, respectively.
Oocytes were considered viable when the cytoplasm was stained positively with calcein-
AM (green) and chromatin was not labelled with ethidium homodimer-1 (red) and they
showed a normal chromatin configuration.
Fertilization parameters were evaluated at 18 hpi. The oocytes were considered
penetrated when they contained one or more swollen sperm heads and/or male pronuclei,
with their corresponding sperm tails, and two polar bodies. The fertilization parameters
evaluated were penetration rate (number of oocytes penetrated/total matured),
monospermy (number of oocytes containing only one male pronucleus/total penetrated),
number of spermatozoa/oocyte (mean number of spermatozoa in penetrated oocytes), and
efficiency of fertilization (number of monospermic oocytes/total inseminated).
At 2 and 7 days after IVF, the cleavage rate (number of oocytes divided to 2–4
cells/total) and blastocyst formation rate (number of blastocyst/total cleaved),
122
respectively, were evaluated under a stereomicroscope. An embryo that had cleaved to
the two-cell stage or beyond was counted as cleaved, and an embryo with a clear
blastocele was defined as a blastocyst
4.7. Statistical analyses
Statistical analysis was conducted with Sigma Plot 11.0 (Systat Software Inc.,
USA). For percentage comparison between treatments, chi-square test and Fisher's exact
test were used. Data of means comparison among treatments of n° spermatozoa/oocyte
was performed by Mann-Whitney test. Data was presented as mean (± SEM) and
percentages. In all cases, a probability of P<0.05 indicated a significant difference.
5. Acknowledgements
This research was financially supported by CNPq, CAPES and FUNCAP. The
authors thank Thalles Gothardo Pereira Nunes and Renato Felix da Silva, for assistance with
this study.
6. Conflicts of Interest
We wish to confirm that there are no known conflicts of interest associated with
this publication and there has been no significant financial support for this work that could
have influenced its outcome.
123
7. Figures and tables
Figure 1. Experimental design and endpoints of experiment 1 and 2.
In vitro maturation (IVM), in vitro fertilization (IVF), in vitro embryo culture (IVC),
hours post insemination (hpi).
124
Table 1. Rates of viable oocytes, germinal vesicle (GV), meiotic resumption and metaphase II (MII) rates, after in vitro maturation of
porcine oocytes in control medium alone or supplemented with DXR, A. oncocalyx or onco A (experiment 1).
Treatments Total Viable oocytes
Oocyte chromatin configuration Maturation
Efficiency
GV Meiotic
resumption* GVBD MI MII MII / total
(n) % % % % % % %
Control 157 81.53 (128/157) A 7.81 (10/128) A 92.19 (118/128) B 2.34 (3/128) 26.56 (34/128) B 63.28 (81/128) A 51.59 (81/157) A
DXR 187 12.83 (24/187) D 8.33 (2/24) A 91.67 (22/24) AB - 45.83 (11/24) AB 45.83 (11/24) AB 5.88 (11/187) C
A. oncocalyx 181 48.62 (88/181) C 7.95 (7/88) A 92.05 (81/88) B - 59.09 (52/88) A 32.95 (29/88) B 16.02 (29/181) B
Onco A 163 59.51 (97/163) B 1.03 (1/97) A 98.97 (96/97) A - 64.95 (63/97) A 34.02 (33/97) B 20.25 (33/163) B
A,B,C,D Distinct capital letters represent significant differences among treatments (P < 0.05).
n Total number of analyzed oocytes per treatment. * Includes GVBD, MI and MII oocytes.
125
Table 2. Rates of viable oocytes, matured, penetrated, monospermy and efficiency rates and number of spermatozoa per oocyte after
previous exposure (only during in vitro maturation) to DXR, A. oncocalyx or onco A(experiment 1).
Endpoints *
Treatments Total Viability Matured / viable
Penetrated /
matured
Monospermy /
penetrated
IVF Efficiency
(2pn/total) # SPZ / oocyte
(n) % % % % % %
Control 251 78.49 (197/251) A 96.95 (191/197) A 67.02 (128/191) A 57.03 (73/128) A 29.08 (73/251) A 1.94+ 0.14 A
DXR 170 38.82 (66/170) C 93.93 (62/66) A 77.42 (48/62) A 52.08 (25/48) A 14.71 (25/170) B 1.72+ 0.17 A
A. oncocalyx 291 68.73 (200/291) B 77.50 (155/200) B 76.77 (119/155) A 45.38 (54/119) A 18.56 (54/291) B 2.15+ 0.13 A
Onco A 252 66.67 (168/252) B 83.92 (141/168) B 69.50 (98/141) A 51.02 (50/98) A 19.84 (50/252) B 2.15 + 0.2 A A,B,C Distinct capital letters represent significant differences among treatments (P < 0.05).
n Total number of analyzed oocytes per treatment. * All the endpoints were evaluated 18 hpi.
126
Figure 2. Percentage of cleaved (A) and blastocyst/cleaved (B) after previous exposure (only during in vitro maturation) to DXR, A.
oncocalyx or onco A, only.a,b,c Distinct letters represent significant differences among treatments (P < 0.05) (experiment 1).
127
Table 3. Rates of viable oocytes, matured, penetrated, monospermy and efficiency rates and number of spermatozoa per oocyte after 18hpi
exposure (only during in vitro embryo culture) to DXR, A. oncocalyx or onco A (experiment 2).
Endpoints *
Treatments Total Viability Matured / viable
Penetrated /
matured
Monospermy /
penetrated
Efficiency
(2pn/total) # SPZ / oocyte
(n) % % % _% % %
Control 71 71.83 (51/71) AB 96.07 (49/51) A 85.71(42/49) A 54.76 (23/42) A 32.39 (23/71) A 1.43 + 0.1 B
DXR 87 59.7 (52/87) B 98.07 (51/52) A 64.7 (33/51) B 45.45 (15/33) AB 17.24 (15/87) BC 1.86+ 0.16 AB
A. oncocalyx 88 75 (66/88) A 93.93 (62/66) A 69.35 (43/62) B 51.16 (22/43) AB 25 (22/88) AC 1.72+ 0.14 B
Onco A 73 58.9 (43/73) B 97.67 (42/43) A 59.52 (25/42) B 28 (7/25) B 9.59 (7/73) B 2.51 + 0.28 A
A,B,C Distinct capital letters represent significant differences among treatments (P < 0.05).
n Total number of analyzed oocytes per treatment. * All the endpoints were evaluated 18 hpi.
128
Figure 3. Percentage of cleaved (A) and blastocyst / cleaved (B) after exposure (only during in vitro embryo culture) to DXR, A. oncocalyx
or onco A. a,b Distinct letters represent significant differences among treatments (P < 0.05) (experiment 2).
129
8. References
1. Cragg GM, Grothaus PG, Newman DJ: New Horizons for Old Drugs and Drug Leads. J
Nat Prod 2014;77:703–723.
2. Oktem O, Oktay K: Quantitative assessment of the impact of chemotherapy on ovarian
follicle reserve and stromal function. Cancer 2007 Nov 15;110:2222–9.
3. Kropp J, Roti ECR, Ringelstetter A, Khatib H, Abbott DH, Salih SM: Dexrazoxane
Diminishes Doxorubicin- Induced Acute Ovarian Damage and Preserves Ovarian
Function and Fecundity in Mice. PLoS One 2015;10:1–25.
4. Graham JG, Quinn ML, Fabricant DS, Farnsworth NR: Plants used against cancer – an
extension of the work of Jonathan Hartwell. J Ethnopharmacol 2000;73:347–377.
5. Braga R: Plantas do Nordeste, especialmente do Ceará. ed 3rd Mossoró, 1976.
6. Ferreira MAD, Nunes ODRH, Leal LKAM, Pessoa ODL, de Lemos TLG, Viana GSDB:
Antioxidant effects in the quinone fraction from Auxemma oncocalyx TAUB. Biol
Pharm Bull 2003;26:595–599.
7. Pessoa C, Mendes CS, Pessoa LO, Sabino SH, Lemos T., Moraes MO: Avaliação da
atividade antitumoral de Auxemma oncocalyx Taub. (Pau Branco).; in : VII Annual
Meeting of the Federação de Sociedades de Biologia Experimental, Caxambu, MG,
Brazil. 1992, pp 26–29.
8. Lino CS, Pessoa ODL, Lemos TLC, Viana GSB: Estudo da atividade analgésica e
antiedematogênica do extrato hidroalcoólico de Auxemma oncocalyx e oncocalyxona A;
in : Simpósio De Plantas Medicinais Do Brasil. 1996, p 95.
9. Ferreira MAD, Nunes ODRH, Fontenele JB, Pessoa ODL, Lemos TLG, Viana GS.:
Analgesic and anti-inflammatory activities of a fraction rich in oncocalyxone A isolated
from Auxemma oncocalyx. Phytomedicine 2004;11:315–322.
10. Costa-Lotufo LV, Cunha GMA, Farias PAM, Viana GSB, Cunha KMA, Pessoa C, et al.:
The cytotoxic and embryotoxic effects of kaurenoic acid , a diterpene isolated from
Copaifera langsdorffii oleo-resin. Toxicon 2002;40:1231–1234.
11. Pessoa C, Vieira FMAC, Lemos TG, Moraes MO, Lima PDL, Rabenhorst SHB, et al.:
Oncocalyxone A from Auxemma oncocalyx lacks genotoxic activity in
phytohemagglutinin-stimulated lymphocytes. Teratog Carcinog Mutagen 2003 Jan;Suppl
1:215–20.
130
12. Leiva-revilla J, Lima LF, Castro SV, Campello CC, Araújo VR, Celestino JJH, et al.:
Fraction of Auxemma oncocalyx and Oncocalyxone A affects the in vitro survival and
development of caprine preantral follicles enclosed in ovarian cortical tissue. Forsch
Komplementarmed 2016;in press.
13. Schoevers EJ, Fink-Gremmels J, Colenbrander B, Roelen BAJ: Porcine oocytes are most
vulnerable to the mycotoxin deoxynivalenol during formation of the meiotic spindle.
Theriogenology 2010;74:968–978.
14. Santos RR, Schoevers EJ, Roelen BA: Usefulness of bovine and porcine IVM/IVF
models for reproductive toxicology. Reprod Biol Endocrinol 2014;12:117.
15. Gil M, Abeydeera L, Day B, Vazquez J, Roca J, Martinez E: Effect of the volume of
medium and number of oocytes during in vitro fertilization on embryo development in
pigs. Theriogenology 2003;60:767–776.
16. Abeydeera LR, Day BN: In vitro penetration of pig oocytes in a modified Tris-buffered
medium: effect of BSA, caffeine and calcium. Theriogenology 1997;48:537–544.
17. Mitry MA, Edwards JG: Doxorubicin induced heart failure: Phenotype and molecular
mechanisms. Int J Cardiol Hear Vasc 2016;10:17–24.
18. Li X, Yu C, Wang Z, Zhang Y, Liu X, Zhou D, et al.: DNA Topoisomerase II Is
Dispensable for Oocyte Meiotic Resumption but Is Essential for Meiotic Chromosome
Condensation and Separation in Mice. Biol Reprod 2013;89:118.
19. Sbardelotto AB: Estudo do mecanismo de citotoxicidade da oncocalixona-a em leucemia
promielocítica humana – linhagem HL-60 [dissertation]. Universidade federal de Ceará;
2013.
20. Wei Q, Ding W, Shi F: Roles of poly (ADP-ribose) polymerase (PARP1) cleavage in the
ovaries of fetal, neonatal, and adult pigs. Reproduction 2013;146:593–602.
21. Chen Z, Kang X, Wang L, Dong H, Wang C, Xiong Z, et al.: Rictor / mTORC2 Pathway
in Oocytes Regulates Folliculogenesis , and Its Inactivation Causes Premature Ovarian
Failure. J Biol Chem 2015;290:6387–6396.
22. Johannes JW, Almeida L, Daly K, Ferguson AD, Grosskurth SE, Guan H, et al.:
Discovery of AZ0108 , an orally bioavailable phthalazinone PARP inhibitor that blocks
centrosome clustering. Bioorg Med Chem Lett 2015;25:5743–5747.
23. Weaver AN, Yang ES: Beyond DNA repair : additional functions of PARP-1 in cancer.
Front Oncol 2013;3:1–11.
131
24. Marangos P, Stevense M, Niaka K, Lagoudaki M, Nabti I, Jessberger R, et al.: DNA
damage-induced metaphase I arrest is mediated by the spindle assembly checkpoint and
maternal age. Nat Commun 2015;6:1–10.
25. Jiang M-X, Shi Y, Sun Z-G, Zhang Z, Zhu Y: Inhibition of the Binding between RGS2
and β-Tubulin Interferes with Spindle Formation and Chromosome Segregation during
Mouse Oocyte Maturation In vitro. PLoS One 2016;11.
26. Bar-Joseph H, Ben-Aharon I, Rizel S, Stemmer SM, Tzabari M, Shalgi R: Doxorubicin-
induced apoptosis in germinal vesicle (GV) oocytes. Reprod Toxicol 2010 Dec;30:566–
72.
27. Wakefield SL, Lane M, Mitchell M: Impaired Mitochondrial Function in the
Preimplantation Embryo Perturbs Fetal and Placental Development in the Mouse. Biol
Reprod 2011;84:572–580.
28. Ferreira MAD, do Nascimento NRF, de Sousa CM, Pessoa ODL, de Lemos TLG,
Ventura JS, et al.: Oncocalyxone A inhibits human platelet aggregation by increasing
cGMP and by binding to GP Ib-alpha glycoprotein. Br J Pharmacol 2008 Jul;154:1216–
1224.
29. Zhang M, Hong H, Zhou B, Jin S, Wang C, Fu M, et al.: The expression of atrial
natriuretic peptide in the oviduct and its functions in pig spermatozoa. J Endocrinol
2006;189:493–507.
30. Zhang M, Tang H, Shen G, Zhou B, Wu Z, Peng Z, et al.: Atrial natriuretic peptide
induces an acrosome reaction in giant panda spermatozoa and enhances their penetration
of salt-stored porcine oocytes. Theriogenology 2005;64:1297–308.
31. Wang Q, Sun S, Han J, Kwak Y, Kim N, Cui X: Doxorubicin Induces Early Embryo
Apoptosis by Inhibiting Poly ( ADP ribose ) Polymerase. In vivo (Brooklyn)
2012;834:827–834.
32. Ran H, Hyoun D, Gyeong M, Sung J, Ho J, Taek H: Biochemical and Biophysical
Research Communications The regulation of autophagy in porcine blastocysts :
Regulation of PARylation-mediated autophagy via mammalian target of rapamycin
complex 1 ( mTORC1 ) signaling. Biochem Biophys Res Commun 2016;473:899–906.
33. Lee HYERAN, Gupta MK, Kim DUKH, Hwang JHO, Kwon B, Lee HT: Poly ( ADP-
ribosyl ) ation Is Involved in Pro-Survival Autophagy in Porcine Blastocysts. Mol
Reprod Dev 2016;83:37–49.
132
34. Costa-Lotufo LV, Ferreira MAD, Lemos TLG, Pessoa ODL, Viana GSB, Cunha GM.:
Toxicity to sea urchin egg development of the quinone fraction obtained from Auxemma
oncocalyx. Brazilian J Med Biol Res 2002;35:927–930.
35. Schoevers EJ, Santos RR, Fink-gremmels J, Roelen BAJ: Toxicity of beauvericin on
porcine oocyte maturation and preimplantation embryo development. Reprod Toxicol
2016;65:159–169.
133
10 CONCLUSÕES
Os resultados obtidos ao longo desta tese permitiram concluir que:
Fase I:
A. oncocalyx e onco A afetaram a foliculogênese caprina in vitro de uma forma
concentração-dependente, apresentando-se menos tóxica do que a DXR.
Fase II:
A. oncocalyx e onco A não apresentaram efeito tóxico sobre o desenvolvimento
de folículos secundários isolados caprinos, nem sobre as taxas de maturação in
vitro de CCOs. No entanto, estas drogas influenciaram negativamente a
viabilidade dos oócitos caprinos após a MIV.
A DXR, ao contrário da A. oncocalyx e onco A, reduziu a sobrevivência, formação
de antro e crescimento folicular de folículos pré-antrais isolados caprinos
cultivados in vitro.
Fase III:
A adição de DXR durante a MIV ou o CIV afetou negativamente a eficiência da
FIV e as taxas de clivagem na espécie suína. Além disso, a exposição de CCOs à
DXR apenas durante MIV, foi mais prejudicial à viabilidade oocitária e a
formação de blastocistos, do que a A. oncocalyx e a onco A.
134
11 PERSPECTIVAS
A tecnologia do ovário artificial foi utilizada com sucesso no presente trabalho
para a realização de um teste de toxidade reprodutiva comparando-se uma droga utilizada
comercialmente (DXR) para a terapia do câncer, com substâncias (A. oncocalyx e onco
A) oriundas de uma planta (Pau-Branco do sertão) pertencentemente ao bioma da
caatinga, com potencial anticancerígeno. O efeito menos tóxico da onco A em relação a
DXR sobre a foliculogênese e o desenvolvimento embrionário, abre novas perspectivas
para o emprego da referida substância no tratamento de câncer em mulheres. No entanto,
mais testes são necessários para um melhor entendimento da atuação das substâncias e
seus efeitos sobre a reprodução.
135
REFERÊNCIAS
ABEYDEERA, L. R.; DAY, B. N. In vitro penetration of pig oocytes in a modified
Tris-buffered medium: effect of BSA, caffeine and calcium. Theriogenology, v. 48, n.
4, p. 537–544, 1997.
ABIR, R.; NITKE, S.; BEN-HAROUSH, A.; FISCH, B. In vitro maturation of human
primordial ovarian follicles: Clinical significance, progress in mammals, and methods
for growth evaluation. Histology and Histopathology, v. 21, p. 887–898, 2006.
ALBUQUERQUE, U. P.; OLIVEIRA, R. F. Is the use-impact on native caatinga
species in Brazil reduced by the high species richness of medicinal plants? Journal of
Ethnopharmacology, v. 113, p. 156–170, 2007.
ALMEIDA, V.; LEITÃO, A.; REINA, L.; MONTANARI, C.; DONNICI, C.; LOPES,
M. Cancer and cell cicle-specific and cell cicle nonspecific anticancer DNA-interactive
agents: an introduction. Química Nova, v. 28, p. 118–129, 2005.
AMORIM, C. A.; RONDINA, D.; RODRIGUES, A. P. R.; GONÇALVES, P. B. D.;
DE FIGUEIREDO, J. R.; GIORGETTI, A. Cryopreservation of isolated ovine
primordial follicles with propylene glycol and glycerol. Fertility and sterility, v. 81
Suppl 1, n. March, p. 735–40, mar. 2004.
AMSTERDAM, A.; ROTMENSCH, S.; BEN-ZE’EV, A. Coordinated regulation of
morphological and biochemical differentiatiion in a steroidogenic cell : the granulosa
cell model. Trends Biochem Sci, v. 14, n. September, p. 3725–3728, 1989.
ARAÚJO, L. U.; GRABE-GUIMARÃES, A.; FURTADO, C. V.; MARTINS, C.;
SILVA-BARCELLOS, M. Profile of Wound Healing induced by allantoin. Acta
cirúrgica Brasileira, v. 25, n. 5, p. 460–466, 2010.
ARAÚJO, V. R.; SILVA, G. M.; DUARTE, A. B. G.; MAGALHÃES, D. M.;
ALMEIDA, A. P. Vascular endothelial growth factor-A165 (VEGF-A165) stimulates
the in vitro development and oocyte competence of goat preantral follicles. Cell Tissue
Res, v. 165, p. 273–281, 2011.
ARUNAKUMARI, G.; SHANMUGASUNDARAM, N.; RAO, V. H. Development of
morulae from the oocytes of cultured sheep preantral follicles. Theriogenology, v. 74,
n. 5, p. 884–894, 2010.
BAHIA, M. O.; ESTEFHANE, B.; BURBANO, R. R.; AMORIM, M. I. M.;
DUBEAUO, H. Genotoxic effects of mercury on in vitro cultures of human cells. Anais
Acad Brasil Cienc, v. 71, p. 437–443, 1999.
BAHMANI, M.; SHIRZAD, H.; SHAHINFARD, N.; SHEIVANDI, L.; RAFIEIAN-
KOPAEI, M. Cancer Phytotherapy : Recent Views on the Role of Antioxidant and
Angiogenesis Activities. Journal of evidence-based complementary and alternative
medicine, p. 1–11, 2016.
136
BAREKATI, Z.; GOURABI, H.; REZAZADEH, M.; EFTEKHARI, P. Previous
maternal chemotherapy by cyclophosphamide ( Cp ) causes numerical chromosome
abnormalities in preimplantation mouse embryos. Reproductive Toxicology, v. 26, p.
278–281, 2008.
BAR-JOSEPH, H.; BEN-AHARON, I.; RIZEL, S.; STEMMER, S. M.; TZABARI, M.;
SHALGI, R. Doxorubicin-induced apoptosis in germinal vesicle (GV) oocytes.
Reproductive toxicology (Elmsford, N.Y.), v. 30, n. 4, p. 566–72, dez. 2010.
BARRETO, A. C. H.; SANTIAGO, V. R.; FREIRE, R. M.; MAZZETTO, S. E.;
DENARDIN, J. C.; MELE, G.; CAVALCANTE, I. M.; RIBEIRO, M. E. N. P.;
RICARDO, N. M. P. S.; GONÇALVES, T.; CARBONE, L.; LEMOS, T. L. G.;
PESSOA, O. D. L.; FECHINE, P. B. A. Magnetic nanosystem for cancer therapy using
oncocalyxone A, an antitomour secondary metabolite isolated from a Brazilian plant.
International Journal of Molecular Sciences, v. 14, n. 9, p. 18269–18283, jan. 2013.
BECKERS, J.; DRION, P.; FIGUEIREDO, J. The ovarian follicle in cow: in vivo
growth and in vitro culture. Reprod Dom Anim, v. 31, p. 543–548, 1996.
BEN-AHARON, I.; BAR-JOSEPH, H.; TZARFATY, G.; KUCHINSKY, L.; RIZEL,
S.; STEMMER, S. M.; SHALGI, R. Doxorubicin-induced ovarian toxicity.
Reproductive biology and endocrinology : RB&E, v. 8, p. 20, jan. 2010.
BHATIA, M. Apoptosis versus necrosis. merican Journal of Physiol Renal
Physiology, v. 284, p. 608–627, 2004.
BOLTON, J. L.; TRUSH, M. A.; PENNING, T. M.; DRYHURST, G.; MONKS, T. J.
Role of Quinones in Toxicology. Chemical Research in Toxicology, v. 13, n. 3, p.
135–160, mar. 2000.
BOUAYED, J.; BOHN, T. Exogenous Antioxidants—Double-Edged Swords in
Cellular Redox State: Health Beneficial Effects at Physiologic Doses versus Deleterious
Effects at High Doses. Oxidative Medicine and Cellular Longevity, v. 3, n. 4, p. 228–
237, 2010.
BOUKANDOU, M. M.; MEWONO, L.; ABOUGHE, A. S. Toxicity studies of
medicinal plants used in sub-Saharan Africa. Journal of ethnopharmacology, v. 4, n.
174, p. 618–27, 2015.
BRAGA, R. Plantas do nordeste, especialmente do ceará. 3rd. ed. [s.l: s.n.]
BRAW-TAL, R.; YOSSEFI, S. Studies in vivo and in vitro on the initiation of follicle
growth in the bovine ovary. Journal of Reproduction and Fertility, v. 109, p. 165–
171, 1997.
BRIEN, M. J. O.; PENDOLA, J. K.; EPPIG, J. J. A Revised Protocol for In Vitro
Development of Mouse Oocytes from Primordial Follicles Dramatically Improves Their
Developmental Competence. Biology of reproduction, v. 68, n. November 2002, p.
1682–1686, 2003.
137
BRUNO, J. B.; CELESTINO, J. J. H.; LIMA-VERDE, I. B.; MATOS, M. H. T.; LIMA,
L. F.; NAME, K. P. O.; ARAÚJO, V. R.; SARAIVA, M. V. A.; MARTINS, F. S.;
CAMPELLO, C. C.; SILVA, J. R. V; BÁO, S. N.; FIGUEIREDO, J. R. Vasoactive
Intestinal Peptide Improves the Survival and Development of Caprine Preantral
Follicles after in vitro Tissue Culture. Cell Tissues Orgas, v. 191, n. 5, p. 414–21,
2010.
CANIPARI, R. Oocyte – granulosa cell interactions. Human Reproduction Update, v.
6, n. 3, p. 279–289, 2000.
CARABATSOS, M.; SELLITTO, C.; GOODENOUGH, D.; ALBERTINI, D. Oocyte-
granulosa cell heterologous gap junctions are required for the coordination of nuclear
and cytoplasmic meiotic competence. Developmental Biology, v. 226, p. 167–179,
2000.
CARROLL, J.; WHITTINGHAM, D. .; WOOD, M. J. Effect of dibutyryl cyclic
adenosine monophosphate on granulosa cell proliferation , oocyte growth and meiotic
maturation in isolated mouse primary ovarian follicles cultured in collagen gels.
Journal of reproduction and fertility, v. 92, p. 197–207, 1991.
CELESTINO, J. J. H.; LIMA-VERDE, I. B.; BRUNO, J. B.; MATOS, M. H. T.;
CHAVES, R. N.; SARAIVA, M. V. a; SILVA, C. M. G.; FAUSTINO, L. R.;
ROSSETTO, R.; LOPES, C. a P.; DONATO, M. a M.; PEIXOTO, C. a; CAMPELLO,
C. C.; SILVA, J. R. V; FIGUEIREDO, J. R. Steady-state level of bone morphogenetic
protein-15 in goat ovaries and its influence on in vitro development and survival of
preantral follicles. Molecular and cellular endocrinology, v. 338, n. 1–2, p. 1–9, 16
maio 2011.
CHABNER, B.; ROBERTS, T. G. JR. Timeline: Chemotherapy and the war on cancer.
Nature Reviews Cancer, v. 5, p. 65–72, 2005.
CHAVES, R. N.; DUARTE, A. B. G.; MATOS, M. H. T.; FIGUEIREDO, J. R.
Sistemas de cultivo in vitro para o desenvolvimento de oócitos imaturos de mamíferos.
Rev. Bras. Reprod. Anim., v. 34, p. 37–49, 2010.
CHEN, Z.; KANG, X.; WANG, L.; DONG, H.; WANG, C.; XIONG, Z.; ZHAO, W.;
JIA, C.; LIN, J.; ZHANG, W.; YUAN, W.; ZHONG, M.; DU, H.; BAI, X. Rictor /
mTORC2 Pathway in Oocytes Regulates Folliculogenesis , and Its Inactivation Causes
Premature Ovarian Failure. The journal of biological chemistry, v. 290, n. 10, p.
6387–6396, 2015.
CHOW, W.-H.; DONG, L. M.; DEVESA, S. S. Epidemiology and risk factors for
kidney cancer. Nature Reviews Urology, v. 7, n. 5, p. 245–257, 2010.
CORTVRINDT, R.; SMITZ, J. In vitro Follicle Growth : Achievements in Mammalian
Species. Reprod Dom Anim, v. 36, p. 3–9, 2001.
138
COSTA-LOTUFO, L. V.; CUNHA, G. M. A.; FARIAS, P. A. M.; VIANA, G. S. B.;
CUNHA, K. M. A.; PESSOA, C.; MORAES, M. O.; SILVEIRA, E. R.; GRAMOSA,
N. V.; RAO, V. S. . The cytotoxic and embryotoxic effects of kaurenoic acid , a
diterpene isolated from Copaifera langsdorffii oleo-resin. Toxicon, v. 40, p. 1231–1234,
2002a.
COSTA-LOTUFO, L. V.; FERREIRA, M. A. D.; LEMOS, T. L. G.; PESSOA, O. D.
L.; VIANA, G. S. B.; CUNHA, G. M. . Toxicity to sea urchin egg development of the
quinone fraction obtained from Auxemma oncocalyx. Brazilian Journal of Medical
and Biological Research, v. 35, n. 8, p. 927–930, 2002b.
CRAGG, G. M.; GROTHAUS, P. G.; NEWMAN, D. J. New Horizons for Old Drugs
and Drug Leads. Journal of natural products, v. 77, p. 703–723, 2014.
CRAGG, G. M.; NEWMAN, D. J. Plants as a source of anti-cancer agents. Journal of
ethnopharmacology, v. 100, n. 1–2, p. 72–9, 22 ago. 2005.
DA COSTA, G. M.; LEMOS, T. L. G.; PESSOA, D. L.; MONTE, F. J. Q.; BRAZ-
FILHO, R. Glaziovianol , a New Terpenoid Hydroquinone from Auxemma glazioviana.
Journal of natural products, v. 62, n. 7, p. 1044–1045, 1999.
DA SILVA, T.; COSTA, C.; GALVÃO, A.; BOMFIM, L.; RODRIGUES, A.; MOTA,
M.; DANTAS, A.; DOS SANTOS, T.; SOARES, M.; BEZERRA, D. Cytotoxic
potential of selected medicinal plants in northeast Brazil. BMC Complement Altern
Med, v. 16, p. 199, 2016.
DE CLERCK, L. S.; BRIDTS, C. H.; MERTENS, A. M.; MOENS, M. M.; STEVENS,
W. J. Use of fluorescent dyes in the determination of adherence of human leucocytes to
endothelial cells and the effect of fluorochromes on cellular function. Journal of
Immunological Methods, v. 172, p. 115–124, 1994.
DE VOS, M. De; DEVROEY, P.; FAUSER, B. C. J. M. Primary ovarian insufficiency.
Lancet, v. 376, n. 9744, p. 911–921, 2010.
DETTRAKUL, S.; SURERUM, S.; RAJVIROONGIT, S.; KITTAKOOP, P.
Biomimetic Transformation and Biological Activities of Globiferin , a Terpenoid
Benzoquinone from Cordia globifera. Journal of natural products, v. 72, p. 861–865,
2009.
DEWICK, P. M. Medicinal natural products−a biosynthetic approach. [s.l: s.n.]
2009.
DUARTE, A. B. G.; ARAÚJO, V. R.; CHAVES, R. N.; DA SILVA, G. M.; LUZ, V.
B.; THOMAS, K. H.; MAGALHÃES-PADILHA, D. M.; ALMEIDA, A. P.; LOBO, C.
H.; CAMPELLO, C. C.; FIGUEIREDO, J. R. Insulin-like growth factor II ( IGF-II )
and follicle stimulating hormone ( FSH ) combinations can improve the in vitro
development of grown oocytes enclosed in caprine preantral follicles. Growth
Hormone & IGF Research, v. 23, n. 1–2, p. 37–44, 2013.
DUARTE, M. C. T. Atividade Antimicrobiana de Plantas Medicinais e Aromáticas
139
Utilizadas no Brasil. Multiciência, v. 7, p. 17, 2006.
DUBUISSON, D.; DENNIS, S. G. The formalin test: A quantitative study of the
analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats.
Pain, v. 4, p. 161–174, out. 1977.
EPPIG, J. J.; O’BRIEN, M. J. Development in vitro of mouse oocytes from primordial
follicles. Biology of reproduction, v. 54, n. 1, p. 197–207, 1996.
EPPIG, J. J.; SCHROEDER, a C. Capacity of mouse oocytes from preantral follicles to
undergo embryogenesis and development to live young after growth, maturation, and
fertilization in vitro. Biology of reproduction, v. 41, n. 2, p. 268–276, 1989.
EPPIG, J.; PENDOLA, F.; WIIGGLESWORTH, K.; PENDOLA, J. Mouse oocytes
regulate metabolic cooperativity between granulosa cells and oocytes: amino acid
transport. Biol Reprod, v. 73, p. 351–357, 2005.
FAUSTINO, L. R.; CARVALHO, A. A.; FIGUEIREDO, J. R.; RODRIGUES, A. P. R.
Criopreservação de tecido ovariano: limitações e perspectivas para a preservação da
fertilidade de fêmeas. Acta Scientiae Veterinariae, v. 39, n. 3, p. 1–16, 2011.
FERREIRA, E.; VIREQUE, A.; ADONA, P.; MEIRELLES, F.; FERRIANI, R.;
NAVARRO, P. Cytoplasmic maturation of bovine oocytes: Structural and biochemical
modifications and acquisition of developmental competence. Theriogenology, v. 71, p.
836–848, 2009.
FERREIRA, M. A. D.; DO NASCIMENTO, N. R. F.; DE SOUSA, C. M.; PESSOA, O.
D. L.; DE LEMOS, T. L. G.; VENTURA, J. S.; SCHATTNER, M.; CHUDZINSKI-
TAVASSI, A. M. Oncocalyxone A inhibits human platelet aggregation by increasing
cGMP and by binding to GP Ib-alpha glycoprotein. British journal of pharmacology,
v. 154, p. 1216–1224, jul. 2008.
FERREIRA, M. A. D.; NUNES, O. D. R. H.; FONTENELE, J. B.; PESSOA, O. D. L.;
LEMOS, T. L. G.; VIANA, G. S. . Analgesic and anti-inflammatory activities of a
fraction rich in oncocalyxone A isolated from Auxemma oncocalyx. Phytomedicine :
international journal of phytotherapy and phytopharmacology, v. 11, n. 4, p. 315–
322, 2004.
FERREIRA, M. A. D.; NUNES, O. D. R. H.; FUJIMURA, A. H. Y.; PESSOA, O. D.
L.; LEMOS, T. L. G.; VIANA, G. S. B. Inhibition of platelet activation by quinones
isolated from Auxemma oncocalyx Taub. Res Commun Mol Pathol Pharmacol, v.
106, p. 97–107, 1999.
FERREIRA, M. A. D.; NUNES, O. D. R. H.; LEAL, L. K. A. M.; PESSOA, O. D. L.;
DE LEMOS, T. L. G.; VIANA, G. S. D. B. Antioxidant effects in the quinone fraction
from Auxemma oncocalyx TAUB. Biological & pharmaceutical bulletin, v. 26, n. 5,
p. 595–599, 2003.
FIGUEIREDO, J. R. Bioética: Repensando o uso das biotécnicas reprodutivas. Cienc.
Vet. Tróp, v. 11, n. 1, p. 116–118, 2008.
140
FIGUEIREDO, J. R.; RODRIGUES, A. P. R.; SILVA, J. R. V.; SANTOS, R. R.
Cryopreservation and in vitro culture of caprine preantral follicles. Reproduction,
fertility, and development, v. 23, n. 1, p. 40–7, jan. 2011a.
FIGUEIREDO, J. R. De; CELESTINO, J. J. D. H.; FAUSTINO, L. R.; RODRIGUES,
A. P. R. In vitro culture of caprine preantral follicles: Advances, limitations and
prospects. Small Ruminant Research, v. 98, n. 1–3, p. 192–195, jun. 2011b.
FORTUNE, J. E. The early stages of follicular development: Activation of primordial
follicles and growth of preantral follicles. Animal reproduction science, v. 78, p. 135–
163, 2003.
FRAGOULI, E.; WELLS, D.; DELHANTY, J. D. A. Chromosome abnormalities in the
human oocyte. Cytogenetic Genome Research, v. 133, p. 107–118, 2011.
GERRITSE, R.; BEERENDONK, C.; TIJINK, M.; HEETKAMP, A.; KREMER, J.;
BRAAT, D.; WESTPHAL, J. Optimal perfusion of an intact ovary as a prerequisite for
successful ovarian cryopreservation. Human Reproduction, v. 23, n. 2, p. 329–35,
2008.
GIL, M.; ABEYDEERA, L.; DAY, B.; VAZQUEZ, J.; ROCA, J.; MARTINEZ, E.
Effect of the volume of medium and number of oocytes during in vitro fertilization on
embryo development in pigs. Theriogenology, v. 60, p. 767–776, 2003.
GONÇALVES, P. B. D.; BARRETA, M. H.; SANDRI, L. R.; FERREIRA, R.;
ANTONIAZZI, A. Q. Produção in vitro de embriões bovinos: o estado da arte. Rev.
Bras. Reprod. Anim., v. 31, n. 2, p. 212–217, 2007.
GONÇALVES, P. B. D.; FIGUEIREDO, J. R.; FIGUEIREDO, V. J. Biotécnicas
aplicadas à reprodução animal. [s.l: s.n.] 2008.
GOSSELL-WILLIAMS, M.; SIMON, O. R.; WEST, M. E. The Past and Present Use of
Plants for Medicines. West Indian Med J, v. 55, n. 4, p. 217–218, 2006.
GRAHAM, J. G.; QUINN, M. L.; FABRICANT, D. S.; FARNSWORTH, N. R. Plants
used against cancer – an extension of the work of Jonathan Hartwell. Journal of
ethnopharmacology, v. 73, p. 347–377, 2000.
GURIB-FAKIM, A. Medicinal plants: Traditions of yesterdayand drugs of tomorrow.
Molecular Aspects of medicine, v. 27, p. 1–93, 2006.
HASLAM, R. J.; DICKINSON, N. T.; JANG, E. K. Cyclic nucleotides and
phosphodiesterases in platelets. Thromb Haemost, v. 82, p. 412–423, 1999.
HIRAO, Y.; NAGAI, T.; KUBO, M.; MIYANO, T.; MIYAKE, M.; KATO, S. In vitro
growth and maturation of pig oocytes. Journal of reproduction and fertility, v. 100, n.
2, p. 333–339, 1994.
JIANG, M.-X.; SHI, Y.; SUN, Z.-G.; ZHANG, Z.; ZHU, Y. Inhibition of the Binding
between RGS2 and β-Tubulin Interferes with Spindle Formation and Chromosome
Segregation during Mouse Oocyte Maturation In Vitro. Plos one, v. 11, n. 7, 2016.
141
JIN, S. Y.; LEI, L.; SHIKANOV, A.; SHEA, L. D.; WOODRUFF, T. K. A novel two-
step strategy for in vitro culture of early-stage ovarian follicles in the mouse. Fertility
and Sterility, v. 93, n. 8, p. 2633–2639, 2010.
JOHANNES, J. W.; ALMEIDA, L.; DALY, K.; FERGUSON, A. D.; GROSSKURTH,
S. E.; GUAN, H.; HOWARD, T.; IOANNIDIS, S.; KAZMIRSKI, S.; LAMB, M. L.;
LARSEN, N. A.; LYNE, P. D.; MIKULE, K.; OGOE, C.; PENG, B.; PETTERUTI, P.;
READ, J. A.; SU, N.; SYLVESTER, M.; THRONER, S.; WANG, W.; WANG, X.;
WU, J.; YE, Q.; YU, Y.; ZHENG, X.; SCOTT, D. A. Discovery of AZ0108 , an orally
bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering.
Bioorganic & Medicinal Chemistry Letters, v. 25, n. 24, p. 5743–5747, 2015.
JOHNSON, A. L. Intracellular mechanisms regulating cell survival in ovarian follicles.
Animal Reproduction Science, v. 78, p. 185–201, 2003.
KANG, H.; ROH, S. Extended Exposure to Trichostatin A after Activation Alters the
Expression of Genes Important for Early Development in Nuclear Transfer Murine
Embryos. Theriogenology, v. 73, n. 5, p. 623–631, 2010.
KNIGHT, P. G.; GLISTER, C. Focus on TGF- b Signalling TGF- b superfamily
members and ovarian follicle development. Reproduction, v. 132, p. 191–206, 2006.
KORT, J. D.; EISENBERG, M. L.; MILLHEISER, L. S.; WESTPHAL, L. M. Fertility
Issues in Cancer Survivorship. CA Cancer J Clin, v. 64, n. 2, p. 118–134, 2014.
KROPP, J.; ROTI, E. C. R.; RINGELSTETTER, A.; KHATIB, H.; ABBOTT, D. H.;
SALIH, S. M. Dexrazoxane Diminishes Doxorubicin- Induced Acute Ovarian Damage
and Preserves Ovarian Function and Fecundity in Mice. Plos one, v. 10, n. 11, p. 1–25,
2015.
LEE, H. Y. E. R. A. N.; GUPTA, M. K.; KIM, D. U. K. H.; HWANG, J. H. O.; KWON,
B.; LEE, H. T. Poly ( ADP-ribosyl ) ation Is Involved in Pro-Survival Autophagy in
Porcine Blastocysts. Molecular reproduction and development, v. 83, p. 37–49, 2016.
LEE, S.; CHOI, S.; CHOO, Y.; KIM, O.; TRAN, P.; DAO, C.; MIN, B.; JH, L.
Sappanone A exhibits anti-inflammatory effects via modulation of Nrf2 and NF-κB. nt
Immunopharmacol, v. 28, n. 1, p. 328–36, 2015.
LEIVA-REVILLA, J.; LIMA, L. F.; CASTRO, S. V.; CAMPELLO, C. C.; ARAÚJO,
V. R.; CELESTINO, J. J. H.; PESSOA, O. D. L.; SILVEIRA, E. R.; RODRIGUES, A.
P. R.; FIGUEIREDO, J. . Fraction of Auxemma oncocalyx and Oncocalyxone A affects
the in vitro survival and development of caprine preantral follicles enclosed in ovarian
cortical tissue. Forschende Komplementärmedizin, p. in press, 2016.
LEYVA, A.; PESSOA, O.; BOOGAERDT, F.; SOKAROSKI, R.; LEMOS, T. G.;
WETMORE, L. A.; HURUTA, R. R.; MORAES, M. O. Oncocalyxones A and C, 1,4-
Antracenediones from Auxemma oncocalyx: Comparison with Anticancer 1,9-
Anthracenediones. Anticancer Research, v. 20, n. 2A, p. 1029–1032, 2000.
142
LI, X.; YU, C.; WANG, Z.; ZHANG, Y.; LIU, X.; ZHOU, D.; FAN, H. DNA
Topoisomerase II Is Dispensable for Oocyte Meiotic Resumption but Is Essential for
Meiotic Chromosome Condensation and Separation in Mice. Biology of reproduction,
v. 89, n. 5, p. 118, 2013.
LIMA, D. A. Plantas da caatinga. [s.l: s.n.] 1989.
LIMA, P. M. Avaliação da atividade de extratos de folhas de momordica charantia,
auxemma oncocalyx e ziziphus joazeiro sobre bactérias e lavras de culex
quinquefasciatus. 2008.
LINO, C. S.; PESSOA, O. D. L.; LEMOS, T. L. C.; VIANA, G. S. B. Estudo da
atividade analgésica e antiedematogênica do extrato hidroalcoólico de Auxemma
oncocalyx e oncocalyxona A. In: Simpósio De Plantas Medicinais Do Brasil,
Anais...1996.
LIVAK, K. J.; SCHMITTGEN, T. D. Analysis of Relative Gene Expression Data Using
Real- Time Quantitative PCR and the 2 -DDCT Method. Methods, v. 408, n. 25, p.
402–408, 2001.
LÖBERMANN, F.; WEISHEIT, L.; TRAUNER, D. Intramolecular Vinyl Quinone
Diels-Alder Reactions: Asymmetric Entry to the Cordiachrome Core and Synthesis of d
Synthesis of (-) - Isoglaziovianol. Organic Letters, v. 15, n. 17, p. 4324–4326, 2013.
MACHADO, M.; MELO-JUNIOR, M. Avaliação do efeito antitumoral da Kalanchoe
brasilienisis sobre o sarcoma 180 em camundongos. Revista Eletrônica de Farmácia,
v. 1, p. 1–6, 2009.
MAIA, G. M. Caatinga: árvores e arbustos e suas utilidades. D & Z, p. 413, 2004.
MAILER, K.; PETIRING, D. H. Inhibition of oxidative phosphorylation in tumor cells
and mitochondria by daunomycin and adriamycin. Biochemical Pharmacology, v. 25,
p. 6–10, 1976.
MARANGOS, P.; STEVENSE, M.; NIAKA, K.; LAGOUDAKI, M.; NABTI, I.;
JESSBERGER, R.; CARROLL, J. DNA damage-induced metaphase I arrest is
mediated by the spindle assembly checkpoint and maternal age. Nature
Communications, v. 6, n. May, p. 1–10, 2015.
MARQUES, W. B.; DOS SANTOS, H. S.; PESSOA, O. D. L.; BRAZ-FILHO, R.;
LEMOS, T. L. G. Anthracene derivatives from Auxemma oncocalyx. Phytochemistry,
v. 55, n. 7, p. 793–797, dez. 2000.
MCCULLY, J. D.; WAKIYAMA, H.; HSIEH, Y. J.; JONES, M.; LEVITSKY, S.
Differential contribution of necrosis and apoptosis in myocardial ischemia-reperfusion
injury. American Journal of Physiology, Heart and Circulatory Physiology, v. 286,
p. 1923–1935, 2004.
MCLAUGHLIN, E.; MCIVER, S. Awakening the oocyte: Controlling primordial
follicle development. Reproduction, v. 137, p. 1–11, 2009.
143
MCLAUGHLIN, M.; TELFER, E. E. Oocyte development in bovine primordial
follicles is promoted by activin and FSH within a two-step serum-free culture system.
Reproduction, v. 139, n. 6, p. 971–978, 2010.
MEIROW, D.; BIEDERMAN, H.; ANDERSON, R. A.; WALLACE, W. H. B. Toxicity
of Chemotherapy and Radiation on Female Reproduction. Clinical obstetrics and
gynecology, v. 53, n. 4, p. 727–739, 2010.
MINOTTI, G.; MENNA, P.; SALVATORELLI, E.; CAIRO, G.; GIANNI, L.
Anthracyclines : Molecular Advances and Pharmacologic Developments in Antitumor
Activity and Cardiotoxicity. Pharmacological reviews, v. 56, n. 2, p. 185–229, 2004.
MITRY, M. A.; EDWARDS, J. G. Doxorubicin induced heart failure: Phenotype and
molecular mechanisms. Int J Cardiol Heart Vasc, v. 10, p. 17–24, 2016.
MONKS, T. J.; LAU, S. S. Toxicology of quinone-thioethers. Critical Reviews in
Toxicology, v. 22, p. 243–270, 1992.
MORAES, M. O.; FONTELES, M. C.; MORAES, M. E. A.; MACHADO, M. I. L.;
MATOS, F. J. A. Screening for anticancer activity of plants from the Northeast of
Brazil. Fitoterapia, v. 68, p. 234–239, 1997.
MORITA, Y.; TILLY, J. L. Oocyte apoptosis: Like sand through and hourglass.
Developmental Biology, v. 213, p. 1–17, 1999.
MUNN, C.; KISER, L.; WETZNER, S.; BAER, J. Ovary volume in young and
premenopausal adults: US determination. Work in progress. Radiology, v. 159, p. 731–
732, 1986.
NEWMAN, D. J.; CRAGG, G. M.; SNADER, K. M. Natural Products as Sources of
New Drugs over the Period 1981 - 2002. Journal of natural products, v. 66, p. 1022–
1037, 2003.
NOZELLA, E. F. Valor nutricional de espécies arbóreo-arbustivas nativas da
caatinga e utilização de tratamentos físico-químicos para redução do teor de
taninos. [s.l: s.n.] 2006.
OKTEM, O.; OKTAY, K. Quantitative assessment of the impact of chemotherapy on
ovarian follicle reserve and stromal function. Cancer, v. 110, n. 10, p. 2222–9, 15 nov.
2007.
ORISAKA, M.; TAJIMA, K.; TSANG, B. K.; KOTSUJI, F. Oocyte–granulosa–theca
cell inter-actions during preantral follicular development. journal of ovarian research,
v. 7, n. 2, p. 1–7, 2009.
PESSOA, C.; LEMOS, T. L. G.; PESSOA, O. D. L.; MORAES, M. O.; COSTA-
LOTUFO, L. V.; LEYVA, A. Cytotoxicity of derivatives of oncocalyxone A from
Auxemma oncocalyx Taub. ARKIVOC, v. vi, p. 89–94, 2004.
144
PESSOA, C.; MENDES, C. S.; PESSOA, L. O.; SABINO, S. H.; LEMOS, T. .;
MORAES, M. O. Avaliação da atividade antitumoral de Auxemma oncocalyx Taub.
(Pau Branco). In: VII Annual Meeting of the Federação de Sociedades de Biologia
Experimental, Caxambu, MG, Brazil., Anais...1992.
PESSOA, C.; SILVEIRA, E. R.; LEMOS, T. L. G.; WETMORE, L. A.; MORAES, M.
O.; LEYVA, A. Antiproliferative Effects of Compounds Derived from Plants of
Northeast Brazil. Phytotherapy research, v. 14, p. 187–191, 2000.
PESSOA, C.; VIEIRA, F. M. A. C.; LEMOS, T. G.; MORAES, M. O.; LIMA, P. D. L.;
RABENHORST, S. H. B.; LEYVA, A.; BURBANO, R. R. Oncocalyxone A from
Auxemma oncocalyx lacks genotoxic activity in phytohemagglutinin-stimulated
lymphocytes. Teratogenesis, carcinogenesis, and mutagenesis, v. Suppl 1, p. 215–20,
jan. 2003.
PESSOA, O. D. . Contribuição ao conhecimento químico de plantas nativas do
nordeste: auxemma oncocalyx taub. [s.l: s.n.]. 1994.
PESSOA, O. D. .; LEMOS, T. L. G.; CARVALHO, M. G.; BRAZ-FILHO, R.
Cordiachromes from Auxemma oncocalyx. Phytochemistry, v. 40, n. 6, p. 1777–1786,
1995.
PESSOA, O. D. L.; LEMOS, T. L. G.; SILVEIRA, E. R.; BRAZ-FILHO, R. Novel
cordiachromes isolated from Auxemma oncocalyx. Natural Product Research, v. 2, p.
145–150, 1993.
PESSOA, O. D.; LEMOS, T. L. G. Allantoin and fatty acid composition in Auxemma
oncocalyx. Revista Brasileira de Farmácia, v. 78, p. 9–10, 1997.
PICTON, H. Activation of follicle development: The primordial follicle.
Theriogenology, v. 55, p. 1193–1210, 2001.
QUNAIBI, E. A.; DISI, A. M.; TAHA, M. O. Phenytoin enhances collagenization in
excision wounds and tensile strength in incision wounds. Pharmazie, v. 64, p. 584–586,
2009.
RAN, H.; HYOUN, D.; GYEONG, M.; SUNG, J.; HO, J.; TAEK, H. Biochemical and
Biophysical Research Communications The regulation of autophagy in porcine
blastocysts : Regulation of PARylation-mediated autophagy via mammalian target of
rapamycin complex 1 ( mTORC1 ) signaling. Biochemical and Biophysical Research
Communications, v. 473, n. 4, p. 899–906, 2016.
RATES, S. M. K. Plants as source of drugs. Toxicology, v. 39, p. 603–13, 2001.
REINER, T.; POZAS, A.; GOMEZ, L.; PEREZ-STABLE, C. Low dose combinations
of 2-methoxyestradiol and docetaxel block prostate câncer cells in mitosis and increase
apoptosis. Cancer Letters, v. 8, p. 21–31, 2009.
145
REKHADEVI, P. V.; DIGGS, D. L.; HUDERSON, A. C.; HARRIS, K. L.;
ARCHIBONG, A. E.; RAMESH, A. Metabolism of the environmental toxicant
benzo(a)pyrene by subcellularfractions of human ovary. Hum Exp Toxicol, v. 33, n. 2,
p. 196–202, 2014.
RODGERS, R. J.; IRVING-RODGERS, H. F. Morphological classification of bovine
ovarian follicles. Reproduction, v. 319, n. 2, p. 309–318, 2005.
SAEIDNIA, S.; ABDOLLAHI, M. Toxicological and pharmacological concerns on
oxidative stress and related diseases. Toxicology and applied pharmacology, v. 273,
n. 3, p. 442–55, 15 dez. 2013.
SANTOS, R. R.; SCHOEVERS, E. J.; ROELEN, B. A. Usefulness of bovine and
porcine IVM/IVF models for reproductive toxicology. Reproductive biology and
endocrinology : RB&E, v. 12, n. 1, p. 117, 2014.
SARAIVA, M.; CELESTINO, J.; ARAÚJO, V.; CHAVES, R.; ALMEIDA, A.; LIMA-
VERDE, I.; DUARTE, A.; SILVA, G.; MARTINS, F.; BRUNO, J.; MATOS, M.;
CAMPELLO, C.; SILVA, J.; FIGUEIREDO, J. Expression of follicle-stimulating
hormone receptor ( FSHR ) in goat ovarian follicles and the impact of sequential culture
medium on in vitro development of caprine preantral follicles. Zygote, v. 19, n.
December, p. 205–214, 2010.
SAÚDE, M. Da. Instituto Nacional do Câncer (INCA). A estimativa de novos casos
para o ano de 2008 no Estado de Alagoas. [s.l: s.n.]. 2008
SAUMANDE, J. Ovogenèse et folliculogenèse. Recueil de Médecine Vétérinaire, v.
157, p. 29–38, 1981.
SBARDELOTTO, Aline Borba. Estudo do mecanismo de citotoxicidade da
oncocalixona-a em leucemia promielocítica humana – linhagem hl-60. 2013. 103 f.
Dissertação (Mestrado em Farmacologia) – Programa de Pós-Graduação em
Farmacologia do Departamento de fisiologia e farmacologia da Universidade Federal do
Ceará, Fortaleza, 2013.
SCHMITT, A. C.; ALMEIDA, A. B. P. .; SILVEIRA, T. A.; IWAKURA, C. T.;
MENDES, K. F.; SILVA, M. . Avaliação da atividade antimicrobiana in vitro da planta
Bryophyllum pinnatum Kurz (“Folha-da-fortuna”) colhida em Varzea Grande, Mato
Grosso/Brazil. Acta Scientiae Veterinariae, v. 31, n. 1, p. 55–58, 2003.
SCHOEVERS, E. J.; FINK-GREMMELS, J.; COLENBRANDER, B.; ROELEN, B. A.
J. Porcine oocytes are most vulnerable to the mycotoxin deoxynivalenol during
formation of the meiotic spindle. Theriogenology, v. 74, n. 6, p. 968–978, 2010.
SCHOEVERS, E. J.; SANTOS, R. R.; FINK-GREMMELS, J.; ROELEN, B. A. J.
Toxicity of beauvericin on porcine oocyte maturation and preimplantation embryo
development. Reproductive Toxicology, v. 65, p. 159–169, 2016.
146
SHALE, T.; STIRK, W.; VAN STADEN, J. Screening of medicinal plants used in
Lesotho for anti-bacterial and anti-inflammatory activity. Journal of
ethnopharmacology, v. 67, p. 347–354, 1999.
SHARAPIN, N. Medicinal plants: pharmacopoeial prescriptions. Anais da Academia
Brasileira de Ciencias, v. 71, p. 295–298, 1999.
SHRESTHA, J.; SHANBHAG, T.; SHENOY, S.; AMUTHAN, A.; PRABHU, K.;
SHARMA, S.; BANERJEE, S.; KAFLE, S. Antiovulatory and abortifacient effects of
Areca catechu (betel nut) in female rats. Indian J Pharmacol, v. 42, n. 5, p. 306–311,
2010.
SILVA, C. M. G.; CASTRO, S. V; FAUSTINO, L. R.; RODRIGUES, G. Q.; BRITO, I.
R.; SARAIVA, M. V. A.; ROSSETTO, R.; SILVA, T. F. P.; CAMPELLO, C. C.;
FIGUEIREDO, J. R. Moment of addition of LH to the culture medium improves in vitro
survival and development of secondary goat pre-antral follicles. Reproduction in
domestic animals = Zuchthygiene, v. 46, n. 4, p. 579–84, ago. 2011.
SILVA, J. R. V.; VAN DEN HURK, R.; COSTA, S. H. F.; ANDRADE, E. R.; NUNES,
A. P.; FERREIRA, F. V. .; LÔBO, R. N. B.; FIGUEIREDO, J. R. Survival and growth
of goat primordial follicles after in vitro culture of ovarian cortical slices in media
containing coconut water. Animal reproduction science, v. 81, p. 273–86, abr. 2004.
SOUSA, C. M.; NASCIMENTO, N. R. F.; LEMOS, T. L. G.; PESSOA, O. D. L.;
FERREIRA, M. A. D. Avaliação da Atividade Antiagregante Plaquetária da
oncocalixona A (Onco a) e vasoconstritora da Fração quinona da Auxemma oncocalyx.
In: Reunião Anual Da Sociedade Brasileira De Química, Anais...2002.
SPEARS, N.; BOLAND, N.; MURRAY, A.; GOSDEN, R. Mouse oocytes derived from
in vitro grown primary ovarian follicles are fertile. Hum Reprod, v. 9, p. 527–532,
1994.
STEFANSDOTTIR, A.; FOWLER, P. A.; POWLES-GLOVER, N.; ANDERSON, R.
A.; SPEARS, N. Use of ovary culture techniques in reproductive toxicology.
Reproductive Toxicology, v. 49, p. 117–135, 2014.
SUN, F.; BETZENDAHL, I.; SHEN, Y.; CORTVRINDT, R.; SMITZ, J.;
EICHENLAUB-RITTER, U. Preantral follicle culture as a novel in vitro assay in
reproductive toxicology testing in mammalian oocytes. Mutagenesis, v. 19, n. 1, p. 13–
25, 2004.
SUN, Z.; PARK, S.; HWANG, E.; ZHANG, M.; SEO, S.; LIN, P.; YI, T. Thymus
vulgaris alleviates UVB irradiation induced skin damage via inhibition of MAPK/AP-1
and activation of Nrf2-ARE antioxidant system. J Cell Mol Med., v. XX, p. 1–13,
2016.
SUTTON, M.; GILCHRIST, R.; THOMPSON, J. Effects of in-vivo and in-vitro
environments on the metabolism of the cumulus–oocyte complex and its influence on
oocyte developmental capacity. Hum Reprod Update, v. 9, p. 35–48, 2003.
147
TELFER, E. E.; MCLAUGHLIN, M.; DING, C.; THONG, K. J. A two-step serum-free
culture system supports development of human oocytes from primordial follicles in the
presence of activin. Human Reproduction, v. 23, n. 5, p. 1151–1158, 2008.
TIGRE, C. B. Silvicultura para as matas xerófilas: defesa dos recursos naturais
renováveis. [s.l: s.n.]. 1970.
TOKARSKA-SCHLATTNER, M.; ZAUGG, M.; ZUPPINGER, C.; WALLIMANN,
T.; SCHLATTNER, U. New insights into doxorubicin-induced cardiotoxicity : The
critical role of cellular energetics. Journal of molecular and cellular cardiology, v.
41, p. 389–405, 2006.
TRIPATHI, A.; KUMAR, K.; CHAUBE, S. Meiotic cell cycle arrest in mammalian
oocytes. J Cell Physiol, v. 223, p. 592–600, 2010.
TURAN, V.; BEDOSCHI, G.; MOY, F.; OKTAY, K. Safety and feasibility of
performing two consecutive ovarian stimulation cycles with the use of letrozole-
gonadotropin protocol for fertility preservation in breast cancer patients. Fertility and
sterility, v. 100, n. 6, p. 1681–1685, 2013.
WAKEFIELD, S. L.; LANE, M.; MITCHELL, M. Impaired Mitochondrial Function in
the Preimplantation Embryo Perturbs Fetal and Placental Development in the Mouse.
Biology of reproduction, v. 84, p. 572–580, 2011.
WANDJI, S.; SRSEN, V.; NATHANIELSZ, P. W.; EPPIG, J. J.; FORTUNE, J. E.
Initiation of growth of baboon primordial follicles in vitro. Human Reproduction, v.
12, p. 1993–2001, 1997.
WANG, Q.; SUN, S.; HAN, J.; KWAK, Y.; KIM, N.; CUI, X. Doxorubicin Induces
Early Embryo Apoptosis by Inhibiting Poly ( ADP ribose ) Polymerase. in vivo, v. 834,
p. 827–834, 2012.
WEAVER, A. N.; YANG, E. S. Beyond DNA repair : additional functions of PARP-1
in cancer. Frontiers in oncology, v. 3, n. November, p. 1–11, 2013.
WEI, Q.; DING, W.; SHI, F. Roles of poly (ADP-ribose) polymerase (PARP1) cleavage
in the ovaries of fetal, neonatal, and adult pigs. Reproduction, v. 146, p. 593–602,
2013.
WEST, E. .; SHEA, L. D.; WOODRUFF, T. K. Engineering the Follicle
Microenvironment. Semin reprod med, v. 25, n. 4, p. 287–299, 2007.
XU, M.; KREEGER, P. K.; SHEA, L. D.; TERESA, K. Tissue-Engineered Follicles
Produce Live, Fertile Offspring. tissue eng, v. 12, n. 10, p. 2739–2746, 2009.
XUYING, W.; JIANGBO, Z.; YUPING, Z.; XILI, M.; ZHEN, L.; FEI, W.; GUIFENG,
X.; TIANBAO, Z. A novel method for toxicology: in vitro culture system of a rat
preantral follicle. Toxicology and industrial health, v. 27, n. 7, p. 637–45, 2011.
148
YOUNG, J.; MCNEILLY, A. Theca: The forgotten cell of the ovarian follicle.
Reproduction, v. 140, p. 489–504, 2010.
ZAMORANO, P. L.; MAHESH, V. B.; BRANN, D. W. Quantitative RT-PCR for
neuroendocrine studies. A minireview. Neuroendocrinology, v. 63, p. 397–407, 1996.
ZHANG, M.; HONG, H.; ZHOU, B.; JIN, S.; WANG, C.; FU, M.; WANG, S.; XIA, G.
The expression of atrial natriuretic peptide in the oviduct and its functions in pig
spermatozoa. Journal of endocrinology, v. 189, p. 493–507, 2006.
ZHANG, M.; TANG, H.; SHEN, G.; ZHOU, B.; WU, Z.; PENG, Z.; ZHANG, J.; YAN,
J.; XIA, G. Atrial natriuretic peptide induces an acrosome reaction in giant panda
spermatozoa and enhances their penetration of salt-stored porcine oocytes.
Theriogenology, v. 64, n. 6, p. 1297–308, 2005.
ZHANG, P.; LOUHIO, H.; TUURI, T.; SJOBERG, J.; HREINSSON, J.; TELFER, E.
E.; HOVATTA., O. In vitro effect of cyclic adenosine 30,50-monophosphate (cAMP)
on early human ovarian follicles. Journal of Assisted Reproduction and Genetics, v.
21, p. 310–306, 2004.